Mutant tRNA for codon extension

By introducing cytidine into tRNA and modifying the tRNA sequence, the problem of inability to distinguish NNA and NNG codons in the prior art is solved, which significantly improves the accuracy of the translation system and reduces the misreading of NNU codons.

CN119080856APending Publication Date: 2024-12-06CHUGAI PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411191830.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-12-26
Filing Date
2019-12-26
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art cannot effectively distinguish NNA and NNG codons, and lacks means to distinguish NNU codons.

Method used

The chemically synthesized tRNA fragment is linked to lycytidine by enzymatic reaction, introducing lycytidine to position 34 of tRNA and having different sequences at positions 35 and 36, thereby distinguishing NNA and NNG codons in the translation system, and Mutation of tRNA is generated by modifying tRNA to reduce misreading of NNU codons.

Benefits of technology

The selective distinction between NNA and NNG codons is achieved, and the misreading of NNU codons is significantly reduced, and the accuracy of the translation system is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005015317280000071
    Figure BDA0005015317280000071
  • Figure BDA0005015317280000081
    Figure BDA0005015317280000081
  • Figure BDA0005015317280000091
    Figure BDA0005015317280000091
Patent Text Reader

Abstract

In some embodiments, the present disclosure relates to a mutant tRNA in which the first letter of the anticodon has been replaced with either lysine or agmatine, and a translation system comprising the mutant tRNA. In a specific embodiment, the present disclosure provides a mutant tRNA capable of selectively translating a codon NNA. In another embodiment, the present disclosure provides a translation system capable of translating two or three types of amino acids from a single codon cassette. In yet another embodiment, the present disclosure provides novel methods for the synthesis of lysine diphosphate, agmatine diphosphate, and derivatives thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application with a filing date of December 26, 2019, Chinese patent application number 201980090364.4, and invention name “Mutant tRNA for codon expansion”. Technical Field

[0002] The present disclosure relates to tRNAs and translation systems, and methods of using the same. Background Art

[0003] Display libraries are a very useful technology that can be used to efficiently obtain molecules that bind to target proteins in an evolutionary engineering manner. In order to use display libraries to obtain molecules that show high binding ability to any target molecule, or to obtain multiple molecules that bind to different epitopes, a highly diverse library needs to be panned. In order to construct a highly diverse library, the number or type of structural units of the library can be increased; however, when there are restrictions on molecular weight from the perspective of membrane permeability, the number of structural units will also be limited. Therefore, strategies to increase the diversity of structural units are important for increasing library diversity.

[0004] In a reconstructed cell-free translation system such as PURESYSTEM (Non-Patent Literature (NPL) 1), the natural codon-amino acid correspondence may change because the concentrations of components such as amino acids, tRNAs, and aminoacyl-tRNA synthetases (ARSs) can be adjusted. The use of such a translation system enables the construction of a display library in which 20 or more different types of arbitrary structural units are introduced. However, in the Escherichia coli translation system using three-base codons, due to the swing rule, in principle, only 32 different structural units can be introduced. To give a more specific explanation, in addition to the Watson-Crick base pair, there is some "swing (play)" in the pairing of the third letter of the codon and the first letter of the anticodon, which allows pairing between G and U, called a wobble base pair. Therefore, the anticodon GNN decodes NNU and NNC codons, and the anticodon UNN decodes NNA and NNG codons. Therefore, it is impossible to distinguish these codons, and the maximum number of different amino acids that can be introduced into a codon frame is limited to two (Non-Patent Literature 2).

[0005] On the other hand, in nature, there are methods that can distinguish AUA and AUG codons. One such example is the introduction of a lysine modification of E. coli tRNA Ile2 at position 34 (the first letter of the anticodon). It is known that this modification causes tRNA Ile2 to only decode AUA codons, but not AUG codons (Non-Patent Document 3). This modification is a modification that is made possible by isoleucine tRNA-lysine synthetase (tRNA Ile-Cytidine synthase; TilS) (Non-patent document 4). Since its substrate tRNA is only tRNA Ile2, it is not easy to introduce cytidine into other tRNAs (Non-patent document 5).

[0006] Reference List

[0007] [Non-patent literature]

[0008] [Non-patent document 1] Shimizu et al., Nat Biotechnol. 2001Aug; 19(8): 751-755

[0009] [Non-patent document 2] Iwane et al., Nat Chem. 2016Apr; 8(4): 317-325

[0010] [Non-patent document 3] Grosjean et al., Trends Biochem Sci. 2004Apr; 29(4): 165-168

[0011] [Non-patent document 4] Suzuki T et al., FEBS Lett. 2010 Jan 21; 584(2): 272-277

[0012] [Non-patent document 5] Lajoie et al., J Mol Biol. 2016 Feb 27; 428(5Pt B): 1004-1021 Summary of the invention

[0013] Technical issues

[0014] As described above, the introduction of cytosine into tRNA Ile2 at position 34 (the first letter of the anticodon) can distinguish between AUA and AUG codons. However, there are no other tRNAs modified with cytosine in nature. In addition, no artificial means for distinguishing between NNA and NNG codons have been reported. The present invention is completed in view of this situation. The purpose of the present disclosure is to provide a new method that can distinguish between NNA and NNG codons.

[0015] Solutions to the problem

[0016] Herein, the inventors connected chemically synthesized tRNA fragments with lysine (also known as 2-lysylcytidine) by enzymatic reaction to prepare tRNA, wherein lysine was introduced at position 34 and had different sequences at positions 35 and 36 (the second and third letters of the anticodon). When the translation system containing these tRNAs was reconstructed and amino acid translation was performed, it was found that any of these translation systems could distinguish between NNA and NNG codons. In addition, during these inspections, it was found that although the tRNA with the UNN anticodon not only decoded NNA and NNG codons, but also decoded NNU codons, the tRNA introducing lysine significantly reduced this misreading of the NNU codon.

[0017] The present invention is based on such discovery and specifically includes the following illustrative embodiments:

[0018] [1] A mutant tRNA produced by modifying tRNA, wherein the modification includes modifying the tRNA so that 1 N 2 N 3 In the anticodon represented by 1 is any one of lysine (k2C), lysine derivatives, agmatidine (agm2C) and agmatidine derivatives, wherein N 2 and N 3 Any nucleoside with the second and third letters of the anticodon, respectively;

[0019] [2] The mutant tRNA according to [1], wherein N 1 is cytidine (C), and the transformation from cytidine (C) to lysine (k2C) cannot be synthesized by lysine synthetase (tRNA Ile - lysine synthetase; TilS) catalyzed, the lysine synthetase has the amino acid sequence of SEQ ID NO: 51;

[0020] [3] The mutant tRNA according to [1], wherein N 1 is cytidine (C), and the transformation from cytidine (C) to agmatidine (agm2C) cannot be synthesized by agmatidine synthetase (tRNA Ile - agmatidine synthase; catalyzed by TiaS), the agmatidine synthase having the amino acid sequence of SEQ ID NO: 52;

[0021] [4] The mutant tRNA according to any one of [1] to [3], comprising 1M 2 A represents the codon complementary to the anticodon (where M 1 and M 2 The nucleotides representing the first and second letters of the codon, respectively; M 1 and M 2 Each is selected from any one of adenosine (A), guanosine (G), cytidine (C) and uridine (U); the nucleoside of the third letter corresponds to adenosine);

[0022] [5] The mutant tRNA according to [4], wherein the anticodon is composed of k2CN 2 N 3 or agm2CN 2 N 3 Indicates (wherein the first letter of the anticodon is lysine (k2C) or agmatidine (agm2C), the second letter (N 2 ) nucleotide and the third letter (N 3 ) nucleotides were respectively 2 and M 1 complementary);

[0023] [6] The mutant tRNA according to [5], wherein N 2 and N 3 Each is selected from any one of adenosine (A), guanosine (G), cytidine (C) and uridine (U);

[0024] [7] The mutant tRNA according to any one of [1] to [6], wherein the tRNA is an initiator tRNA or an elongator tRNA;

[0025] [8] The mutant tRNA according to any one of [1] to [7], wherein the tRNA is derived from a prokaryotic organism or a eukaryotic organism;

[0026] [9] The mutant tRNA according to any one of [4] to [8], wherein M 1 and M 2 A codon selected from the group consisting of codon boxes, wherein a codon with an A as the third letter nucleoside and a codon with a G as the third letter nucleoside both encode the same amino acid in the natural genetic code table;

[0027]

[10] The mutant tRNA according to any one of [4] to [8], wherein M 1 and M 2 A codon selected from the group consisting of codon boxes, wherein a codon with a third letter nucleoside of U and a codon with a third letter nucleoside of A both encode the same amino acid in the natural genetic code table;

[0028]

[11] The mutant tRNA according to any one of [4] to [8], wherein M 1 and M 2 A codon selected from the group consisting of codon boxes, wherein the codon with a third letter nucleoside of U, the codon with a third letter nucleoside of C, the codon with a third letter nucleoside of A, and the codon with a third letter nucleoside of G all encode the same amino acid in the natural genetic code table;

[0029]

[12] The mutant tRNA according to any one of [4] to [8], wherein M 1 and M 2 A codon selected from the group consisting of codon boxes, wherein a codon with an A as the third letter nucleoside and a codon with a G as the third letter nucleoside encode different amino acids in the natural genetic code table;

[0030]

[13] The mutant tRNA according to any one of [4] to [8], wherein M 1 and M 2 A codon selected from the group consisting of codon boxes, wherein the codon with the third letter nucleoside being A and / or the codon with the third letter nucleoside being G is a stop codon in the natural genetic code table;

[0031]

[14] The mutant tRNA according to any one of [4] to [8], wherein M 1 is uridine (U), M 2 is cytidine (C);

[0032]

[15] The mutant tRNA according to any one of [4] to [8], wherein M 1 is cytidine (C), M 2 is uridine (U);

[0033]

[16] The mutant tRNA according to any one of [4] to [8], wherein M 1 is cytidine (C), M 2 is cytidine (C);

[0034]

[17] The mutant tRNA according to any one of [4] to [8], wherein M 1 is cytidine (C), M 2 is guanosine (G);

[0035]

[18] The mutant tRNA according to any one of [4] to [8], wherein M 1 is adenosine (A), M 2 is uridine (U);

[0036]

[19] The mutant tRNA according to any one of [4] to [8], wherein M 1 is guanosine (G), M2 is uridine (U);

[0037]

[20] The mutant tRNA according to any one of [4] to [8], wherein M 1 is guanosine (G), M 2 is cytidine (C);

[0038]

[21] The mutant tRNA according to any one of [4] to [8], wherein M 1 is guanosine (G), M 2 is guanosine (G);

[0039]

[22] The mutant tRNA according to

[14] , wherein N 2 is guanosine (G), N 3 is adenosine (A);

[0040]

[23] The mutant tRNA according to

[15] , wherein N 2 is adenosine (A), N 3 is guanosine (G);

[0041]

[24] The mutant tRNA according to

[16] , wherein N 2 is guanosine (G), N 3 is guanosine (G);

[0042]

[25] The mutant tRNA according to

[17] , wherein N 2 is cytidine (C), N 3 is guanosine (G);

[0043]

[26] The mutant tRNA according to

[18] , wherein N 2 is adenosine (A), N 3 is uridine (U);

[0044]

[27] The mutant tRNA according to

[19] , wherein N 2 is adenosine (A), N 3 is cytidine (C);

[0045]

[28] The mutant tRNA according to

[20] , wherein N 2 is guanosine (G), N 3 is cytidine (C);

[0046]

[29] The mutant tRNA according to

[21] , wherein N 2 is cytidine (C), N 3 is cytidine (C);

[0047]

[30] The mutant tRNA according to any one of [1] to

[29] , wherein an amino acid or an amino acid analog is linked to the 3′ terminus;

[0048]

[31] The mutant tRNA according to

[30] , wherein the amino acid is a natural amino acid or an unnatural amino acid;

[0049]

[32] The mutant tRNA according to

[31] , wherein the natural amino acid is selected from the group consisting of glycine (Gly), alanine (Ala), serine (Ser), threonine (Thr), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), histidine (His), glutamic acid (Glu), aspartic acid (Asp), glutamine (Gln), asparagine (Asn), cysteine ​​(Cys), methionine (Met), lysine (Lys), arginine (Arg) and proline (Pro);

[0050]

[33] The mutant tRNA according to

[32] , wherein the natural amino acid is selected from the group consisting of glycine (Gly), alanine (Ala), serine (Ser), threonine (Thr), valine (Val), leucine (Leu), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), histidine (His), glutamic acid (Glu), aspartic acid (Asp), glutamine (Gln), asparagine (Asn), cysteine ​​(Cys), lysine (Lys), arginine (Arg) and proline (Pro);

[0051]

[34] A translation system comprising a plurality of different tRNAs, wherein the system comprises the mutant tRNA according to any one of [1] to

[33] ;

[0052]

[35] A translation system according to

[34] , wherein M 1 M 2 The codon represented by A can be compared with M 1 M 2 A codon different from the codon indicated by A is more selectively translated by the mutant tRNA, and the mutant tRNA can more selectively translate M than tRNAs other than the mutant tRNA 1 M 2 A represents the codon;

[0053]

[36] The translation system according to

[34] or

[35] , comprising (a) the mutant tRNA of any one of [1] to

[33] , and (b) a tRNA having a tRNA residue corresponding to M 1 M 2G represents the tRNA with the complementary anticodon of the codon;

[0054]

[37] The translation system according to

[36] , wherein the anticodon of the tRNA according to

[36] (b) is CN 2 N 3 、ac4CN 2 N 3 or CmN 2 N 3 (where ac4C represents N4-acetylcytidine and Cm represents 2'-O-methylcytidine);

[0055]

[38] A translation system according to

[36] or

[37] , wherein M 1 M 2 The codon represented by G can be compared with M 1 M 2 The codon represented by G is more selectively translated by the tRNA described in

[36] (b), and the tRNA described in

[36] (b) can more selectively translate M than tRNAs other than the tRNA described in

[36] (b). 1 M 2 G represents the codon;

[0056]

[39] The translation system according to any one of

[36] to

[38] , wherein the amino acid or amino acid analogues linked to the tRNAs of

[36] (a) and

[36] (b) are different from each other;

[0057]

[40] A translation system according to

[39] , wherein the two amino acids can be selected from M 1 M 2 A and M 1 M 2 G codon translation;

[0058]

[41] A translation system according to

[39] , wherein M 1 M 2 A and M 1 M 2 G codons can encode amino acids or amino acid analogs that are different from each other;

[0059]

[42] The translation system according to any one of

[34] to

[41] , further comprising (c) comprising 1 M 2 U or M 1 M 2 C represents the tRNA with the complementary anticodon of the codon;

[0060]

[43] The translation system according to

[42] , wherein the anticodon of the tRNA of

[42] (c) is selected from AN2 N 3 GN 2 N 3 , QN 2 N 3 and GluQN 2 N 3 The group consisting of (wherein Q represents queuosine, GluQ represents glutamyl-queuosine);

[0061]

[44] A translation system according to

[42] or

[43] , wherein M 1 M 2 U or M 1 M 2 The codon represented by C can be compared with M 1 M 2 U or M 1 M 2 The codons different from the codons indicated by C are more selectively translated by the tRNA

[42] (c), and the tRNA

[42] (c) can more selectively translate M than tRNAs other than the tRNA

[42] (c). 1 M 2 U or M 1 M 2 C represents the codon;

[0062]

[45] The translation system according to any one of

[42] to

[44] , wherein the amino acid or amino acid analogue linked to the tRNA of

[36] (a),

[36] (b) and

[42] (c) is different from each other;

[0063]

[46] The translation system according to

[45] , wherein the three amino acids can be obtained from M 1 M 2 U, M 1 M 2 C.M. 1 M 2 A and M 1 M 2 G composed of codon boxes for translation;

[0064]

[47] A translation system according to

[45] , wherein in the translation system 1 M 2 U, M 1 M 2 C.M. 1 M 2 A and M 1 M 2 In the codon box composed of G;

[0065] (i)M 1 M 2A.M. 1 M 2 G and M 1 M 2 U may encode different amino acids or amino acid analogs from each other, or

[0066] (ii)M 1 M 2 A.M. 1 M 2 G and M 1 M 2 C can encode amino acids or amino acid analogs that are different from each other;

[0067]

[48] ​​The translation system according to any one of

[45] to

[47] , wherein the unnatural amino acid is linked to at least one of the tRNAs of

[36] (a),

[36] (b) and

[42] (c);

[0068]

[49] The translation system according to any one of

[34] to

[48] , which can translate more than 20 amino acids;

[0069]

[50] The translation system according to any one of

[34] to

[49] , which is a cell-free translation system;

[0070]

[51] The translation system according to

[50] , which is a reconstructed cell-free translation system;

[0071]

[52] The translation system according to

[50] or

[51] , comprising a ribosome derived from Escherichia coli;

[0072]

[53] A method for producing a peptide, comprising translating a nucleic acid using the translation system according to any one of

[34] to

[52] ;

[0073]

[54] The method according to

[53] , wherein the peptide has a cyclic portion;

[0074]

[55] A peptide produced by the method according to

[53] or

[54] ;

[0075]

[56] A method for producing a peptide library, comprising translating a nucleic acid library using the translation system according to any one of

[34] to

[52] ;

[0076]

[57] A peptide library produced by the method according to

[56] ;

[0077]

[58] A method for identifying a peptide having binding activity to a target molecule, comprising contacting the target molecule with the peptide library according to

[57] ;

[0078]

[59] A nucleic acid-peptide complex comprising a peptide and a nucleic acid encoding the peptide, wherein the nucleic acid encoding the peptide comprises three codons of the following (A) or (B):

[0079] (A)M 1 M 2 U,M 1 M 2 A and M 1 M 2 G;

[0080] (A)M 1 M 2 C,M 1 M 2 A and M 1 M 2 G;

[0081] And the amino acids corresponding to the three codons are different in the peptide.

[0082]

[60] A library comprising the nucleic acid-peptide complex according to

[59] ;

[0083]

[61] The following compound or its salt:

[0084]

[0085]

[62] A method for producing a mutant tRNA having lysine at position 34 according to the tRNA numbering convention, comprising linking the compound according to

[61] and a nucleic acid fragment constituting tRNA by an enzymatic reaction;

[0086]

[63] A method for producing a mutant tRNA having lysine at position 34 according to the tRNA numbering convention and having an amino acid or an amino acid analogue linked to the 3' terminus, comprising linking the compound according to

[61] , one or more nucleic acid fragments constituting tRNA, and an amino acid or an amino acid analogue by an enzymatic reaction;

[0087]

[64] The following compound or its salt:

[0088]

[0089]

[65] A method for producing a mutant tRNA having agmatidine at position 34 according to the tRNA numbering convention, comprising linking the compound according to

[64] and a nucleic acid fragment constituting tRNA by an enzymatic reaction;

[0090]

[66] A method for producing a mutant tRNA having agmatidine at position 34 according to the tRNA numbering convention and having an amino acid or an amino acid analogue linked to the 3' terminus, comprising linking the compound according to

[64] , one or more nucleic acid fragments constituting tRNA, and an amino acid or an amino acid analogue by an enzymatic reaction;

[0091]

[67] The method according to

[63] or

[66] , wherein the amino acid is an amino acid other than methionine (Met) and isoleucine (Ile);

[0092]

[68] A mutant tRNA produced by the method according to

[62] or

[65] ;

[0093]

[69] A mutant tRNA having an amino acid or an amino acid analog attached to the 3' terminus, produced by the method according to

[63] ,

[66] or

[67] ;

[0094]

[70] A translation system comprising the mutant tRNA according to

[68] and / or

[69] ;

[0095]

[71] A method for producing a peptide, comprising translating a nucleic acid using the translation system according to

[70] ;

[0096]

[72] A method for producing lysine diphosphate or a derivative thereof, or agmatidine diphosphate or a derivative thereof represented by the following formula A,

[0097]

[0098] (in:

[0099] R 1 and R 2 Each independently is H or C 1 -C 3 alkyl,

[0100] L is C 2 -C 6 Straight chain alkylene or C 2 -C 6 Straight chain alkenylene, optionally substituted by one or more selected from hydroxyl and C 1 -C 3 The alkyl group is substituted with a substituent, wherein C 2 -C 6 The carbon atoms of the straight chain alkylene group are optionally substituted by an oxygen atom or a sulfur atom,

[0101] M is a single bond

[0102]

[0103] Wherein the wavy line indicates the point of connection to the carbon atom, the * indicates the point of connection to the hydrogen atom, and the ** indicates the point of connection to the nitrogen atom, provided that when M is a single bond, the H connected to M does not exist).

[0104] The method comprises the following steps:

[0105] The intramolecular cyclization is a compound represented by the following formula B1:

[0106]

[0107] (PG 11 is a protecting group for an amino group)

[0108] To obtain a compound represented by the following formula C1:

[0109]

[0110] (PG 11 Same as above);

[0111] An amine represented by the following formula D1 is introduced:

[0112]

[0113] (Among them, R 1 , R 2 , L, M as above)

[0114] Or a salt of a compound represented by formula C1 to obtain a compound represented by the following formula E1:

[0115]

[0116] (Among them, R 1 , R 2 , L, M, PG 11 Same as above);

[0117] PG 12 and / or PG 13 The compound represented by formula E1 is introduced to obtain a compound represented by the following formula F1A or F1B:

[0118]

[0119] (in:

[0120] R 2 It is C 1 -C 3 alkyl,

[0121] PG 12 is a protecting group for amino groups,

[0122] PG 13 is a protecting group for a carboxyl group or an imino group, and

[0123] R 1 , L, M and PG 11 Same as above,

[0124] The premise is that when M is a single bond, there is no PG 13 hour);

[0125] The acetone compound in the compound represented by formula F1A or F1B is removed and PG is introduced 14 and PG 15 , to obtain a compound represented by the following formula G1A or G1B:

[0126]

[0127] (in:

[0128] R 2 It is C 1 -C 3 alkyl,

[0129] PG 14 is a protecting group for the hydroxyl group,

[0130] PG 15 is a protecting group for the hydroxyl group, and

[0131] R 1 , L, M, PG 11 PG 12 PG 13 Same as above);

[0132] PG 16 Introduced into the compound represented by formula G1A or G1B to obtain the compound represented by the following formula H1A or H1B:

[0133]

[0134] (in:

[0135] R 2 It is C 1 -C 3 alkyl,

[0136] PG 16 is a protecting group for a hydroxyl group and / or an amino group, and

[0137] R 1 , L, M, PG 11 PG 12 PG 13 PG 14 PG 15Same as above);

[0138] Removal of PG from a compound represented by formula H1A or H1B 14 and PG 15 , to obtain a compound represented by formula I1A or I1B:

[0139]

[0140] (in:

[0141] R 2 It is C 1 -C 3 Alkyl, and

[0142] R 1 , L, M, PG 11 PG 12 PG 13 PG 16 Same as above);

[0143] The compound represented by formula I1A or I1B is phosphitated and then oxidized to obtain a compound represented by the following formula J1A or J1B:

[0144]

[0145] (in:

[0146] R 2 It is C 1 -C 3 alkyl,

[0147] PG 17 is a protecting group for the hydroxyl group, and

[0148] R 1 , L, M, PG 11 PG 12 PG 13 and PG 16 Same as above);

[0149] Removal of PG from the compound represented by Formula J1A 11 PG 12 PG 13 and PG 17 , or removing PG from the compound represented by formula J1B 11 PG 13 and PG 17 , to obtain a compound represented by the following formula K1:

[0150]

[0151] (in:

[0152] R 2 Is H or C 1 -C 3 Alkyl, and

[0153] R 1 , R 2 , L, M and PG 16 Ibid.); and

[0154] Removal of PG from the compound represented by formula K1 16 , to obtain a compound represented by formula A;

[0155]

[73] The method according to

[72] , wherein the compound represented by formula A is cytosine diphosphate:

[0156]

[0157] , or agmatidine diphosphate:

[0158]

[0159]

[74] The method according to

[72] , wherein PG 11 is p-bromobenzoyl, optionally substituted benzoyl, pyridinecarbonyl or acetyl;

[0160]

[75] The method according to

[72] , wherein PG 12 It is Fmoc;

[0161]

[76] The method according to

[72] , wherein when M is

[0162]

[0163] PG 13 is methyl, ethyl or optionally substituted benzyl, and when M is

[0164]

[0165] PG 13 is optionally substituted benzyl, Cbz or optionally substituted benzyloxycarbonyl;

[0166]

[77] The method according to

[72] , wherein PG 14 and PG 15 Together they form a di-tert-butylsilyl group;

[0167]

[78] The method according to

[72] , wherein PG 16 It's TOM;

[0168]

[79] The method according to

[72] , wherein PG 17It is cyanoethyl;

[0169]

[80] The method according to

[72] , wherein the intramolecular cyclization is carried out in the presence of diisopropyl azodicarboxylate and triphenylphosphine;

[0170]

[81] The method according to

[72] , wherein the introduction of the amine represented by formula D1 or a salt thereof is carried out in the presence of lithium chloride and DBU;

[0171]

[82] The method according to

[72] , wherein PG 12 Fmoc, used to introduce PG 12 The reagents are (2,5-dioxopyrrolidin-1-yl)(9H-fluoren-9-yl)methyl carbonate and sodium carbonate;

[0172]

[83] The method according to

[72] , wherein PG 13 It is a methyl group, used to introduce PG 13 The reagents are N, N'-diisopropylcarbodiimide, methanol and N, N-dimethyl-4-aminopyridine;

[0173]

[84] The method according to

[72] , wherein the reagent for removing acetone compounds is TFA;

[0174]

[85] The method according to

[72] , wherein PG 14 and PG 15 The di-tert-butylsilyl group is formed together, and the reagent used to introduce the di-tert-butylsilyl group is di-tert-butylsilyl bis(trifluoromethanesulfonate);

[0175]

[86] The method according to

[72] , wherein PG 16 TOM, used to introduce PG 16 The reagents are DIPEA and (triisopropylsilyloxy)methyl chloride;

[0176]

[87] The method according to

[72] , wherein the PG 14 and PG 15 The reagent is a hydrogen fluoride pyridine complex;

[0177]

[88] The method according to

[72] , wherein the reagent for phosphitylation is bis(2-cyanoethyl)-N,N-diisopropylaminophosphoramidite;

[0178]

[89] The method according to

[72] , wherein the reagent used for oxidation is tert-butyl hydroperoxide;

[0179]

[90] The method according to

[72] , wherein the PG 11 PG 12 PG13 and PG 17 The reagents are bis-(trimethylsilyl)acetamide and DBU;

[0180]

[91] The method according to

[72] , wherein the PG 16 The reagent is ammonium fluoride;

[0181]

[92] The method according to

[72] , wherein R 1 It is H;

[0182]

[93] The method according to

[72] , wherein R 2 It is H;

[0183]

[94] The method according to

[72] , wherein C 2 -C 6 Straight chain alkylene or C 2 -C 6 Straight chain alkenylene is C 4 -C 5 Straight chain alkylene or C 4 -C 5 Straight chain alkenylene;

[0184]

[95] The method according to

[72] , wherein L is -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 、-(CH 2 ) 2 -O-CH 2 -、-(CH 2 ) 2 -S-CH 2 -、-CH 2 CH(OH)(CH 2 ) 2 -or-CH 2 CH=CH- (cis or trans);

[0185]

[96] A method for producing lysine diphosphate or a derivative thereof, or agmatidine diphosphate or a derivative thereof represented by the following formula A,

[0186]

[0187] (in:

[0188] R 1 and R 2 Each independently is H or C 1 -C 3 alkyl,

[0189] L is C 2 -C 6 A straight chain alkylene group or optionally one or more selected from hydroxyl and C 1 -C 3 The substituents of the group consisting of alkyl groups are substituted with C 2 -C 6 Straight chain alkenylene, where C 2 -C 6 A carbon atom of a straight-chain alkylene group is replaced by an oxygen atom or a sulfur atom.

[0190] M is a single bond,

[0191]

[0192] where the wavy line indicates the point of attachment to a carbon atom, the * indicates the point of attachment to a hydrogen atom, and the ** indicates the point of attachment to a nitrogen atom, provided that when M is a single bond, the H attached to M does not exist),

[0193] The method comprises the following steps:

[0194] The intramolecular cyclization is a compound represented by the following formula B2:

[0195]

[0196] (PG 21 is a protecting group for an amino group)

[0197] To obtain a compound represented by the following formula C2:

[0198]

[0199] (PG 21 Same as above);

[0200] An amine represented by the following formula D2A or D2B is introduced:

[0201]

[0202] (in:

[0203] R 2 It is C 1 -C 3 alkyl,

[0204] PG 22 is a protecting group for amino groups,

[0205] PG 23 is a protecting group for a carboxyl group or an imino group, and

[0206] R 1 , L and M are the same as above,

[0207] The premise is that when M is a single bond, there is no PG 13 );

[0208] Or a salt of a compound represented by formula C2 to obtain a compound represented by the following formula E2A or E2B:

[0209]

[0210] (in:

[0211] R 2 It is C 1 -C 3 Alkyl, and

[0212] R 1 , L, M, PG 21 PG 22 and PG 23 Same as above);

[0213] Remove the acetone compound from the compound represented by formula E2A or E2B and introduce PG 24 and PG 25 , to obtain a compound represented by the following formula F2A or F2B:

[0214]

[0215] (in:

[0216] R 2 It is C 1 -C 3 alkyl,

[0217] PG 24 is a protecting group for the hydroxyl group,

[0218] PG 25 is a protecting group for the hydroxyl group, and

[0219] R 1 , R 2 , L, M, PG 21 PG 22 and PG 23 Same as above);

[0220] PG 26 Introduced into the compound represented by formula F2A or F2B to obtain the compound represented by the following formula G2A or G2B:

[0221]

[0222] (in:

[0223] R 2 It is C1 -C 3 alkyl,

[0224] PG 26 is a protecting group for the hydroxyl group, and

[0225] R 1 , R 2 , L, M, PG 21 PG 22 PG 23 PG 24 and PG 25 Same as above);

[0226] Removal of PG from a compound represented by formula G2A or G2B 24 and PG 25 , to obtain a compound represented by formula H2A or H2B:

[0227]

[0228] (in:

[0229] R 2 It is C 1 -C 3 Alkyl, and

[0230] R 1 , L, M, PG 21 PG 22 PG 23 and PG 26 Same as above);

[0231] The compound represented by formula H2A or H2B is phosphitated and then oxidized to obtain the compound represented by the following formula I2A or I2B:

[0232]

[0233] (in:

[0234] R 2 It is C 1 -C 3 alkyl,

[0235] PG 27 is a protecting group for the hydroxyl group, and

[0236] R 1 , L, M, PG 21 PG 22 PG 23 and PG 26 Same as above);

[0237] Removal of PG from the compound represented by formula I2A 21PG 22 PG 23 and PG 27 , or removing PG from the compound represented by formula I2B 21 PG 23 and PG 27 , to obtain a compound represented by the following formula J2:

[0238]

[0239] (in:

[0240] R 2 Is H or C 1 -C 3 Alkyl, and

[0241] R 1 , L, M and PG 26 Ibid.); and

[0242] Removal of PG from the compound represented by Formula J2 26 , to obtain a compound represented by formula A;

[0243]

[97] The method according to

[96] , wherein the compound represented by formula A is cytosine diphosphate:

[0244] or

[0245] or agmatidine diphosphate:

[0246]

[0247]

[98] The method according to

[96] , wherein PG 21 is Cbz, optionally substituted benzyloxycarbonyl or optionally substituted benzyl;

[0248]

[99] The method according to

[96] , wherein PG 22 is Cbz, optionally substituted benzyloxycarbonyl or optionally substituted benzyl;

[0249]

[100] The method according to

[96] , wherein when M is

[0250]

[0251] PG 23 is an optionally substituted benzyl group, and when M is

[0252]

[0253] PG 23is optionally substituted benzyl, Cbz or optionally substituted benzyloxycarbonyl;

[0254]

[101] The method according to

[96] , wherein PG 24 and PG 25 Together they form a di-tert-butylsilyl group;

[0255]

[102] The method according to

[96] , wherein PG 26 is tetrahydropyranyl, tetrahydrofuranyl or methoxymethyl;

[0256]

[103] The method according to

[96] , wherein PG 27 It is benzyl;

[0257]

[104] The method according to

[96] , wherein the intramolecular cyclization is carried out in the presence of diisopropyl azodicarboxylate and triphenylphosphine;

[0258]

[105] The method according to

[96] , wherein the introduction of the amine represented by formula D2 or a salt thereof is carried out in the presence of lithium chloride and DBU;

[0259]

[106] The method according to

[96] , wherein the reagent for removing acetone compounds is TFA;

[0260]

[107] The method according to

[96] , wherein PG 24 and PG 25 The di-tert-butylsilyl group is formed together, and the reagent used to introduce the di-tert-butylsilyl group is di-tert-butylsilyl bis(trifluoromethanesulfonate);

[0261]

[108] The method according to

[96] , wherein PG 26 Is a tetrahydropyranyl group, used to introduce PG 26 The reagents are TFA and 3,4-dihydro-2H-pyran;

[0262]

[109] The method according to

[96] , wherein the PG 24 and PG 25 The reagent is tetrabutylammonium fluoride;

[0263]

[110] The method according to

[96] , wherein the reagent for phosphitylation is dibenzyl N,N-diisopropylphosphoramidite;

[0264]

[111] The method according to

[96] , wherein the reagent used for oxidation is Dess-Martin periodinane;

[0265]

[112] The method according to

[96] , wherein PG is removed by catalytic hydrogenation 21PG 22 PG 23 and PG 27 ;

[0266]

[113] The method according to

[96] , wherein the PG 26 The reagent is hydrochloric acid;

[0267]

[114] The method according to

[96] , wherein R 1 It is H;

[0268]

[115] The method according to

[96] , wherein R 2 It is H;

[0269]

[116] The method according to

[96] , wherein C 2 -C 6 Straight chain alkylene or C 2 -C 6 Straight chain alkenylene is C 4 -C 5 Straight chain alkylene or C 4 -C 5 Straight chain alkenylene; and

[0270]

[117] The method according to

[96] , wherein L is -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 、-(CH 2 ) 2 -O-CH 2 -、-(CH 2 ) 2 -S-CH 2 -、-CH 2 CH(OH)(CH 2 ) 2 -or-CH 2 CH=CH- (cis or trans). BRIEF DESCRIPTION OF THE DRAWINGS

[0271] Figure 1 Shown are mass spectra of products formed by RNase fragmentation of tRNA(Glu)uga-CA(UR-1) prepared using a ligation reaction as described in Example 10. The upper panel shows the results for a fragment having a CCCUUGp sequence, and the lower panel shows the results for a fragment having a CCCUGp sequence.

[0272] Figure 2Shown are mass spectra of products formed by RNase fragmentation of tRNA(Glu)Lga-CA(LR-1) prepared using a ligation reaction as described in Example 10. The upper graph shows the results for a fragment having a CCCULGp sequence, the middle graph shows the results for a fragment having a CCCUGp sequence, and the lower graph shows the results for a fragment having a CCCUUGp sequence.

[0273] Figure 3 Shown are mass spectra of products formed by RNase fragmentation of tRNA(Glu)Lag-CA(LR-2) prepared using a ligation reaction as described in Example 10. The upper graph shows the results for a fragment having a CCCULAGp sequence, the middle graph shows the results for a fragment having a CCCUAGp sequence, and the lower graph shows the results for a fragment having a CCCUUAGp sequence.

[0274] Figure 4 Shown are mass spectra of products formed by RNase fragmentation of tRNA(Glu)Lac-CA(LR-3) prepared using a ligation reaction as described in Example 10. The upper graph shows the results for a fragment having the sequence of CCCULACACGp (SEQ ID NO: 197), the middle graph shows the results for a fragment having the sequence of CCCUACACGp, and the lower graph shows the results for a fragment having the sequence of CCCUUACACGp (SEQ ID NO: 198).

[0275] Figure 5 Shown are mass spectra of products formed by RNase fragmentation of tRNA(Glu)Lcc-CA(LR-4) prepared using a ligation reaction as described in Example 10. The upper graph shows the results for a fragment having a CCCULCCACGp (SEQ ID NO: 199) sequence, the middle graph shows the results for a fragment having a CCCUCCACGp sequence, and the lower graph shows the results for a fragment having a CCCUUCCACGp (SEQ ID NO: 200) sequence.

[0276] Figure 6The mass spectrum of tRNA(Asp)Lag-CA(LR-5) prepared by using a ligation reaction as described in Example 10 is shown. The upper figure shows the results for a nucleic acid having the sequence pGGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUULAGGUGCAGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC (SEQ ID NO: 134) (target substance), the middle figure shows the results for a nucleic acid having the sequence pGGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUUAGGUGCAGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC (SEQ ID NO: 201) (a byproduct formed when pLp is not ligated), and the lower figure shows the results for a nucleic acid having the sequence pGGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUUUAGGUGCAG GGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC (SEQ ID NO: 154) (a byproduct formed when pUp instead of pLp is ligated).

[0277] Figure 7 Shown are mass spectra of products formed by RNase fragmentation of tRNA(AsnE2)Lag-CA(LR-6) prepared using a ligation reaction as described in Example 10. The upper graph shows the results for a fragment having an AUULAGp sequence, the middle graph shows the results for a fragment having an AUUAGp sequence, and the lower graph shows the results for a fragment having an AUUUAGp sequence.

[0278] Figure 8 Shown are mass spectra of products formed by RNase fragmentation of tRNA(Glu)Lcg-CA(LR-7) prepared using a ligation reaction as described in Example 10. The upper graph shows the results for a fragment having a CCCULCGp sequence, the middle graph shows the results for a fragment having a CCCUCGp sequence, and the lower graph shows the results for a fragment having a CCCUUCGp sequence.

[0279] Fig. 9 Shown are mass spectra of products formed by RNase fragmentation of tRNA(Glu)Lau-CA(LR-8) prepared using a ligation reaction as described in Example 10. The upper figure shows the results for a fragment having a CCCULAUACGp (SEQ ID NO: 202) sequence, the middle figure shows the results for a fragment having a CCCUAUACGp sequence, and the lower figure shows the results for a fragment having a CCCUUAUACGp (SEQ ID NO: 203) sequence.

[0280] Fig.10 Shown are mass spectra of products formed by RNase fragmentation of tRNA(Agm)ag-CA(AR-1) prepared using a ligation reaction as described in Example 10. The upper graph shows the results for a fragment having a CCCU(Agm)AGp sequence, the middle graph shows the results for a fragment having a CCCUAGp sequence, and the lower graph shows the results for a fragment having a CCCUUAGp sequence.

[0281] Fig.11 1 is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids distinguishing in a single codon box as described in Examples 12 to 13. The codons evaluated were UCU, UCA, and UCG. The vertical axis of the graph shows the amount of peptide translated when each combination of tRNA and mRNA described below is translated (see Table 12 for specific measurements).

[0282] (Left side of the picture)

[0283] tRNA: Compound AAtR-1 (anticodon: aga; amino acid: dA)

[0284] Compound AAtR-2 (anticodon: uga; amino acid: SPh2Cl)

[0285] Compound AAtR-5 (anticodon: cga; amino acid: nBuG)

[0286] mRNA: mR-1 (containing UCU codon)

[0287] mR-2 (containing UCA codon)

[0288] mR-3 (containing UCG codon)

[0289] (Middle side of the picture)

[0290] tRNA: Compound AAtR-1 (anticodon: aga; amino acid: dA)

[0291] Compound AAtR-3 (anticodon: uga; amino acid: SPh2Cl)

[0292] Compound AAtR-5 (anticodon: cga; amino acid: nBuG)

[0293] mRNA: mR-1 (containing UCU codon)

[0294] mR-2 (containing UCA codon)

[0295] mR-3 (containing UCG codon)

[0296] (right side of the picture)

[0297] tRNA: Compound AAtR-1 (anticodon: aga; amino acid: dA)

[0298] Compound AAtR-4 (anticodon: Lga; amino acid: SPh2Cl)

[0299] Compound AAtR-5 (anticodon: cga; amino acid: nBuG)

[0300] mRNA: mR-1 (containing UCU codon)

[0301] mR-2 (containing UCA codon)

[0302] mR-3 (containing UCG codon)

[0303] Fig.12 1 is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids distinguishing in a single codon box as described in Examples 12 to 13. The codons evaluated were CUU, CUA, and CUG. The vertical axis of the graph shows the amount of peptide translated when each combination of tRNA and mRNA described below is translated (see Table 13 for specific measurements).

[0304] (Left side of the picture)

[0305] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0306] Compound AAtR-7 (anticodon: uag; amino acid: Pic2)

[0307] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0308] mRNA: mR-4 (containing CUU codon)

[0309] mR-5 (containing CUA codon)

[0310] mR-6 (containing CUG codon)

[0311] (right side of the picture)

[0312] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0313] Compound AAtR-8 (anticodon: Lag; amino acid: Pic2)

[0314] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0315] mRNA: mR-4 (containing CUU codon)

[0316] mR-5 (containing CUA codon)

[0317] mR-6 (containing CUG codon)

[0318] Fig.13 1 is a graph showing the effect of evaluating the presence or absence of lysine modification on the results of translation of three amino acids that distinguish in a single codon box as described in Examples 12 to 13. The codons evaluated were GUU, GUA, and GUG. The vertical axis of the graph shows the amount of peptide translated when each combination of tRNA and mRNA described below is used for translation (see Table 14 for specific measurements).

[0319] (Left side of the picture)

[0320] tRNA: Compound AAtR-10 (anticodon: aac; amino acid: nBuG)

[0321] Compound AAtR-11 (anticodon: uac; amino acid: Pic2)

[0322] Compound AAtR-13 (anticodon: cac; amino acid: dA)

[0323] mRNA: mR-7 (containing GUU codon)

[0324] mR-8 (containing GUA codon)

[0325] mR-9 (containing GUG codon)

[0326] (right side of the picture)

[0327] tRNA: Compound AAtR-10 (anticodon: aac; amino acid: nBuG)

[0328] Compound AAtR-12 (anticodon: Lac; amino acid: Pic2)

[0329] Compound AAtR-13 (anticodon: cac; amino acid: dA)

[0330] mRNA: mR-7 (containing GUU codon)

[0331] mR-8 (containing GUA codon)

[0332] mR-9 (containing GUG codon)

[0333] Fig.141 is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids that distinguish in a single codon box as described in Examples 12 to 13. The codons evaluated were GGU, GGA, and GGG. The vertical axis of the graph shows the amount of peptide translated when translation was performed using each combination of tRNA and mRNA described below (see Table 15 for specific measurements).

[0334] (Left side of the picture)

[0335] tRNA: Compound AAtR-14 (anticodon: gcc; amino acid: dA)

[0336] Compound AAtR-15 (anticodon: ucc; amino acid: Pic2)

[0337] Compound AAtR-17 (anticodon: ccc; amino acid: MeHph)

[0338] mRNA: MR-10 (containing GGU codon)

[0339] MR-11 (contains GGA codon)

[0340] MR-12 (containing GGG codon)

[0341] (right side of the picture)

[0342] tRNA: Compound AAtR-14 (anticodon: gcc; amino acid: dA)

[0343] Compound AAtR-16 (anticodon: Lcc; amino acid: Pic2)

[0344] Compound AAtR-17 (anticodon: ccc; amino acid: MeHph)

[0345] mRNA: mR-10 (containing GGU codon)

[0346] mR-11 (containing GGA codon)

[0347] mR-12 (containing GGG codon)

[0348] Fig.15 1 is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids distinguishing in a single codon box as described in Examples 12 to 13. The codons evaluated were CUU, CUA, and CUG. The vertical axis of the graph shows the amount of peptide translated when each combination of tRNA and mRNA described below is translated (see Table 16 for specific measurements).

[0349] (Left side of the picture)

[0350] tRNA: Compound AAtR-19 (anticodon: aag; amino acid: nBuG)

[0351] Compound AAtR-20 (anticodon: uag; amino acid: SPh2Cl)

[0352] Compound AAtR-22 (anticodon: cag; amino acid: dA)

[0353] mRNA: mR-4 (containing CUU codon)

[0354] mR-5 (containing CUA codon)

[0355] mR-6 (containing CUG codon)

[0356] (right side of the picture)

[0357] tRNA: Compound AAtR-19 (anticodon: aag; amino acid: nBuG)

[0358] Compound AAtR-21 (anticodon: Lag; amino acid: SPh2Cl)

[0359] Compound AAtR-22 (anticodon: cag; amino acid: dA)

[0360] mRNA: mR-4 (containing CUU codon)

[0361] mR-5 (containing CUA codon)

[0362] mR-6 (containing CUG codon)

[0363] Fig.16 1 is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids distinguishing in a single codon box as described in Examples 12 to 13. The codons evaluated were CUU, CUA, and CUG. The vertical axis of the graph shows the amount of peptide translated when each combination of tRNA and mRNA described below is translated (see Table 17 for specific measurements).

[0364] (Left side of the picture)

[0365] tRNA: Compound AAtR-23 (anticodon: aag; amino acid: nBuG)

[0366] Compound AAtR-24 (anticodon: uag; amino acid: SPh2Cl)

[0367] Compound AAtR-26 (anticodon: cag; amino acid: dA)

[0368] mRNA: mR-4 (containing CUU codon)

[0369] mR-5 (containing CUA codon)

[0370] mR-6 (containing CUG codon)

[0371] (right side of the picture)

[0372] tRNA: Compound AAtR-23 (anticodon: aag; amino acid: nBuG)

[0373] Compound AAtR-25 (anticodon: Lag; amino acid: SPh2Cl)

[0374] Compound AAtR-26 (anticodon: cag; amino acid: dA)

[0375] mRNA: mR-4 (containing CUU codon)

[0376] mR-5 (containing CUA codon)

[0377] mR-6 (containing CUG codon)

[0378] Fig.17 1 is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids distinguishing in a single codon box as described in Examples 12 to 13. The codons evaluated were CUU, CUA, and CUG. The vertical axis of the graph shows the amount of peptide translated when each combination of tRNA and mRNA described below is translated (see Table 18 for specific measurements).

[0379] (Left side of the picture)

[0380] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0381] Compound AAtR-27 (anticodon: uag; amino acid: MeHph)

[0382] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0383] mRNA: mR-4 (containing CUU codon)

[0384] mR-5 (containing CUA codon)

[0385] mR-6 (containing CUG codon)

[0386] (right side of the picture)

[0387] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0388] Compound AAtR-28 (anticodon: Lag; amino acid: MeHph)

[0389] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0390] mRNA: mR-4 (containing CUU codon)

[0391] mR-5 (containing CUA codon)

[0392] mR-6 (containing CUG codon)

[0393] Fig.18 1 is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids that distinguish in a single codon box as described in Examples 12 to 13. The codons evaluated were CUU, CUA, and CUG. The vertical axis of the graph shows the amount of peptide translated when each combination of tRNA and mRNA described below is translated (see Table 19 for specific measurements).

[0394] (Left side of the picture)

[0395] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0396] Compound AAtR-29 (anticodon: uag; amino acid: F3Cl)

[0397] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0398] mRNA: mR-4 (containing CUU codon)

[0399] mR-5 (containing CUA codon)

[0400] mR-6 (containing CUG codon)

[0401] (right side of the picture)

[0402] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0403] Compound AAtR-30 (anticodon: Lag; amino acid: F3Cl)

[0404] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0405] mRNA: mR-4 (containing CUU codon)

[0406] mR-5 (containing CUA codon)

[0407] mR-6 (containing CUG codon)

[0408] Fig.19 1 is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids distinguishing in a single codon box as described in Examples 12 to 13. The codons evaluated were CUU, CUA, and CUG. The vertical axis of the graph shows the amount of peptide translated when each combination of tRNA and mRNA described below is translated (see Table 20 for specific measurements).

[0409] (Left side of the picture)

[0410] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0411] Compound AAtR-31 (anticodon: uag; amino acid: SiPen)

[0412] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0413] mRNA: mR-4 (containing CUU codon)

[0414] mR-5 (containing CUA codon)

[0415] mR-6 (containing CUG codon)

[0416] (right side of the picture)

[0417] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0418] Compound AAtR-32 (anticodon: Lag; amino acid: SiPen)

[0419] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0420] mRNA: mR-4 (containing CUU codon)

[0421] mR-5 (containing CUA codon)

[0422] mR-6 (containing CUG codon)

[0423] Fig. 20is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids that distinguish in a single codon box as described in Examples 12 to 13. The codons evaluated were CGU, CGA, and CGG. The vertical axis of the graph shows the amount of peptide translated when translation was performed using each combination of tRNA and mRNA described below (for specific measured values, see Table 21). tRNA: Compound AAtR-33 (anticodon: gcg; amino acid: dA)

[0424] Compound AAtR-34 (anticodon: Lcg; amino acid: Pic2)

[0425] Compound AAtR-35 (anticodon: ccg; amino acid: nBuG)

[0426] mRNA: mR-13 (containing CGU codon)

[0427] mR-14 (containing CGA codon)

[0428] mR-15 (containing CGG codon)

[0429] Fig.21 is a graph showing the results of evaluating the effect of the presence or absence of lysine modification on the translation of three amino acids that distinguish in a single codon box as described in Examples 12 to 13. The codons evaluated were AUU, AUA, and AUG. The vertical axis of the graph shows the amount of peptide translated when translation was performed using each combination of tRNA and mRNA described below (see Table 22 for specific measured values). tRNA: Compound AAtR-36 (anticodon: aau; amino acid: nBuG)

[0430] Compound AAtR-37 (anticodon: Lau; amino acid: Pic2)

[0431] Compound AAtR-38 (anticodon: cau; amino acid: dA)

[0432] mRNA: mR-16 (including AUU codon)

[0433] mR-17 (including AUA codon)

[0434] mR-18 (including AUG codon)

[0435] Fig. 22It is a figure showing the results of evaluating the presence or absence of agmatidine modification on the effect of translation of three amino acids distinguishing in a single codon box as described in Examples 12 to 13. The codons evaluated are CUU, CUA and CUG. The vertical axis of the figure shows the amount of peptide translated when each combination of tRNA and mRNA described below is translated (for specific measured values, see Table 23).

[0436] (Left side of the picture)

[0437] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0438] Compound AAtR-39 (anticodon: uag; amino acid: SPh2Cl)

[0439] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0440] mRNA: mR-4 (containing CUU codon)

[0441] mR-5 (containing CUA codon)

[0442] mR-6 (containing CUG codon)

[0443] (right side of the picture)

[0444] tRNA: Compound AAtR-6 (anticodon: aag; amino acid: nBuG)

[0445] Compound AAtR-40 (anticodon: (Agm)ag; amino acid: SPh2Cl)

[0446] Compound AAtR-9 (anticodon: cag; amino acid: dA)

[0447] mRNA: mR-4 (containing CUU codon)

[0448] mR-5 (containing CUA codon)

[0449] mR-6 (containing CUG codon) DETAILED DESCRIPTION

[0450] I. Definitions

[0451] For the purpose of interpreting this specification, the following definitions will apply, and whenever applicable, terms used in the singular will also include the plural, and vice versa. It should be understood that the terms used herein are only for the purpose of describing specific embodiments and are not restrictive. If any of the following definitions conflict with any document incorporated herein by reference, the following definitions shall prevail.

[0452] "Codon" refers to a group of three nucleosides (triplets) corresponding to each amino acid when the genetic information in the living body is translated into protein. For DNA, four bases are used, adenine (A), guanine (G), cytosine (C) and thymine (T). For mRNA, four bases are used, adenine (A), guanine (G), cytosine (C) and uracil (U). The table showing the correspondence between each codon and amino acid is called a genetic code table or a codon table, and 20 kinds of amino acids are assigned to 61 codons, excluding stop codons (Table 1). The genetic code table shown in Table 1 is applicable to almost all eukaryotic organisms and prokaryotes (true bacteria and archaea); therefore, it is called a standard genetic code table or a universal genetic code table. In the present disclosure, the genetic code table for naturally occurring organisms is called a natural genetic code table, which is distinguished from an artificially reprogrammed genetic code table (the correspondence between codons and amino acids is transformed). In the genetic code table, four codons that have the same first and second letters and differ only in the third letter are usually grouped into a box, which is called a codon box.

[0453] [Table 1]

[0454]

[0455] In the present disclosure, a codon in an mRNA may be represented as "M 1 M 2 M 3 In this paper, M 1 、M 2 and M 3 The nucleotides represent the first, second, and third letters of the codon, respectively.

[0456] "Anticon" refers to three consecutive nucleosides on tRNA, corresponding to the codon on mRNA. Similar to mRNA, anticodon uses four bases, adenine (A), guanine (G), cytosine (C) and uracil (U). In addition, modified bases obtained by modifying these bases can be used. When the codon is specifically recognized by the anticodon, the genetic information on the mRNA is read and translated into protein. The codon sequence in the 5' to 3' direction on the mRNA is complementary to the anticodon sequence in the 5' to 3' direction on the tRNA; therefore, complementary nucleotide pairs are formed between the first, second and third letter nucleosides of the codon and the third, second and first letter nucleosides of the anticodon, respectively.

[0457] In the present disclosure, the anticodon in tRNA can be represented by “N 1 N 2 N 3 " indicates. Among them, N 1、N 2 and N 3 N represents the first, second, and third letter of the anticodon, respectively. According to the tRNA numbering convention described below, N 1 、N 2 and N 3 They are numbered as positions 34, 35, and 36 of tRNA respectively.

[0458] In the present disclosure, combinations of nucleic acids that can form thermodynamically stable base pairs are referred to as being "complementary" to each other. In addition to Watson-Crick base pairs, such as adenosine and uridine (AU) and guanosine and cytidine (GC), combinations of nucleic acids that form non-Watson-Crick base pairs, such as guanosine and uridine (GU), inosine and uridine (IU), inosine and adenosine (IA), and inosine and cytidine (IC) may also be included in the "complementary" nucleic acid combinations of the present disclosure. In particular, between the first letter of the codon and the third letter of the anticodon, and between the second letter of the codon and the second letter of the anticodon, only Watson-Crick base pairs are allowed to form, while the space between the third letter of the codon and the first letter of the anticodon has some fluctuations (swings); therefore, non-Watson-Crick base pairs, such as those described above (swing hypothesis), may be allowed to form.

[0459] "Messenger RNA (mRNA)" refers to RNA that carries genetic information that can be translated into proteins. Genetic information is encoded on mRNA in the form of codons, and each of these codons corresponds to one of all 20 different amino acids. Protein translation starts with the start codon and ends with the stop codon. In principle, the start codon in eukaryotes is AUG, but in prokaryotes (eubacteria and archaea), GUG and UUG can be used as start codons in addition to AUG. AUG is the codon that encodes methionine (Met), and in eukaryotes and archaea, translation starts directly from methionine. On the other hand, in eubacteria, only the start codon AUG corresponds to N-formylmethionine (fMet); therefore, translation starts from formylmethionine. There are three stop codons: UAA (ochre), UAG (amber), and UGA (milky white). When the stop codon is recognized by a protein called a translation termination factor (release factor (RF)), the peptide chain synthesized to that point dissociates from the tRNA, and the translation process ends.

[0460] "Transfer RNA (tRNA)" refers to a short RNA of 100 or fewer bases that mediates peptide synthesis using mRNA as a template. In terms of secondary structure, it has a clover-like structure consisting of three stem loops (D arm, anticodon arm and T arm) and a stem (acceptor stem). Depending on the tRNA, additional variable loops may be included. The anticodon arm has a region consisting of three consecutive nucleosides, called an anticodon, and when the anticodon forms a base pair with the codon on the mRNA, the codon is recognized. At the same time, at the 3' end of the tRNA there is a nucleic acid sequence (CCA sequence) consisting of cytidine-cytidine-adenosine, and amino acids are added to the adenosine residue at the end (specifically, the 2nd or 3rd hydroxyl of the ribose of the adenosine residue forms an ester bond with the carboxyl group of the amino acid). The tRNA to which amino acids have been added is called aminoacyl tRNA. In the present disclosure, aminoacyl tRNA is also included in the definition of tRNA. In addition, as described later, it is known to remove 2 terminal residues (C and A) from the CCA sequence of tRNA, and then use it for the method of the synthesis of aminoacyl-tRNA. Such tRNA with 3' end CA sequence removed is also included in the definition of tRNA in the present disclosure. Amino acids are added to tRNA in vivo by an enzyme called aminoacyl-tRNA synthetase (aaRS or ARS). Generally, each amino acid has an aminoacyl-tRNA synthetase, and each aminoacyl-tRNA synthetase only specifically recognizes a specific tRNA as a substrate for multiple tRNAs; therefore, the corresponding relationship between tRNA and amino acid is strictly controlled.

[0461] Each nucleoside in tRNA is numbered according to the tRNA numbering convention (Sprinzl et al., Nucleic Acids Res (1998) 26: 148-153). For example, the anticodon is numbered from 34 to 36, and the CCA sequence is numbered from 74 to 76.

[0462] "Initiator tRNA" is a specific tRNA used at the start of mRNA translation. The initiator tRNA linked to the initiator amino acid is catalyzed by the translation initiation factor (IF), introduced into the ribosome, and binds to the start codon on the mRNA, thereby initiating translation. Since AUG, which is a methionine codon, is generally used as the initiator codon, the initiator tRNA has an anticodon corresponding to AUG and has methionine (formylmethionine in prokaryotes) linked to the initiator amino acid as the initiator amino acid. Examples of initiator tRNA include tRNA fMet (SEQ ID NOs: 10 and 11).

[0463] "Elongator tRNA" is a tRNA used for peptide chain elongation reaction during translation. In peptide synthesis, the amino acid-linked elongator tRNA is sequentially transported to the ribosome by the GTP-bound translation elongation factor (EF) EF-Tu / eEF-1, which promotes the elongation reaction of the peptide chain. Examples of elongator tRNA include tRNAs corresponding to various amino acids (SEQ ID NOs: 1 to 9 and 12 to 50).

[0464] "Lysine" is a modified nucleoside also known as 2-lysylcytidine (k2C or L). Lysine is used as the first letter nucleoside of the anticodon in the tRNA corresponding to isoleucine (tRNAIle2) in true bacteria. tRNA Ile 2 is synthesized in a precursor state carrying the anticodon CAU, and then the first letter cytidine (C) of the anticodon is transformed (converted) into lysine (k2C) by an enzyme called tRNA Ile-lysine synthetase (TilS). As a result, tRNAIle2 carrying the anticodon k2CAU is provided (Muramatsu et al., J Biol Chem (1988) 263: 9261-9267; and Suzuki et al., FEBS Lett (2010) 584: 272-277). It is known that the anticodon k2CAU only specifically recognizes the AUA codon of isoleucine. In addition, it is believed that isoleucyl-tRNA synthetase recognizes tRNA Ile2 as a substrate, and aminoacylation of tRNA Ile2 (addition of isoleucine thereto) occurs only when the anticodon is modified to k2CAU. The amino acid sequence of E. coli TilS is shown in SEQ ID NO:51.

[0465] "Agmatidine" is a modified nucleoside also known as 2-agmatinylcytidine (agm2C or Agm). Agmatidine is used as the first letter nucleoside of the anticodon in the tRNA corresponding to isoleucine (tRNA Ile2) in archaea. tRNA Ile2 is synthesized in a precursor state carrying the anticodon CAU, and then the first letter cytidine (C) of the anticodon is transformed (converted) into agmatidine (agm2C) by an enzyme called tRNA Ile-agmatidine synthetase (TiaS). As a result, tRNAIle2 carrying the anticodon agm2CAU is provided (Ikeuchi et al., Nat Chem Biol (2010) 6 (4): 277-282). It is known that the anticodon agm2CAU only specifically recognizes the AUA codon of isoleucine. Furthermore, it is believed that isoleucyl-tRNA synthetase recognizes tRNAIle2 as a substrate, and aminoacylation of tRNAIle2 (addition of isoleucine thereto) occurs only when the anticodon is modified to agm2CAU. The amino acid sequence of TiaS of the archaeon Methanosarcina acetivorans is shown as SEQ ID NO:52.

[0466] <Definition of Substituents, etc.>

[0467] In the present disclosure, "alkyl" refers to a monovalent group derived from an aliphatic hydrocarbon by removing an arbitrary hydrogen atom; its backbone does not contain heteroatoms or unsaturated carbon-carbon bonds; and it has a hydrocarbon group or a subset of hydrocarbon group structures containing hydrogen and carbon atoms. The carbon chain length n ranges from 1 to 20. Examples of alkyl groups include C 2 -C 10 Alkyl, C 1 -C 6 Alkyl and C 1 -C 3 Specific examples of the alkyl group include methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, tert-butyl, sec-butyl, 1-methylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1,2-dimethylpropyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1,1,2,2-tetramethylpropyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, isopentyl and neopentyl.

[0468] In the present disclosure, "cycloalkyl" refers to a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, including monocyclic, bicyclic and spirocyclic rings. Examples of cycloalkyl groups include C 3 -C 10 Specific examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and bicyclo[2.2.1]heptyl.

[0469] In the present disclosure, an "alkenyl group" is a monovalent group having at least one double bond (two adjacent sp2 carbon atoms). Depending on the arrangement of the double bond and substituents (if present), the double bond geometry may be trans (entgegen) (E) or cis (zusammen) (Z), as well as cis or trans configuration. It may be a straight chain or branched alkenyl group, including straight chain alkenyl groups containing internal alkenes. Examples of alkenyl groups include C 2 -C 10 Alkenyl and C 2 -C 6 Specific examples of alkenyl groups include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl (including cis and trans forms), 3-butenyl, pentenyl, and hexenyl.

[0470] In the present disclosure, an "alkynyl group" is a monovalent group having at least one triple bond (two adjacent SP carbon atoms). It can be a straight chain or branched chain alkynyl group, and includes an inner alkylene group. Examples of alkynyl groups include C 2 -C 10 Alkynyl and C 2 -C 6 Alkynyl, specific examples include ethynyl, 1-propynyl, propargyl, 3-butynyl, pentynyl, hexynyl, 3-phenyl-2-propynyl, 3-(2'-fluorophenyl)-2-propynyl, 2-hydroxy-2-propynyl, 3-(3-fluorophenyl)-2-propynyl and 3-methyl-(5-phenyl)-4-pentynyl.

[0471] In the present disclosure, "aryl" refers to a monovalent aromatic hydrocarbon ring. Examples of aryl groups include C 6 -C 10 Specific examples of the aryl group include phenyl and naphthyl (eg, 1-naphthyl and 2-naphthyl).

[0472] In the present disclosure, "heteroaryl" refers to a monovalent aromatic ring group containing heteroatoms in the atoms constituting the ring, and may be partially saturated. The ring may be a monocyclic ring or a fused bicyclic ring (e.g., a bicyclic heteroaryl formed by fusion with benzene or a monocyclic heteroaryl). The number of atoms constituting the ring is, for example, 5 to 10 (5- to 10-membered heteroaryl). The number of heteroatoms contained in the atoms constituting the ring is, for example, 1 to 5. Specific examples of heteroaryl groups include furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, benzofuranyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, quinolyl, isoquinolyl, cinnamyl, quinazolinyl, quinoxalinyl, benzodioxolane, indolizinyl and imidazopyridinyl.

[0473] In the present disclosure, "arylalkyl (aralkyl)" is a group containing an aryl group and an alkyl group, and for example refers to a group in which at least one hydrogen atom of the above-mentioned alkyl group is substituted with an aryl group. Examples of the aralkyl group include C 5 -C 10 Aryl C 1 -C 6 Alkyl group, specific examples include benzyl group.

[0474] In the present disclosure, "alkylene" refers to a divalent group derived by further removing one arbitrary hydrogen atom from the above-mentioned "alkyl", and may be linear or branched. Examples of linear alkylene include C 2 -C 6 Straight chain alkylene, C 4 -C 5 Straight chain alkylene, etc. Specific examples include -CH 2 -、-(CH 2 ) 2 -、-(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 - and - (CH 2 ) 6 -. Examples of branched alkylene groups include C 2 -C 6 Branched alkylene and C 4 -C 5 Branched alkylene. Specific examples include -CH(CH 3 )CH 2 -、-C(CH 3 ) 2 -、-CH(CH 3)CH 2 CH 2 -、-C(CH 3 ) 2 CH 2 -、-CH 2 CH(CH 3 )CH 2 -、CH 2 C(CH 3 ) 2 -, and -CH 2 CH 2 CH(CH 3 )-.

[0475] In the present disclosure, "alkenylene" refers to a divalent group derived by further removing one arbitrary hydrogen atom from the above-mentioned "alkenyl", and may be linear or branched. Depending on the arrangement of double bonds and substituents (if present), it may take the form of trans (entgegen) (E) or cis (zusammen) (Z), as well as cis or trans configuration. Examples of straight-chain alkenylene include C 2 -C 6 Straight chain alkenylene and C 4 -C 5 Straight chain alkenylene. Specific examples include -CH=CH-, -CH=CHCH 2 -、-CH 2 CH=CH-、-CH=CHCH 2 CH 2 -、-CH 2 CH=CHCH 2 -、-CH 2 CH 2 CH=CH-、-CH=CHCH 2 CH 2 CH 2 -、-CH 2 CH=CHCH 2 CH 2 -、-CH 2 CH 2 CH=CHCH 2 -and-CH 2 CH 2 CH 2 CH=CH-.

[0476] In the present disclosure, "arylene" refers to a divalent group derived by further removing an arbitrary hydrogen atom from the above aryl group. The ring may be a monocyclic ring or a condensed ring. The number of atoms constituting the ring is not particularly limited, for example, 6 to 10 (C 6 -C 10Specific examples of the arylene group include a phenylene group and a naphthylene group.

[0477] In the present disclosure, "heteroarylene" refers to a divalent group derived by further removing an arbitrary hydrogen atom from the above-mentioned heteroaryl. The ring can be a monocyclic or condensed ring. The number of atoms constituting the ring is not particularly limited, but is, for example, 5 to 10 (5 to 10 yuan heteroarylene). As heteroarylene, specific examples include pyrrole diyl, imidazole diyl, pyrazole diyl, pyridine diyl, pyridazine diyl, pyrimidine diyl, pyrazine diyl, triazole diyl, triazine diyl, isoxazole diyl, oxazole diyl, oxadiazole diyl, isothiazole diyl, thiazole diyl, thiadiazole diyl, furan diyl and thiophene diyl.

[0478] "Translation system" in the present disclosure is defined as a concept including a method for translating peptides and a kit for translating peptides. The translation system generally includes ribosomes, translation factors, tRNA, amino acids, aminoacyl-tRNA synthetases (aaRS) and factors required for peptide translation reactions, such as ATP and GTP, as constituent components. The main types of translation systems include translation systems utilizing living cells and translation systems utilizing cell extract solutions (cell-free translation systems). As a translation system utilizing living cells, a known example is a system (Nowak et al., Science (1995) 268: 439-442) in which required aminoacyl-tRNA and mRNA are introduced into living cells such as African clawed frog oocytes and mammalian cells by microinjection or lipofection to translate peptides. Known examples of cell-free translation systems include translation systems utilizing an extract solution from Escherichia coli (Chen et al., Methods Enzymol (1983) 101: 674-690), yeast (Gasior et al., J Biol Chem (1979) 254: 3965-3969), wheat germ (Erickson et al., Methods Enzymol (1983) 96: 38-50), rabbit reticulocytes (Jackson et al., Methods Enzymol (1983) 96: 50-74), HeLa cells (Barton et al., Methods Enzymol (1996) 275: 35-57), or insect cells (Swerdel et al., Comp Biochem Physiol B (1989) 93: 803-806), etc. Such a translation system can be appropriately prepared by a method known to those skilled in the art or a similar method. The cell-free translation system also includes a translation system constructed by isolating and purifying each factor required for peptide translation and reconstruction (reconstructed cell-free translation system) (Shimizu et al., Nat Biotech (2001) 19: 751-755). The reconstructed cell-free translation system may generally include ribosomes, amino acids, tRNA, aminoacyl-tRNA synthetase (aaRS), translation initiation factors (e.g., IF1, IF2, and IF3), translation elongation factors (e.g., EF-Tu, EF-Ts, and EF-G), translation termination factors (e.g., RF1, RF2, and RF3), ribosome recycling factors (RRF), NTPs as energy sources, energy regeneration systems, and other factors required for translation. When a transcription reaction from DNA is also performed, RNA polymerase and the like may be further included. The various factors contained in the cell-free translation system may be isolated and purified by methods well known to those skilled in the art, and the reconstructed cell-free translation system may be appropriately constructed using them.Alternatively, commercially available reconstituted cell-free translation systems, such as those from Gene Frontier, can be used. or from New England BioLabs For the reconstructed cell-free translation system, the desired translation system can be constructed by reconstructing only the necessary components among the translation system components.

[0479] Aminoacyl-tRNA is synthesized by a specific combination of amino acid, tRNA and aminoacyl-tRNA synthetase, and is used for peptide translation. Instead of the above combination, aminoacyl-tRNA can be directly used as a component of the translation system. Especially, when it is difficult to use aminoacyl-tRNA synthetase aminoacylated amino acid such as non-natural amino acid for translation, it is necessary to use the tRNA aminoacylated with non-natural amino acid in advance as a component.

[0480] Translation is initiated by adding mRNA to the translation system. The mRNA generally contains a sequence encoding the target peptide, and may further contain a sequence for improving the efficiency of the translation reaction (e.g., a Shine-Dalgarno (SD) sequence in prokaryotes, or a Kozac sequence in eukaryotes). Pre-transcribed mRNA may be added directly to the system, or a template DNA containing a promoter and an RNA polymerase suitable for DNA (e.g., a T7 promoter and T7 RNA polymerase) may be added to the system instead of the mRNA, so that the mRNA will be transcribed from the template DNA.

[0481] II. Compositions and Methods

[0482] <Mutated tRNA>

[0483] On the one hand, the present disclosure provides modified tRNA. Specifically, the present invention provides mutant tRNA produced by modifying tRNA. The tRNA to be modified can be a natural tRNA derived from any organism (e.g., E. coli), or a non-natural tRNA obtained by artificially synthesizing a sequence different from the natural tRNA sequence. Alternatively, they can be tRNAs obtained by artificially synthesizing a sequence identical to the natural tRNA sequence. In the present disclosure, any modification introduced into tRNA is an artificial modification, and any mutant tRNA produced by modification has a nucleic acid sequence that does not exist in nature.

[0484] In some embodiments, the tRNA modification in the present disclosure refers to introducing at least one modification selected from the following groups into one or more nucleosides constituting tRNA: (i) addition (adding any new nucleoside to an existing tRNA), (ii) deletion (deleting any nucleoside from an existing tRNA), (iii) replacement (replacing any nucleoside in an existing tRNA with another arbitrary nucleoside), (iv) insertion (adding a new arbitrary nucleoside between any two nucleosides in an existing tRNA), and (v) modification (changing the partial structure (e.g., nucleotide or sugar moiety) of any nucleoside in an existing tRNA to another structure). Any structure of tRNA (e.g., D arm, anticodon arm, T arm, acceptor stem, variable loop, etc.) can be modified. In certain embodiments, the tRNA modification in the present disclosure is performed on the anticodon contained in the anticodon arm. In a further embodiment, the tRNA modification in the present disclosure is performed on at least one of the first, second, and third letter nucleosides of the anticodon. According to the nucleoside numbering rule in tRNA, the first, second, and third letter nucleosides of the anticodon correspond to the 34th, 35th, and 36th positions of tRNA, respectively. In this article, the first, second and third letter nucleosides of the anticodon can be represented by N, 1 、N 2 and N 3 . In certain embodiments, the tRNA modification in the present disclosure includes modifying the nucleoside of the first letter of the anticodon. The number of nucleosides modified in the tRNA of the present disclosure can be any number not less than 1. In some embodiments, the number of nucleosides modified in the tRNA of the present disclosure is 20 or less, 15 or less, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1. In another embodiment, the nucleic acid sequence of the modified tRNA has 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity compared to the nucleic acid sequence before modification.

[0485] In a specific embodiment, tRNA modification in the present disclosure refers to replacing one or more of the nucleosides constituting tRNA. Regarding the type of nucleosides, the substituted nucleosides can be any nucleosides present in natural tRNA or any nucleosides not present in natural tRNA (synthesized nucleosides). In addition to the four typical nucleosides adenosine, guanosine, cytidine and uridine, natural tRNA also includes modified forms obtained by modifying these four nucleosides (modified nucleosides). In some embodiments, the nucleosides present in the natural tRNA can be selected from the following nucleosides: adenosine (A); cytidine (C); guanosine (G); uridine (U); 1-methyladenosine (m1A); 2-methyladenosine (m2A); N6-isopentenyl adenosine (i6A); 2-methylthio-N6-isopentenyl adenosine (ms2i6A); N6-methyladenosine (m6A); N6-threonylaminoformyl adenosine (t6A); N6-methyl-N6-threonylaminoformyl adenosine (m6t6A); 2-methylthio-N6-threonylaminoformyl adenosine (ms2t6A); 2'-O-methyladenosine (Am); inosine (I); 1-methylinosine (m1I); 2'-O-ribosyladenosine (phosphate) (Ar(p)); N6-(cis-hydroxyisopentenyl)adenosine (io6A); 2-thiocytidine (s2C); 2'-O-methylcytidine (Cm); N4-acetylcytidine (ac4C); 5-methylcytidine (m5C); 3-methylcytidine (m3C); lysine (k2C); 5-formylcytidine (f5C); 2'-O-methyl-5-formylcytidine (f5Cm); agmatidine (agm2C); 2'-O-ribosylguanosine (phosphate) (Gr(p)); 1-methylguanosine (m1G); N 2-methylguanosine (m2G); 2'-O-methylguanosine (Gm); N2,N2-dimethylguanosine (m22G); N2,N2,2'-O-trimethylguanosine (m22Gm); 7-methylguanosine (m7G); archaeoside (G*); quercetin (Q); mannosylquercetin (manQ); galactosylquercetin (galQ); whitinoside (yW); peroxywhitinoside (o2yW ); 5-methylaminomethyluridine (mnm5U); 2-thiouridine (s2U); 2'-O-methyluridine (Um); 4-thiouridine (s4U); 5-carbamoylmethyluridine (ncm5U); 5-methoxycarbonylmethyluridine (mcm5U); 5-methylaminomethyl-2-thiouridine (mnm5s2U); 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2 U); uridine 5-hydroxyacetic acid (cmo5U); 5-methoxyuridine (mo5U); 5-carboxymethylaminomethyluridine (cmnm5U); 5-carboxymethylaminomethyl-2-thiouridine (cmnm5s2U); 3-(3-amino-3-carboxypropyl)uridine (acp3U); 5-(carboxyhydroxymethyl)uridine methyl ester (mchm5U); 5-carboxymethylaminomethyl-2'-O-methyluridine (cmnm5Um); 5-carbamoylmethyl-2'-O-methyluridine (ncm5Um); dihydrouridine (D); pseudouridine (Ψ); 1-methylpseudouridine (m1Ψ); 2'-O-methylpseudouridine (Ψm); 5-methyluridine (m5U); 5-methyl-2-thiouridine (m5s2U); and 5,2'-O-dimethyluridine (m5Um). In certain embodiments, one or more nucleosides constituting the tRNA of the present disclosure are replaced by lysine or agmatidine. Nucleoside derivatives obtained by modifying a portion of the nucleoside structure present in the above-mentioned natural tRNA (e.g., nucleotide moiety) can also be used for substitution. In certain embodiments, one or more nucleosides constituting the tRNA of the present disclosure are replaced by lysine derivatives or agmatidine derivatives.

[0486] The modified tRNA in the present disclosure can be appropriately selected from tRNAs having any nucleic acid sequence. In some embodiments, tRNA is any one of tRNA Ala, tRNA Arg, tRNA Asn, tRNA Asp, tRNA Cys, tRNA Gln, tRNA Glu, tRNAGly, tRNA His, tRNA Ile, tRNA Leu, tRNA Lys, tRNA Met, tRNAPhe, tRNA Pro, tRNA Ser, tRNA Thr, tRNA Trp, tRNA Tyr, and tRNAVal. In addition to the above 20 tRNAs, tRNA fMet, tRNA Sec (selenocysteine), tRNA Pyl (pyrrolysine), tRNAAsnE2, etc. can also be used. In a specific embodiment, tRNA is any one of tRNAGlu, tRNA Asp, and tRNA AsnE2. For some tRNAs, exemplary nucleic acid sequences are shown in SEQ ID NOs: 1 to 50. The term "tRNA body" is sometimes used to refer to the main part of tRNA (the main part of the structure, consisting of nucleic acid).

[0487] Furthermore, in the present disclosure, tRNA can be expressed as follows.

[0488] - "tRNAXxx" or "tRNA(Xxx)" ...means the tRNA (full length) corresponding to amino acid Xxx (eg, tRNA Glu or tRNA(Glu)).

[0489] - "tRNA(Xxx)nnn" ...means a tRNA corresponding to amino acid Xxx, which is a tRNA (full length) having an anticodon sequence of nnn (eg, tRNA(Glu)uga or tRNA(Glu)Lga)).

[0490] - "tRNA(Xxx)nnn-CA" ...means tRNA corresponding to amino acid Xxx, which is tRNA with an anticodon sequence of nnn (eg, tRNA(Glu)uga-CA and tRNA(Glu)Lga-CA) (the CA sequence at the 3' end has been removed).

[0491] In certain embodiments, the tRNA modification of the present disclosure includes replacing the first nucleoside (N 1) is replaced with any one of lysine, lysine derivatives, agmatine or agmatine derivatives. Herein, a lysine derivative refers to a molecule produced by modifying a portion of the structure of lysine (e.g., a nucleotide portion), and when used as a portion of an anticodon, it has the same codon discrimination ability (ability to form complementary base pairs) as lysine. In addition, agmatine derivative refers to a molecule produced by modifying a portion of the structure of agmatine (e.g., a nucleotide portion), and when used as a portion of an anticodon, it has the same codon discrimination ability (ability to form complementary base pairs) as agmatine.

[0492] Lysine in natural tRNA is synthesized by the action of an enzyme called tRNAIle-lysine synthetase (TilS). TilS has the activity of specifically recognizing the tRNA corresponding to isoleucine (tRNA Ile2) as a substrate and converting the first letter of its anticodon (N 1 ) is transformed (converted) into lysine (k2C). The lysine in the tRNA disclosed herein may be lysine synthesized with or without TilS mediation.

[0493] In the former case (when lysine is synthesized by TilS), the tRNA of the present disclosure can be recognized as a substrate by TilS. That is, when N in the tRNA before modification 1 When it is cytidine, TilS can convert cytidine into lysine. 1 Whether the cytidine at the position of N can be transformed into lysine by TilS, for example, by preparing TilS by gene recombination technology or extracting TilS from biological materials, and then mixing it with N 1 The tRNA containing N is reacted with cytidine under appropriate conditions, and then lysine in the reaction product is detected to confirm (see, for example, Suzuki et al., FEBS Lett (2010) 584: 272-277). Alternatively, the tRNA containing N is reacted with cytidine under appropriate conditions, and then lysine in the reaction product is detected to confirm (see, for example, Suzuki et al., FEBS Lett (2010 1 The tRNA for cytidine is introduced into cells that endogenously express TilS or cells that express TilS through gene recombination technology, and the introduced tRNA is reacted with TilS in the cell under appropriate conditions, and then the cytidine contained in the tRNA is detected for confirmation. In one embodiment of the present disclosure, when N in the tRNA before modification is 1 When it is cytidine, cytidine can be converted into lysine by TilS catalysis.

[0494] On the other hand, in the latter case (when lysine is synthesized without TilS mediation), the tRNA of the present disclosure cannot be recognized as a substrate by TilS. That is, even if the N 1is cytidine, TilS cannot transform cytidine into lysine. In this case, lysine and tRNA containing lysine can be synthesized by a method (e.g., a chemical synthesis method) that does not use TilS. Examples of such synthesis methods are shown in the embodiments described later. In one embodiment of the present disclosure, if N in the tRNA before transformation 1 If tRNA is cytidine, then cytidine cannot be converted to lysine by TilS. The condition under which TilS cannot catalyze the conversion of cytidine to lysine can be expressed as follows: when 10 μg / mL TilS and 1 μM tRNA are incubated at 37°C in 100 mM Hepes-KOH (pH 8.0), 10 mM KCl, 10 mM MgCl 2 When the reaction is carried out in 2 mM DTT, 2 mM ATP and 100 μM lysine for 2 hours, if the activity of converting the cytidine of the natural substrate tRNAIle2 into lysine is 1, the activity of converting the cytidine of the target tRNA into lysine by TilS is reduced by 10 times or more, 20 times or more, 40 times or more, 100 times or more, 200 times or more, or 400 times or more. When the catalytic activity of TilS is reduced, only a large amount of N 1 Still a low-purity target product of a non-modified tRNA for cytidine; Therefore, it may be more advantageous to synthesize lysine by a method (e.g., chemical synthesis) without using TilS rather than by a method using TilS. In a specific embodiment, TilS is TilS from Escherichia coli. In another embodiment, TilS is a wild-type TilS from Escherichia coli with an amino acid sequence of SEQ ID NO:51.

[0495] Furthermore, it has been reported that TilS retains a certain amount of tRNA lysine synthesis ability even after some nucleosides in tRNAIle2 have been transformed into other nucleosides (Ikeuchi et al., Mol Cell (2005) 19:235-246).

[0496] Agmatine in natural tRNA is synthesized by the action of an enzyme called tRNAIle-agmatine synthetase (TiaS). TiaS specifically recognizes the tRNA corresponding to isoleucine (tRNA Ile2) as a substrate and has the function of converting the first letter of its anticodon (N 1 ) into agmatine (agm2C). The agmatine in the tRNA disclosed herein may be agmatine synthesized with or without TiaS mediation.

[0497] In the former case (when agmatine is synthesized by TiaS), the tRNA of the present disclosure can be recognized as a substrate by TiaS. That is, when N in the tRNA before modification 1 When it is cytidine, TiaS can convert cytidine into agmatine. 1 Whether the cytidine at the position of N can be transformed into agmatine by TiaS can be prepared by, for example, gene recombination technology or by extracting TiaS from biological materials, and then reacting TiaS with N 1 The tRNA for cytidine is reacted under appropriate conditions, and then agmatine is detected in the reaction product to confirm (see, for example, Ikeuchi et al., Nat Chem Biol (2010) 6(4): 277-282). Alternatively, the tRNA for cytidine can be used to convert N 1 The tRNA for cytidine is introduced into a cell endogenously expressing TiaS or a cell expressing TiaS by gene recombination technology, and the introduced tRNA is reacted with TiaS in the cell under appropriate conditions, and then the agmatine contained in the tRNA is detected for confirmation. In one embodiment of the present invention, when N in the tRNA before modification is 1 When it is cytidine, cytidine can be converted into agmatine by TiaS catalysis.

[0498] On the other hand, in the latter case (when agmatine is synthesized without TiaS mediation), the tRNA of the present disclosure cannot be recognized as a substrate by TiaS. That is, even if N in the tRNA before modification 1 is cytidine, TiaS cannot transform cytidine into agmatine. In this case, agmatine and tRNA containing agmatine can be synthesized by a method that does not use TiaS (e.g., a chemical synthesis method). In one embodiment of the present disclosure, if N in the tRNA before transformation is 1 If the cytidine is cytidine, then the cytidine cannot be converted into agmatine by TiaS catalysis. The condition that TiaS cannot catalyze the conversion of cytidine into agmatine can be expressed as the following condition: when the activity of TiaS in converting the cytidine of the natural substrate tRNAIle2 into agmatine is 1, then the activity of TiaS in converting the cytidine of the target tRNA into agmatine is reduced by 10 times or more, 20 times or more, 40 times or more, 100 times or more, 200 times or more, or 400 times or more. When the catalytic activity of TiaS is reduced, only a large amount of N 1The low purity target product of the non-modified tRNA is still cytidine; therefore, it may be more advantageous to synthesize agmatine by a method that does not use TiaS (e.g., chemical synthesis) rather than by a method that uses TiaS. In a specific embodiment, TiaS is TiaS from an archaeon. In a further embodiment, TiaS is wild-type TiaS from the archaeon Methanosarcina acetivorans, having the amino acid sequence of SEQ ID NO: 52.

[0499] Furthermore, it has been reported that TiaS still maintains a certain amount of tRNA's agmatine synthesis ability even after some nucleosides in tRNAIle2 have been transformed into other nucleosides (Osawa et al., Nat Struct Mol Biol (2011) 18: 1275-1280).

[0500] In some embodiments, the mutant tRNA of the present disclosure is an initiator tRNA or an elongator tRNA. The tRNA of mutation can be produced by transforming the initiator tRNA or the elongator tRNA, or the mutant tRNA produced by transformation can have the function of being an initiator tRNA or an elongator tRNA. When RNA is used in a translation system, it can be judged whether a certain tRNA has the function of being an initiator by observing whether tRNA (i) is introduced into ribosomes by IF2, and whether the amino acid connected on (ii) tRNA can be used as an initiator amino acid to start peptide translation. In addition, when tRNA is used in a translation system, it can be determined whether a certain tRNA has the function of being an elongator tRNA by observing whether tRNA (i) is introduced into ribosomes by EF-Tu, and whether the amino acid connected to tRNA (ii) can be incorporated into a peptide chain to extend the peptide chain.

[0501] In some embodiments, the mutant tRNA of the present invention is a prokaryotic derived tRNA or a eukaryotic derived tRNA. The mutant tRNA can be produced by modifying the prokaryotic derived tRNA or the eukaryotic derived tRNA, and the mutant tRNA produced by the modification can have the highest nucleic acid sequence identity with the prokaryotic derived tRNA or the eukaryotic derived tRNA. Eukaryotic organisms are further divided into animals, plants, fungi and protists. The mutant tRNA of the present invention can be, for example, a human tRNA. Prokaryotes are further divided into true bacteria and archaea. Examples of true bacteria include Escherichia coli, Bacillus subtilis, lactic acid bacteria and Desulfitobacterium hafniense. Examples of archaea include halophiles, thermophiles, or methanobacteria (e.g., Methanosarcina mazei, Methanosarcina barkeri, and Methanocaldococcus jannaschii). The mutant tRNA of the present disclosure may be, for example, a tRNA derived from Escherichia coli, Desulfitobacterium hafniense, or Methanosarcinamazei.

[0502] In some embodiments, the mutant tRNAs disclosed herein can be translated from M 1 M 2 A represents the codon. In this article, the first letter of the codon is the nucleotide (M 1 ) and the second letter of the nucleoside (M 2 ) are each independently selected from any one of adenosine (A), guanosine (G), cytidine (C) or uridine (U), and the third letter nucleoside is adenosine. In another embodiment, the mutant tRNA disclosed herein has a 1 M 2 A represents a complementary anticodon to a specific codon. In certain embodiments, the mutant tRNA disclosed herein has a k2CN 2 N 3 or agm2CN 2 N 3 Herein, the first letter nucleoside of the anticodon is lysine (k2C) or agmatine (agm2C), and the second letter nucleoside (N 2 ) and the third nucleoside of the third letter (N 3 ) are respectively related to the above M 1 and M 2It is known that lysine and agmatine are both nucleosides that complementarily bind to adenosine. In a further embodiment, N 2 and N 3 Each of M can be independently selected from any one of adenosine (A), guanosine (G), cytidine (C) and uridine (U). Specifically, when M 2 (or M 1 ) is adenosine, N 2 (or N 3 ) is uridine. 2 (or M 1 ) is guanosine, N 2 (or N 3 ) is cytidine. 2 (or M 1 ) is cytidine, N 2 (or N 3 ) is guanosine. 2 (or M 1 ) is uridine, N 2 (or N 3 ) is adenosine.

[0503] In the context of the present disclosure, the embodiment of "a certain tRNA is capable of translating a specific codon" essentially includes the embodiment of "a certain tRNA has an anticodon complementary to a specific codon", and these expressions can be used interchangeably as long as one of the sequences of the anticodon on the tRNA is mentioned.

[0504] The first letter of the nucleotide of the codon that the mutant tRNA of the present disclosure can translate (M 1 ) and the second letter of the nucleoside (M 2 ) can be selected from the nucleotides (M) of the first letter of the codon that constitutes a specific codon box in the genetic code table. 1 ) and the second letter of the nucleoside (M 2 ). In a specific embodiment, the genetic code table is a standard genetic code table. In another embodiment, the genetic code table is a natural genetic code table.

[0505] In one embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2, the codon with A as the third letter and the codon with G as the third letter in the codon box encode the same amino acid. For example, in the codon box represented by UUN, the codon with A as the third letter (UUA) and the codon with G as the third letter (UUG) both encode the same amino acid (Leu); therefore, the first letter nucleoside (U) and the second letter nucleoside (U) in the codon constituting the codon box can be selected as M, respectively. 1 and M 2 .

[0506] In one embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon with U as the third letter and the codon with A as the third letter in the codon box encode the same amino acid. For example, in the codon box represented by AUN, the codon with U as the third letter (AUU) and the codon with A as the third letter (AUA) both encode the same amino acid (Ile); therefore, the first letter nucleoside (A) and the second letter nucleoside (U) in the codon constituting the codon box can be selected as M, ... 1 and M 2 .

[0507] In one embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codons with U as the third letter, the codons with C as the third letter, the codons with A as the third letter, and the codons with G as the third letter in the codon box all encode the same amino acid. For example, in a codon box represented by UCN, the codons with U as the third letter (UCU), the codons with C as the third letter (UCC), the codons with A as the third letter (UCA), and the codons with G as the third letter (UCG) all encode the same amino acid (Ser); therefore, the first letter nucleoside (U) and the second letter nucleoside (C) in the codons constituting the codon box can be selected as M, 1 and M 2 .

[0508] In one embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2, the codons with A as the third letter and the codons with G as the third letter in the codon box encode different amino acids. For example, in the codon box represented by AUN, the codons with A as the third letter (AUA) and the codons with G as the third letter (AUG) both encode different amino acids (Ile and Met); therefore, the first letter nucleoside (A) and the second letter nucleoside (U) in the codons constituting the codon box can be selected as M, ... 1 and M 2 .

[0509] In one embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon with A as the third letter and / or the codon with G as the third letter in the codon box is a stop codon. For example, in the codon box represented by UGN, the codon with A as the third letter (UGA) is a stop codon (opal); therefore, the first letter nucleoside (U) and the second letter nucleoside (G) in the codon constituting the codon box can be selected as M, 1 and M 2 .

[0510] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by UNN. Specifically, the first letter nucleoside (U) and the second letter nucleoside (U) in the codon can be selected as M, 1 and M 2 .

[0511] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by UCN. Specifically, the first letter nucleoside (U) and the second letter nucleoside (C) in the codon can be selected as M, 1 and M 2 .

[0512] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2, the codon in the codon box is represented by UAN. Specifically, the first letter nucleoside (U) and the second letter nucleoside (A) in the codon can be selected as M, 1 and M 2 .

[0513] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by UGN. Specifically, the first letter nucleoside (U) and the second letter nucleoside (G) in the codon can be selected as M, 1 and M 2 .

[0514] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by CUN. Specifically, the first letter nucleoside (C) and the second letter nucleoside (U) in the codon can be selected as M, 1 and M 2 .

[0515] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by CCN. Specifically, the first letter nucleoside (C) and the second letter nucleoside (C) in the codon can be selected as M, 1 and M 2 .

[0516] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by CAN. Specifically, the first letter nucleoside (C) and the second letter nucleoside (A) in the codon can be selected as M, 1 and M 2 .

[0517] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2, the codon in the codon box is represented by CGN. Specifically, the first letter nucleoside (C) and the second letter nucleoside (G) in the codon can be selected as M, 1 and M 2 .

[0518] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by AUN. Specifically, the first letter nucleoside (A) and the second letter nucleoside (U) in the codon can be selected as M, 1 and M 2 .

[0519] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by ACN. Specifically, the first letter nucleoside (A) and the second letter nucleoside (C) in the codon can be selected as M, ... 1 and M 2 .

[0520] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by AAN. Specifically, the first letter nucleoside (A) and the second letter nucleoside (A) in the codon can be selected as M, ... 1 and M 2 .

[0521] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by AGN. Specifically, the first letter nucleoside (A) and the second letter nucleoside (G) in the codon can be selected as M, 1 and M 2 .

[0522] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2, the codon in the codon box is represented by GUN. Specifically, the first letter nucleoside (G) and the second letter nucleoside (U) in the codon can be selected as M, 1 and M 2 .

[0523] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by GCN. Specifically, the first letter nucleoside (G) and the second letter nucleoside (C) in the codon can be selected as M, 1 and M 2 .

[0524] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codons in the codon box are represented by GAN. Specifically, the first letter nucleoside (G) and the second letter nucleoside (A) in the codon can be selected as M, 1 and M 2 .

[0525] In a further embodiment, M 1 and M 2 M can be selected from the codons constituting the codon box 1 and M 2 , the codon in the codon box is represented by GGN. Specifically, the first letter nucleoside (G) and the second letter nucleoside (G) in the codon can be selected as M, 1 and M 2 .

[0526] The third letter nucleoside (N) of the anticodon in the mutant tRNA of the present disclosure 3 ) and the second letter of the nucleoside (N 2 ) can be selected as 1 and M 2 Complementary nucleosides.

[0527] In one embodiment, N 3 and N 2 A can be selected as a nucleoside complementary to the first letter nucleoside (U) and the second letter nucleoside (U) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by UUN. Specifically, A can be selected as N 3 , A can be selected as N 2 .

[0528] In one embodiment, N 3 and N 2 A can be selected as a nucleoside complementary to the first letter nucleoside (U) and the second letter nucleoside (C) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by UCN. Specifically, A can be selected as N 3 , G can be selected as N 2 .

[0529] In one embodiment, N 3 and N 2 Can be selected as a nucleoside complementary to the first letter nucleoside (U) and the second letter nucleoside (A) in the codon constituting the codon box, respectively, the codon in the codon box is represented by UAN. Specifically, A can be selected as N 3 , U can be selected as N 2 .

[0530] In one embodiment, N 3 and N 2 A can be selected as a nucleoside complementary to the first letter nucleoside (U) and the second letter nucleoside (G) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by UGN. Specifically, A can be selected as N 3 , C can be selected as N 2 .

[0531] In one embodiment, N 3 and N 2 Can be selected as a nucleoside complementary to the first letter nucleoside (C) and the second letter nucleoside (U) in the codon constituting the codon box, respectively, the codon in the codon box is represented by CUN. Specifically, C can be selected as N 3 , A can be selected as N 2 .

[0532] In one embodiment, N 3 and N 2 can be selected as nucleosides complementary to the first letter nucleoside (C) and the second letter nucleoside (C) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by CCN. Specifically, G can be selected as N 3 , G can be selected as N 2 .

[0533] In one embodiment, N 3 and N 2can be selected as a nucleoside complementary to the first letter nucleoside (C) and the second letter nucleoside (A) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by CAN. Specifically, G can be selected as N 3 , U can be selected as N 2 .

[0534] In one embodiment, N 3 and N 2 Can be selected as a nucleoside complementary to the first letter nucleoside (C) and the second letter nucleoside (G) in the codon constituting the codon box, respectively, the codon in the codon box is represented by CGN. Specifically, G can be selected as N 3 , C can be selected as N 2 .

[0535] In one embodiment, N 3 and N 2 can be selected as a nucleoside complementary to the first letter nucleoside (A) and the second letter nucleoside (U) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by AUN. Specifically, U can be selected as N 3 , A can be selected as N 2 .

[0536] In one embodiment, N 3 and N 2 can be selected as a nucleoside complementary to the first letter nucleoside (A) and the second letter nucleoside (C) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by ACN. Specifically, U can be selected as N 3 , G can be selected as N 2 .

[0537] In one embodiment, N 3 and N 2 can be selected as a nucleoside complementary to the first letter nucleoside (A) and the second letter nucleoside (A) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by AAN. Specifically, U can be selected as N 3 , U can be selected as N 2 .

[0538] In one embodiment, N 3 and N 2 U can be selected as a nucleoside complementary to the first letter nucleoside (A) and the second letter nucleoside (G) in the codon constituting the codon box, and the codon in the codon box is represented by AGN. Specifically, U can be selected as N 3 , C can be selected as N 2 .

[0539] In one embodiment, N 3 and N 2 Can be selected as a nucleoside complementary to the first letter nucleoside (G) and the second letter nucleoside (U) in the codon constituting the codon box, respectively, the codon in the codon box is represented by GUN. Specifically, G can be selected as N 3 , A can be selected as N 2 .

[0540] In one embodiment, N 3 and N 2 Can be selected as a nucleoside complementary to the first letter nucleoside (G) and the second letter nucleoside (C) in the codon constituting the codon box, respectively, the codon in the codon box is represented by GCN. Specifically, C can be selected as N 3 , G can be selected as N 2 .

[0541] In one embodiment, N 3 and N 2 can be selected as nucleosides complementary to the first letter nucleoside (G) and the second letter nucleoside (A) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by GAN. Specifically, C can be selected as N 3 , U can be selected as N 2 .

[0542] In one embodiment, N 3 and N 2 Can be selected as a nucleoside complementary to the first letter nucleoside (G) and the second letter nucleoside (G) in the codon constituting the codon box, respectively, and the codon in the codon box is represented by GGN. Specifically, C can be selected as N 3 , C can be selected as N 2 .

[0543] In some embodiments, an amino acid or amino acid analog is linked to a mutant tRNA of the present disclosure. The amino acid or amino acid analog is typically linked to the 3' end of the tRNA, or more specifically, to the adenosine residue of the CCA sequence at the 3' end. The specific type of amino acid or amino acid analog linked to the mutant tRNA can be appropriately selected from the following amino acids or amino acid analogs.

[0544] The amino acids in the present disclosure include α-amino acids, β-amino acids and γ-amino acids. Regarding the three-dimensional structure, L-type amino acids and D-type amino acids are included. In addition, the amino acids in the present disclosure include natural and non-natural amino acids. In a specific embodiment, the natural amino acids are composed of the following 20 α-amino acids: glycine (Gly), alanine (Ala), serine (Ser), threonine (Thr), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp), histidine (His), glutamic acid (Glu), aspartic acid (Asp), glutamine (Gln), asparagine (Asn), cysteine ​​(Cys), methionine (Met), lysine (Lys), arginine (Arg) and proline (Pro). Alternatively, the natural amino acids in the present disclosure can be amino acids obtained by removing any one or more amino acids from the above 20 amino acids. In one embodiment, the natural amino acids are composed of 19 kinds of amino acids, excluding isoleucine. In one embodiment, the natural amino acids are composed of 19 kinds of amino acids, excluding methionine. In another embodiment, the natural amino acids consist of 18 amino acids, excluding isoleucine and methionine.Natural amino acids are usually L-amino acids.

[0545] In the present disclosure, non-natural amino acids refer to all amino acids other than the above-mentioned natural amino acids consisting of 20 kinds of α-amino acids. Examples of non-natural amino acids include β-amino acids, γ-amino acids, D-type amino acids, α-amino acids with side chains different from natural amino acids, α,α-disubstituted amino acids, and amino acids with substituents in the main chain amino group (N-substituted amino acids). The side chains of non-natural amino acids are not particularly limited, but in addition to hydrogen atoms, they may also have, for example, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, and cycloalkyl groups. In addition, in the case of α,α-disubstituted amino acids, the two side chains may form a ring. In addition, these side chains may have one or more substituents. In a specific embodiment, the substituent may be selected from any functional group comprising a halogen atom, an O atom, an S atom, an N atom, a B atom, a Si atom, or a P atom. For example, in the present disclosure, "C with a halogen as a substituent" means a non-natural amino acid. 1 -C 6 "Alkyl" refers to an alkyl group in which at least one hydrogen atom is replaced by a halogen atom. 1 -C 6 Specific examples include trifluoromethyl, difluoromethyl, fluoromethyl, pentafluoroethyl, tetrafluoroethyl, trifluoroethyl, difluoroethyl, fluoroethyl, trichloromethyl, dichloromethyl, chloromethyl, pentachloroethyl, tetrachloroethyl, trichloroethyl, dichloroethyl and chloroethyl. In addition, for example, “C having a substituent” 5 -C 10 Aryl C1 -C 6 "C alkyl" refers to a "C alkyl" in which at least one hydrogen atom in an aryl group and / or an alkyl group is replaced by a substituent. 5 -C 10 Aryl C 1 -C 6 In addition, the phrase "having two or more substituents" includes having a functional group (e.g., a functional group containing an S atom) as a substituent, and the functional group has another substituent (e.g., a substituent such as an amino group or a halogen). For specific examples of non-natural amino acids, reference can be made to WO2013 / 100132, WO2018 / 143145, etc.

[0546] The amino group of the non-natural amino acid backbone may be an unsubstituted amino group (NH 2 R represents an alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl or cycloalkyl group optionally having a substituent. In addition, as with proline, the carbon chain connected to the N atom and the α-position carbon atom of the main chain amino group can form a ring. The substituent can be selected from any functional group containing a halogen atom, an O atom, an S atom, an N atom, a B atom, an Si atom or a P atom. Examples of alkyl substitutions of amino groups include N-methylation, N-ethylation, N-propylation and N-butylation, and examples of aralkyl substitutions of amino groups include N-benzylation. Specific examples of N-methyl amino acids include N-methylalanine, N-methylglycine, N-methylphenylalanine, N-methyltyrosine, N-methyl-3-chlorophenylalanine, N-methyl-4-chlorophenylalanine, N-methyl-4-methoxyphenylalanine, N-methyl-4-thiazole alanine, N-methylhistidine, N-methylserine and N-methylaspartic acid.

[0547] Examples of the substituent containing a halogen atom include fluorine (—F), chlorine (—Cl), bromine (—Br), and iodine (—I).

[0548] Examples of substituents containing an O atom include a hydroxyl group (-OH), an oxy group (-OR), a carbonyl group (-C=OR), a carboxyl group (-CO 2 H), oxycarbonyl (-C=O-OR), carbonyloxy (-O–C=O–R), thiocarbonyl (–C=O–SR), carbonylthio (–S–C=O–R), aminocarbonyl (–C=O–NHR), carbonylamino (–NH–C=O–R), oxycarbonylamino (–NH–C=O–OR), sulfonylamino (–NH–SO 2 -R), aminosulfonyl (–SO 2 –NHR), sulfamoylamino (–NH–SO 2–NHR), thiocarboxyl (–C(=O)–SH), carboxylcarbonyl (–C(=O)–CO 2 H).

[0549] Examples of the oxy group (—OR) include an alkoxy group, a cycloalkoxy group, an alkenyloxy group, an alkynyloxy group, an aryloxy group, a heteroaryloxy group, and an aralkyloxy group.

[0550] Examples of the carbonyl group (—C═OR) include a formyl group (—C═OH), an alkylcarbonyl group, a cycloalkylcarbonyl group, an alkenylcarbonyl group, an alkynylcarbonyl group, an arylcarbonyl group, a heteroarylcarbonyl group, and an aralkylcarbonyl group.

[0551] Examples of the oxycarbonyl group (—C═O—OR) include an alkoxycarbonyl group, a cycloalkoxycarbonyl group, an alkenyloxycarbonyl group, an alkynyloxycarbonyl group, an aryloxycarbonyl group, a heteroaryloxycarbonyl group and an aralkyloxycarbonyl group.

[0552] Examples of the carbonyloxy group (—OC═OR) include an alkylcarbonyloxy group, a cycloalkylcarbonyloxy group, an alkenylcarbonyloxy group, an alkynylcarbonyloxy group, an arylcarbonyloxy group, a heteroarylcarbonyloxy group and an aralkylcarbonyloxy group.

[0553] Examples of the thiocarbonyl group (—C═O—SR) include an alkylthiocarbonyl group, a cycloalkylthiocarbonyl group, an alkenylthiocarbonyl group, an alkynylthiocarbonyl group, an arylthiocarbonyl group, a heteroarylthiocarbonyl group and an aralkylthiocarbonyl group.

[0554] Examples of the carbonylthio group (—SC═OR) include an alkylcarbonylthio group, a cycloalkylcarbonylthio group, an alkenylcarbonylthio group, an alkynylcarbonylthio group, an arylcarbonylthio group, a heteroarylcarbonylthio group and an aralkylcarbonylthio group.

[0555] Examples of aminocarbonyl (-C=O-NHR) include alkylaminocarbonyl, cycloalkylaminocarbonyl, alkenylaminocarbonyl, alkynylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl and aralkylaminocarbonyl. In addition, the H atom connected to the N atom in -C=O-NHR may be substituted with a substituent selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and aralkyl.

[0556] Examples of carbonylamino (-NH-C=OR) include alkylcarbonylamino, cycloalkylcarbonylamino, alkenylcarbonylamino, alkynylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino and aralkylcarbonylamino. In addition, the H atom connected to the N atom in-NH-C=OR can be substituted by a substituent selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and aralkyl.

[0557] Examples of oxycarbonylamino (-NH-C=O-OR) include alkoxycarbonylamino, cycloalkyloxycarbonylamino, alkenyloxycarbonylamino, alkynyloxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino and aralkyloxycarbonylamino. In addition, the H atom connected to the N atom in -NH-C=O-OR may be substituted with a substituent selected from the group consisting of an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group and an aralkyl group.

[0558] Sulfonylamino (-NH-SO 2 Examples of -R) include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino and aralkylsulfonylamino. 2 The H atom to which the N atom in -R is attached may be substituted with a substituent selected from the group consisting of an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, and an aralkyl group.

[0559] Aminosulfonyl (-SO 2 Examples of -SO-NHR) include alkylaminosulfonyl, cycloalkylaminosulfonyl, alkenylaminosulfonyl, alkynylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl and aralkylaminosulfonyl. 2 The H atom bonded to the N atom in -NHR may be substituted with a substituent selected from the group consisting of an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, and an aralkyl group.

[0560] Sulfonamide (-NH-SO 2 Examples of -NH-SO include alkylsulfonylamino, cycloalkylsulfonylamino, alkenylsulfonylamino, alkynylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino and aralkylsulfonylamino. 2 At least one of the two H atoms connected to the N atom in -NHR may be substituted with a substituent selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl and aralkyl. When both H atoms are substituted, the substituents may be selected independently of each other, or the two substituents may form a ring.

[0561] Examples of substituents containing an S atom include thiol (-SH), thio (-SR), sulfinyl (-S=O-R), sulfonyl (-S(O) 2 –R) and sulfonic acid (–SO 3 H).

[0562] Examples of the thio group (—SR) include an alkylthio group, a cycloalkylthio group, an alkenylthio group, an alkynylthio group, an arylthiol group, a heteroarylthio group, and an aralkylthio group.

[0563] Examples of the sulfinyl group (—S═OR) include an alkylsulfinyl group, a cycloalkylsulfinyl group, an alkenylsulfinyl group, an alkynylsulfinyl group, an arylsulfinyl group, a heteroarylsulfinyl group and an aralkylsulfinyl group.

[0564] Sulfonyl (-S(O) 2 Examples of -R) include an alkylsulfonyl group, a cycloalkylsulfonyl group, an alkenylsulfonyl group, an alkynylsulfonyl group, an arylsulfonyl group, a heteroarylsulfonyl group and an aralkylsulfonyl group.

[0565] Examples of substituents containing a nitrogen atom include azide (-N 3 ), cyano (-CN), primary amino (-NH 2 ), secondary amino group (-NH-R), tertiary amino group (-NR(R')), amidino group (-C(=NH)-NH 2 ), substituted amidino (-C(=NR)-NR'R"), guanidine (-NH=C(=NH)-NH 2 ), substituted guanidine (-NR-C(=NR'")-NR'R"), and aminocarbonylamino (-NR-CO-NR'R").

[0566] Examples of the secondary amino group (—NH—R) include an alkylamino group, a cycloalkylamino group, an alkenylamino group, an alkynylamino group, an arylamino group, a heteroarylamino group, and an aralkylamino group.

[0567] The two substituents R and R' on the N atom in the tertiary amino group (-NR(R')) can each be independently selected from the group consisting of an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group and an aralkyl group. Examples of tertiary amino groups include, for example, an alkyl (aralkyl) amino group. The two substituents can form a ring.

[0568] The three substituents R, R' and R" on the N atom in the substituted amidino group (-C(=NR)-NR'R") may each be independently selected from the group consisting of a hydrogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group and an aralkyl group. Examples of the substituted amidino group include alkyl (aralkyl) (aryl) amidino groups. These substituents may form a ring together.

[0569] The four substituents R, R', R", and R'" on the N atom in the substituted guanidine group (-NR-C(=NR'")-NR'R") can each be independently selected from the group consisting of a hydrogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, and an aralkyl group. These substituents can form a ring together.

[0570] The three substituents R, R' and R" on the N atom in the aminocarbonylamino group (-NR-CO-NR'R") can each be independently selected from the group consisting of a hydrogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group and an aralkyl group. These substituents can form a ring together.

[0571] Examples of substituents containing a B atom include a boranyl group (-BR(R')) and a dioxaboranyl group (-B(OR)(OR')). The two substituents R and R' on the B atom can each independently be selected from the group consisting of a hydrogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, and an aralkyl group. These substituents can together form a ring.

[0572] Examples of the amino acid analogs in the present disclosure include hydroxycarboxylic acids (hydroxy acids). Hydroxycarboxylic acids include α-hydroxycarboxylic acids, β-hydroxycarboxylic acids, and γ-hydroxycarboxylic acids. Similar to amino acids, side chains other than a hydrogen atom can be attached to the carbon at the α-position in the hydroxycarboxylic acid. Regarding the three-dimensional structure, it can include L-form and D-form. The structure of the side chain can be defined similarly to the side chains of the above-mentioned natural amino acids or unnatural amino acids. Examples of the hydroxycarboxylic acids include glycolic acid, lactic acid, and phenyl lactic acid.

[0573] The amino acids in the present disclosure can be translatable amino acids, and the amino acid analogs can be translatable amino acid analogs. As used herein, a "translatable" amino acid or amino acid analog (collectively referred to as amino acids, etc.) refers to an amino acid, etc. that can be incorporated into a peptide by translation synthesis (e.g., using the translation system described in the present disclosure). Whether a certain amino acid, etc. is translatable can be confirmed by a translation synthesis experiment using a tRNA linked to the amino acid, etc. A reconstituted cell-free translation system can be used in the translation synthesis experiment (see, for example, WO2013100132).

[0574] The unnatural amino acids or amino acid analogs according to the present disclosure can be prepared by conventionally known chemical synthesis methods, the synthesis methods described in the examples discussed later, or synthesis methods similar thereto.

[0575] <Preparation of tRNA>

[0576] Can synthesize tRNA, for example, by preparing the DNA of the required tRNA gene of encoding, then place suitable promoter such as T7, T3 or SP6 in DNA upstream, and use DNA as template to use RNA polymerase adapted to each promoter to carry out transcription reaction.In addition, tRNA can also be prepared by purification from biological material.For example, can be by extracting solution from the material containing tRNA such as cell preparation and adding thereto the probe containing the sequence complementary to the nucleotide sequence of tRNA to reclaim tRNA.In this case, the preparation material can be the cell transformed with the expression vector that can express required tRNA.Usually, the tRNA synthesized by in vitro transcription only contains four kinds of typical nucleosides: adenosine, guanosine, cytidine and uridine.On the other hand, the tRNA synthesized in cell may contain the modified nucleosides produced by typical nucleosides modification.It is believed that the modified nucleosides (for example Lysine) in natural tRNA are specifically introduced into the tRNA by the effect of the enzyme (for example TilS) used for the modification after synthesizing tRNA by transcription.Or, tRNA can also be prepared by the fragment synthesized by transcription or the fragment synthesized by chemistry or the method connected by enzymatic reaction such as described in the following examples.

[0577] Aminoacyl-tRNA can also be prepared by chemical and / or biosynthetic methods. For example, aminoacyl-tRNA synthetase (ARS) can be used to connect amino acid to tRNA to synthesize aminoacyl-tRNA. Amino acid can be a natural amino acid or a non-natural amino acid, as long as it can be used as a substrate for ARS. Alternatively, a natural amino acid can be connected to tRNA and then chemically modified. In addition, since there are many reports that introducing amino acid mutations in ARS enhances their effects on non-natural amino acids (see, for example, WO2006 / 135096, WO2007 / 061136, WO2007 / 103307, WO2008 / 001947, WO2010 / 141851, and WO2015 / 120287), such mutations ARS can be used to connect amino acids to tRNA. In addition to the method using ARS, aminoacyl-tRNA can also be synthesized by, for example, removing the CA sequence from the 3' end of tRNA and connecting aminoacylated pdCpA (a dinucleotide composed of deoxycytidine and adenosine) thereto using RNA ligase (pdCpA method; Hecht et al., J Biol Chem (1978) 253: 4517-4520). A method using pCpA (a dinucleotide composed of cytidine and adenosine) instead of pdCpA is also known (pCpA method; Wang et al., ACS Chem Biol (2015) 10: 2187-2192). In addition, aminoacyl-tRNA can also be synthesized by connecting a non-natural amino acid previously activated by esterification to tRNA using an artificial RNA catalyst (flexizyme) (WO2007 / 066627).

[0578] <Translation System>

[0579] On the one hand, the present disclosure provides a group of tRNAs suitable for peptide translation. A group of tRNAs includes multiple different tRNAs, and multiple different amino acids can be translated from these tRNAs. On the one hand, the present disclosure provides compositions comprising multiple different tRNAs suitable for peptide translation. On the other hand, the present disclosure provides methods for translating peptides, including providing multiple different tRNAs suitable for peptide translation. On the one hand, the present disclosure provides a translation system, which includes multiple different tRNAs suitable for peptide translation. In some aspects, the above-mentioned multiple different tRNAs include mutant tRNAs of the present disclosure. The following description relates to these tRNAs, compositions, translation methods and translation systems suitable for peptide translation.

[0580] In one embodiment, the mutant tRNA of the invention is in the first letter of the anticodon (N 1) has any one of lysine (k2C), lysine derivatives, agmatine (agm2C), or agmatine derivatives. Since lysine and agmatine form complementary base pairs with adenosine (A), their roles in the codon may correspond to those of uridine (U). In some embodiments, the mutant tRNA of the present disclosure can selectively translate the codon from M relative to other codons. 1 M 2 A represents the codon. Other codons can be 1 M 2 A represents a different codon; for example, 1 M 2 U, M 1 M 2 C or M 1 M 2 In certain embodiments, the mutant tRNAs disclosed herein can be modified relative to the codons represented by M 1 M 2 U, M 1 M 2 C and M 1 M 2 All codons represented by G are selectively translated by M 1 M 2 A represents the codon.

[0581] In one embodiment of the present disclosure, "mutant tRNA can selectively translate M 1 M 2 A codon" refers to [tRNA to M 1 M 2 A codon translation amount] for example, not less than two times, not less than three times, not less than four times, not less than five times, not less than six times, not less than seven times, not less than eight times, not less than nine times, not less than 10 times, not less than 15 times, not less than 20 times, not less than 30 times, not less than 40 times, not less than 50 times, not less than 60 times, not less than 70 times, not less than 80 times, not less than 90 times, or not less than 100 times [the amount of tRNA translation for another codon]. For example, whether a mutant tRNA can selectively translate the codon represented by CUA can be judged by whether [the translation amount of tRNA for CUA codon] is, for example, not less than two times, not less than 3 times, not less than 4 times, not less than 5 times, not less than 6 times, not less than 7 times, not less than 8 times, not less than 9 times, not less than 10 times, not less than 15 times, not less than 20 times, not less than 30 times, not less than 40 times, not less than 50 times, not less than 60 times, not less than 70 times, not less than 80 times, not less than 90 times, or not less than 100 times [the translation amount of tRNA for CUG codon].

[0582] Comparison of specific codons (e.g. M 1 M 2 A) and another codon (e.g. M 1 M 2 G) can be translated by, for example, preparing a 1 M 2 A peptide encoding mRNA and another mRNA having the same nucleic acid sequence as the above mRNA except that M 1 M 2 A codon replaced by M 1 M 2 The two mRNAs were translated under the same conditions and the amounts of the two synthetic peptides obtained were compared.

[0583] In another embodiment of the present disclosure, "the mutant tRNA is capable of selectively translating M 1 M 2 A codon" refers to [tRNA to M 1 M 2 A] is reduced to, for example, no more than 1 / 2, no more than 1 / 3, no more than 1 / 4, no more than 1 / 5, no more than 1 / 6, no more than 1 / 7, no more than 1 / 8, no more than 1 / 9, no more than 1 / 10, no more than 1 / 15, no more than 1 / 20, no more than 1 / 30, no more than 1 / 40, no more than 1 / 50, no more than 1 / 60, no more than 1 / 70, no more than 1 / 80, no more than 1 / 90 or no more than 1 / 100 [with UN 2 N 3 The tRNA of the anticodon is 1 M 2 A]. In this article, UN 2 N 3 Anticodon represents the first letter of the anticodon (N 1 ) is uridine, the second letter of the anticodon (N 2 ) and the third letter (N 3 ) are respectively 2 and M 1 The anticodon of the complementary nucleoside. Since the role of lysine and guanidine in the anticodon corresponds to uridine, uridine is chosen for comparison. 1 M 2 Codons other than A can be replaced by M 1 M 2 U, M 1 M 2 C or M 1 M 2For example, whether a mutant tRNA can selectively translate the codon represented by CUA can be determined by whether [the amount of tRNA translating the CUG codon] is reduced to, for example, no more than 1 / 2, no more than 1 / 3, no more than 1 / 4, no more than 1 / 5, no more than 1 / 6, no more than 1 / 7, no more than 1 / 8, no more than 1 / 9, no more than 1 / 10, no more than 1 / 15, no more than 1 / 20, no more than 1 / 30, no more than 1 / 40, no more than 1 / 50, no more than 1 / 60, no more than 1 / 70, no more than 1 / 80, no more than 1 / 90 or no more than 1 / 100 [with UN 2 N 3 The amount of tRNA translated into the CUG codon can be used to determine the translation amount.

[0584] In another embodiment, M 1 M 2 A represents a codon that can be more selectively translated by the mutant tRNA of the present disclosure than other tRNAs. Other tRNAs can be capable of translating a codon different from M. 1 M 2 The tRNA for the codon represented by A, for example, can translate M 1 M 2 U, M 1 M 2 C or M 1 M 2 In a specific embodiment, M 1 M 2 The codon represented by A can be selectively translated by the mutant tRNA of the present disclosure, but not by the codon that can translate M 1 M 2 U codon tRNA, can translate M 1 M 2 C codon and the tRNA that can translate M 1 M 2 The tRNA for the G codon is selectively translated.

[0585] In one embodiment of the present disclosure, "M 1 M 2 The codon represented by A can be selectively translated by the mutant tRNA" means [tRNA for M 1 M 2A codon] for example, not less than two times, not less than three times, not less than four times, not less than five times, not less than six times, not less than seven times, not less than eight times, not less than nine times, not less than ten times, not less than fifteen times, not less than twenty times, not less than thirty times, not less than forty times, not less than fifty times, not less than sixty times, not less than seventy times, not less than eighty times, not less than ninety times, not less than ten times, not less than twenty times, not less than thirty times, not less than forty times, not less than fifty times, not less than sixty times, not less than seventy times, not less than eighty times, not less than ninety times, or not less than one hundred times [other tRNAs for M 1 M 2 [the amount of translation of the CUA codon by tRNA] is, for example, not less than two times, not less than 3 times, not less than 4 times, not less than 5 times, not less than 6 times, not less than 7 times, not less than 8 times, not less than 9 times, not less than 10 times, not less than 15 times, not less than 20 times, not less than 30 times, not less than 40 times, not less than 50 times, not less than 60 times, not less than 70 times, not less than 80 times, not less than 90 times, or not less than 100 times [the amount of translation of the CUA codon by tRNA (e.g., tRNA with a CAG anticodon) capable of translating the CUG codon].

[0586] The translation system comprising the mutant tRNA of the present disclosure can have both of the above characteristics. That is, in a specific embodiment, in the translation system of the present disclosure, (i) the mutant tRNA can selectively translate the codons generated by M over other codons; 1 M 2 A represents the codon, and (ii) M represents the codon 1 M 2 The codon represented by A can be selectively translated by the mutant tRNA of the present invention corresponding to other tRNAs. When this relationship is established, in the translation system of the present invention, the peptide translation using the mutant tRNA of the present invention and the peptide translation using other tRNAs are in an independent relationship, in which they do not interact with each other; in other words, they are in an orthogonal relationship. The translation system of organisms in nature essentially establishes a strict correspondence between codons and amino acids; therefore, adding non-orthogonal mutant tRNAs thereto may disrupt these correspondences and have a fatal effect on the function of the translation system. Therefore, in the translation system of the present invention, the orthogonality established between the mutant tRNA of the present invention and other tRNAs may be one of the important features.

[0587] In one embodiment, the translation system of the present disclosure further comprises a 1 M 2In some embodiments, the translation system of the present disclosure comprises at least two tRNAs: (a) a mutant tRNA described in the present disclosure and (b) a tRNA-G described in the present disclosure. In a specific embodiment, the tRNA with M 1 M 2 The complementary anticodon of the codon represented by G is, for example, CN 2 N 3 、ac4CN 2 N 3 or CmN 2 N 3 In this article, the first letter of each anticodon is cytidine (C), N4-acetylcytidine (ac4C) or 2'-O-methylcytidine (Cm), and the second letter (N 2 ) nucleotide and the third letter (N 3 ) are respectively the same as the above-mentioned M 2 and M 1 Complementary nucleosides. The mutant tRNA and tRNA-G of the present invention may have the same nucleic acid sequence except for the anticodon, or may have different nucleic acid sequences. When the nucleic acid sequences other than the anticodon are the same, the physicochemical properties of the two tRNAs may be similar to each other; therefore, a translation system with more uniform and stable reactivity can be constructed.

[0588] In some embodiments, the tRNA-G of the present disclosure can selectively translate the codons generated by M relative to other codons. 1 M 2 G represents the codon. Other codons can be 1 M 2 G represents a different codon; for example, 1 M 2 U, M 1 M 2 C or M 1 M 2 A represents the codon. In certain embodiments, the tRNA-G of the present disclosure can be used relative to the codon represented by M 1 M 2 U, M 1 M 2 C and M 1 M 2 Any codon represented by A is selectively translated by M 1 M 2 G represents the codon.

[0589] In one embodiment of the present disclosure, a tRNA can selectively translate M 1 M 2The G codon refers to [tRNA to M 1 M 2 G codon] for example, at least two times, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least nine times, at least ten times, at least fifteen times, at least twenty times, at least thirty times, at least forty times, at least fifty times, at least sixty times, at least seventy times, at least eighty times, at least ninety times, at least ten times, at least fifteen times, at least twenty times, at least thirty times, at least forty times, at least fifty times, at least sixty times, at least seventy times, at least eighty times, at least ninety times, or at least one hundred times [the amount of tRNA translated for another codon]. For example, whether a certain mutant tRNA can selectively translate the codon represented by CUG can be judged by observing whether [the translation amount of tRNA for CUG codon] is, for example, not less than two times, not less than 3 times, not less than 4 times, not less than 5 times, not less than 6 times, not less than 7 times, not less than 8 times, not less than 9 times, not less than 10 times, not less than 15 times, not less than 20 times, not less than 30 times, not less than 40 times, not less than 50 times, not less than 60 times, not less than 70 times, not less than 80 times, not less than 90 times, or not less than 100 times [the translation amount of tRNA for CUA codon].

[0590] In another embodiment, M 1 M 2 The codon represented by G can be more selectively translated by tRNA-G of the present disclosure than other tRNAs. Other tRNAs can be capable of translating codons different from M. 1 M 2 The tRNA for the codon represented by G, for example, can translate M 1 M 2 U, M 1 M 2 C or M 1 M 2 In a specific embodiment, M 1 M 2 The codon represented by G can be selectively translated by tRNA-G of the present disclosure, but not by tRNA-G which can translate M. 1 M 2 U codon tRNA, can translate M 1 M 2 C codon and the tRNA that can translate M 1 M 2 Any one of the tRNAs for the A codon is selectively translated.

[0591] In one embodiment of the present disclosure, M 1 M 2 The codon G indicates that a certain tRNA can be selectively translated. 1 M 2G codon] for example, not less than two times, not less than three times, not less than four times, not less than five times, not less than six times, not less than seven times, not less than eight times, not less than nine times, not less than ten times, not less than fifteen times, not less than twenty times, not less than thirty times, not less than forty times, not less than fifty times, not less than sixty times, not less than seventy times, not less than eighty times, not less than ninety times, not less than ten times, not less than twenty times, not less than thirty times, not less than forty times, not less than fifty times, not less than sixty times, not less than seventy times, not less than eighty times, not less than ninety times, or not less than one hundred times [other tRNAs for M 1 M 2 K2CAG codon]. For example, whether the codon represented by CUG can be selectively translated by a certain tRNA can be judged by observing whether [the translation amount of tRNA for CUG codon] is, for example, not less than two times, not less than 3 times, not less than 4 times, not less than 5 times, not less than 6 times, not less than 7 times, not less than 8 times, not less than 9 times, not less than 10 times, not less than 15 times, not less than 20 times, not less than 30 times, not less than 40 times, not less than 50 times, not less than 60 times, not less than 70 times, not less than 80 times, not less than 90 times, or not less than 100 times [the translation amount of tRNA capable of translating CUA codon (e.g., tRNA with k2CAG anticodon) for CUG codon].

[0592] The translation system comprising the tRNA-G of the present disclosure may have a combination of the above two features. That is, in a specific embodiment, in the translation system of the present disclosure, (i) tRNA-G can selectively translate the codons generated by M over other codons; 1 M 2 The codon represented by G, and (ii) the codon represented by M 1 M 2 The codon represented by G can be selectively translated by tRNA-G of the present disclosure relative to other tRNAs. When this relationship is established, in the translation system of the present disclosure, peptide translation using tRNA-G and peptide translation using other tRNAs are independent and do not interact with each other; in other words, they have an orthogonal relationship. In the translation system of the present disclosure, the orthogonality established between tRNA-G and other tRNAs may be one of the important features.

[0593] In another embodiment, the amino acid linked to the mutant tRNA of the present disclosure (hereinafter, the amino acid is also referred to as "amino acid-A") and the amino acid linked to tRNA-G (hereinafter, the amino acid is also referred to as "amino acid-G") may be different from each other. For the mutant tRNA and tRNA-G of the present disclosure, when the above-mentioned orthogonal relationship is established, M 1 M 2 A codon and amino acid - A, M 1 M 2In the current translation system, the G codon and the amino acid -G correspond one to one. That is, in the translation system disclosed in the present invention, two codons (i) and (ii) in the same codon box can be used to generate the amino acid -G. 1 M 2 A and (ii)M 1 M 2 G translates two different amino acids.

[0594] In one embodiment, the translation system of the present disclosure further comprises a 1 M 2 U or M 1 M 2 In some embodiments, the translation system of the present disclosure comprises at least three tRNAs, which are (a) a mutant tRNA described in the present disclosure, (b) a tRNA-G described in the present disclosure, and (c) a tRNA-U / C described in the present disclosure. In a specific embodiment, the tRNA with M 1 M 2 The complementary anticodon of the codon represented by U is, for example, AN 2 N 3 GN 2 N 3 , QN 2 N 3 GluQN 2 N 3 In this article, the first letter of each anticodon is adenosine (A), guanosine (G), quercetin (Q) or glutamyl quercetin (GluQ), and the second letter (N 2 ) nucleotide and the third letter (N 3 ) are respectively the same as the above-mentioned M 2 and M 1 In another embodiment, the complementary nucleoside to M 1 M 2 The complementary anticodon of the codon represented by C is, for example, GN 2 N 3 , QN 2 N 3 GluQN 2 N 3 . Due to the relationship with M 1 M 2 U and M 1 M 2 Many anticodons complementary to the C codon overlap with each other, and the two codons can be regarded as a single codon in the present disclosure. 1 M 2 U or M 1 M2 The complementary anticodon of the codon represented by C is, for example, AN 2 N 3 GN 2 N 3 , QN 2 N 3 GluQN 2 N 3 The mutant tRNA, tRNA-G and tRNA-U / C described in the present disclosure may have the same nucleic acid sequence except for the anticodon, or may have nucleic acid sequences different from each other. When the nucleic acid sequences other than the anticodon are the same, the physicochemical properties of the three tRNAs may be similar to each other; therefore, a translation system with more uniform and stable reactivity can be constructed.

[0595] In some embodiments, the tRNA-U / C of the present disclosure can selectively translate the codons generated by M relative to other codons. 1 M 2 U or M 1 M 2 C represents the codon. Other codons can be 1 M 2 U or M 1 M 2 C represents different codons; for example, they can be replaced by M 1 M 2 A or M 1 M 2 In a specific embodiment, the tRNA-U / C of the present disclosure can be relative to the codon represented by M 1 M 2 A and M 1 M 2 The codon represented by G is selectively translated by M 1 M 2 U or M 1 M 2 C represents the codon.

[0596] In one embodiment of the present disclosure, a tRNA can selectively translate M 1 M 2 U or M 1 M 2 The C codon refers to [tRNA to M 1 M 2 U or M 1 M 2C codon] for example, not less than two times, not less than three times, not less than four times, not less than five times, not less than six times, not less than seven times, not less than eight times, not less than nine times, not less than ten times, not less than fifteen times, not less than twenty times, not less than thirty times, not less than forty times, not less than fifty times, not less than sixty times, not less than seventy times, not less than eighty times, not less than ninety times, not less than ten times, not less than twenty times, not less than thirty times, not less than forty times, not less than fifty times, not less than sixty times, not less than seventy times, not less than eighty times, not less than ninety times, or not less than one hundred times [the amount of tRNA translated for other codons]. For example, whether a certain tRNA can selectively translate the codon represented by CUU or CUC can be judged by observing whether [the translation amount of tRNA for CUU or CUC codon] is, for example, not less than two times, not less than three times, not less than four times, not less than five times, not less than six times, not less than seven times, not less than eight times, not less than nine times, not less than ten times, not less than 15 times, not less than 20 times, not less than 30 times, not less than 40 times, not less than 50 times, not less than 60 times, not less than 70 times, not less than 80 times, not less than 90 times, or not less than 100 times [the translation amount of tRNA for CUA codon].

[0597] In another embodiment, M 1 M 2 U or M 1 M 2 The codon represented by C can be more selectively translated by tRNA-U / C of the present disclosure than other tRNAs. Other tRNAs can be capable of translating codons different from M. 1 M 2 U or M 1 M 2 The tRNA for the codon represented by C, for example, can translate M 1 M 2 A or M 1 M 2 In a specific embodiment, M 1 M 2 U or M 1 M 2 The codon represented by C can be selectively translated by tRNA-U / C of the present disclosure, but not by tRNA-U / C capable of translating M 1 M 2 A codon tRNA and can translate M 1 M 2 Any of the tRNAs for the G codon is selectively translated.

[0598] In one embodiment of the present disclosure, M 1 M 2 U or M 1 M 2 The codon indicated by C can be selectively translated by a certain tRNA.1 M 2 U or M 1 M 2 C codon] for example, not less than two times, not less than three times, not less than four times, not less than five times, not less than six times, not less than seven times, not less than eight times, not less than nine times, not less than ten times, not less than fifteen times, not less than twenty times, not less than thirty times, not less than forty times, not less than fifty times, not less than sixty times, not less than seventy times, not less than eighty times, not less than ninety times, not less than ten times, not less than twenty times, not less than thirty times, not less than forty times, not less than fifty times, not less than sixty times, not less than seventy times, not less than eighty times, not less than ninety times, or not less than one hundred times [other tRNAs for M 1 M 2 U or M 1 M 2 C codon]. For example, whether the codon represented by CUU or CUC can be selectively translated by a certain tRNA can be judged by observing whether [the translation amount of tRNA for CUU or CUC codon] is, for example, not less than two times, not less than 3 times, not less than 4 times, not less than 5 times, not less than 6 times, not less than 7 times, not less than 8 times, not less than 9 times, not less than 10 times, not less than 15 times, not less than 20 times, not less than 30 times, not less than 40 times, not less than 50 times, not less than 60 times, not less than 70 times, not less than 80 times, not less than 90 times, or not less than 100 times [the translation amount of tRNA capable of translating CUA codon (e.g., tRNA with k2CAG anticodon) for CUU or CUC codon].

[0599] The translation system comprising the tRNA-U / C of the present disclosure may have a combination of the above two features. That is, in a specific embodiment, in the translation system of the present disclosure, (i) tRNA-U / C can selectively translate the codons generated by M over other codons; 1 M 2 U or M 1 M 2 C represents the codon, and (ii) the codon represented by M 1 M 2 U or M 1 M 2 The codon represented by C can be selectively translated by the tRNA-U / C of the present disclosure relative to other tRNAs. When this relationship is established, in the translation system of the present disclosure, peptide translation using tRNA-U / C and peptide translation using other tRNAs are independent and do not interact with each other; in other words, they have an orthogonal relationship. In the translation system of the present disclosure, establishing orthogonality between tRNA-U / C and other tRNAs may be one of the important features.

[0600] In another embodiment, the amino acid linked to the mutant tRNA ("amino acid-A"), the amino acid linked to tRNA-G ("amino acid-G"), and the amino acid linked to tRNA-U / C (hereinafter, the amino acid is referred to as "amino acid-U / C") of the present disclosure may be different from each other. For the mutant tRNA, tRNA-G, and tRNA-U / C in the present disclosure, when the above-mentioned orthogonal relationship is established, M 1 M 2 A codon and amino acid - A, M 1 M 2 G codon and amino acid - G, M 1 M 2 U or M 1 M 2 C codons and amino acids -U / C correspond one to one in the current translation system. That is, in the translation system disclosed in the present invention, three codons (i) M 1 M 2 A. (ii) M 1 M 2 G and (iii) M 1 M 2 U or M 1 M 2 C translates three different amino acids. Alternatively, in the translation system disclosed herein, 1 M 2 U, M 1 M 2 C.M. 1 M 2 A and M 1 M 2 The codon box consisting of G translates three different amino acids.

[0601] In some embodiments, an unnatural amino acid can be linked to at least one of the mutant tRNAs, tRNA-G, and tRNA-U / C of the disclosure.

[0602] In some embodiments, the mutant tRNA of the present invention can be assigned to codons constituting at least one codon box in the genetic code table. In further embodiments, the mutant tRNA of the present invention can be assigned to codons constituting multiple codon boxes in the genetic code table. Multiple codon boxes can be, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 codon boxes. In addition to the mutant tRNA, tRNA-G may be assigned to other codons constituting the same codon box (codons different from the codons assigned to the mutant tRNA), or tRNA-U / C may be assigned to other codons constituting the same codon box (codons different from the codons assigned to the mutant tRNA and the codons assigned to the tRNA-G). The codon to which each tRNA will be assigned to constitutes the codon box is determined by the second letter (N) of the anticodon carried by the tRNA. 2 ) nucleotide and the third letter (N 3 ) nucleotides. tRNAs assigned to codons that form different codon boxes have different N 2 and N 3 . In addition, tRNAs assigned to codons constituting different codon boxes may have the same nucleic acid sequence except for the anticodon, or they may have nucleic acid sequences different from each other. When the nucleic acid sequences other than the anticodon are the same, the physicochemical properties of these tRNAs may be similar; therefore, a translation system with more uniform and stable reactivity can be constructed.

[0603] In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, 14, 15, 16, 17, 18, 19, or 20 amino acids can be translated from the translation system of the present disclosure. Alternatively, by using the mutant tRNAs of the present disclosure to distinguish between M in a single codon box, 1 M 2 A and M 1 M 2 G codon, more than 20 amino acids can be translated. In another embodiment, for example, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 or 48 amino acids can be translated from the translation system of the present disclosure.

[0604] In some embodiments, the translation system of the present disclosure is a cell-free translation system. In further embodiments, the translation system of the present disclosure is a reconstructed cell-free translation system. As the cell extract solution in the cell-free translation system and the factors (e.g., ribosomes) required for peptide translation, those from various biomaterials can be used. The example of this biomaterial includes Escherichia coli, yeast, wheat germ, rabbit reticulocytes, HeLa cells and insect cells.

[0605] On the one hand, the disclosure provides a method for producing a peptide, including translating a nucleic acid using a translation system described in the disclosure. The peptide of the disclosure may include a compound in which two or more amino acids are connected by an amide bond. In addition, the peptide of the disclosure may also include a compound in which an amino acid analog, such as a hydroxycarboxylic acid, replaces an amino acid and is connected by an ester bond. The number of amino acids or amino acid analogs contained in the peptide is not particularly limited, as long as it is 2 or more, such as 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, or 11 or more, and 100 or less, 80 or less, 50 or less, 30 or less, 25 or less, 20 or less, 19 or less, 18 or less, 17 or less, 16 or less, 15 or less, 14 or less, 13 or less, or 12 or less. Alternatively, the number may be selected from 9, 10, 11 and 12.

[0606] In one aspect, the peptides of the present disclosure may contain N-substituted amino acids, and the number of N-substituted amino acids included in the peptide may be, for example, 2, 3, 4, 5, 6, 6, 7, 8, 9, or 10. In another embodiment, the peptides of the present disclosure may contain amino acids that are not N-substituted, and the number of N-unsubstituted amino acids may be, for example, 1, 2, 3, or 4. In further embodiments, the peptides of the present disclosure may contain both N-substituted and N-unsubstituted amino acids.

[0607] In some embodiments, the peptide of the present disclosure can be a linear peptide or a peptide comprising a cyclic portion. The peptide comprising a cyclic portion refers to a main chain or side chain of an amino acid or amino acid analog present in the peptide chain connected to the main chain or side chain of another amino acid or amino acid analog present in the same peptide chain, forming a ring structure in the molecule. The peptide with a cyclic portion can be composed of only the cyclic portion, or can include both the cyclic portion and the linear portion. The number of amino acids or amino acid analogs included in the cyclic portion is, for example, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, or 9 or more, and 14 or less, 13 or less, 12 or less, or 11 or less. Alternatively, the number can be selected from 9, 10 and 11. The number of amino acids or amino acid analogs included in the linear portion is, for example, 0 or more, and can be 8 or less, 7 or less, 6 or less, 5 or less or 4 or less. Alternatively, the number can be selected from 0, 1, 2 and 3.

[0608] As a bond for forming a cyclic portion, for example, a peptide bond formed by an amino group and a carboxyl group can be used. In addition, an amide bond, a disulfide bond, an ether bond, a thioether bond, an ester bond, a thioester bond, a carbon-carbon bond, an alkyl bond, an alkenyl bond, a phosphonic acid ether bond, an azo bond, an amine bond, a C=NC bond, a lactam bridge, a carbamoyl bond, a urea bond, a thiourea bond, a thioamide bond, a sulfinyl bond, a sulfonyl bond, a triazole bond, a benzoxazole bond, and these bonds formed by a combination of appropriate functional groups can also be used. The carbon-carbon bond can be formed by a transition metal-catalyzed reaction such as a Suzuki reaction, a Heck reaction, and a Sonogashira reaction. In one embodiment, the peptide of the present disclosure contains at least one group of functional groups capable of forming the above-mentioned bonds in a molecule. The formation of the cyclic portion can be carried out by using a translation system of the present disclosure to produce a linear peptide and then separately carrying out a reaction for connecting the above-mentioned functional groups to each other. For the synthesis of peptides having cyclic portions, see WO2013 / 100132, WO2012 / 026566, WO2012 / 033154, WO2012 / 074130, WO2015 / 030014, WO2018 / 05020, Comb Chem High Throughput Screen (2010) 13: 75-87, Nat Chem Biol (2009) 5: 502-507, Nat Chem Biol (2009) 5: 888-90, Bioconjug Chem (2007) 18: 469-476, Chem Bio Chem (2009) 10: 787-99, Chem. Commun. (Camb) (2011) 47: 9946-9958, etc.

[0609] In some embodiments, the nucleic acid translated in the translation system of the present invention is mRNA. Peptides with a desired amino acid sequence can be encoded in mRNA. By adding mRNA to the translation system of the present invention, mRNA can be translated into peptides. On the other hand, when the translation system contains an RNA polymerase for transcribing DNA into mRNA, by adding DNA to the translation system of the present invention, DNA can be transcribed into mRNA and mRNA can be translated into peptides in combination.

[0610] Methionine is usually present as an initiator amino acid at the N-terminus of the translated peptide, but some methods for introducing amino acids other than methionine into the N-terminus have been reported. They can be used in combination with the method for producing peptides described in the present disclosure. Examples of this method include a method for translating a peptide from a desired amino acid using an initiator tRNA aminoacylated with an amino acid other than methionine (initiation inhibition). In particular, the tolerance for exogenous amino acids at the start of translation is higher than when the peptide chain is extended; therefore, at the N-terminus, even amino acids with structures that are very different from natural amino acids can be used (Goto & Suga, J Am Chem Soc (2009) 131 (14): 5040-5041). Another method includes, for example, a method for translating a peptide from a second or subsequent codon by removing the initiator methionyl tRNA from the translation system or by replacing the initiator amino acid with an amino acid with low translation efficiency other than methionine (initiation read-through; skipping the initiation codon). Another method includes, for example, removing the methionine at the N-terminus of the peptide by allowing enzymes such as peptide deformylase and methionine aminopeptidase to act (Meinnel et al., Biochimie (1993) 75: 1061-1075). A peptide library starting with methionine is prepared, and the above enzyme is allowed to act on the peptide library to prepare a peptide library starting with random amino acids at the N-terminus.

[0611] In another aspect, the present disclosure provides a peptide produced by the method for producing a peptide described in the present disclosure. A peptide obtained by further chemically modifying the peptide produced by the method described in the present disclosure is also included in the peptide provided by the present disclosure.

[0612] In one aspect, the present disclosure provides a method for producing a peptide library, comprising translating a nucleic acid library using a translation system described in the present disclosure. By preparing a plurality of nucleic acid molecules each encoding a peptide and being rich in nucleic acid sequence diversity, and then translating each of them into a peptide, a plurality of peptide molecules rich in amino acid sequence diversity can be produced. The size of the library is not particularly limited, and can be, for example, 10 6 or more, 10 7 or more, 10 8 or more, 10 9 or more, 10 10or more, 10 11 or more, 10 12 or more, 10 13 or more, or 10 14 or more. Nucleic acid can be DNA or RNA. RNA is usually mRNA. DNA is translated into peptides by being transcribed into mRNA. Such nucleic acid library can be prepared by methods known to those skilled in the art or similar methods. By using mixed bases at the desired position when synthesizing nucleic acid library, multiple nucleic acid molecules rich in nucleic acid sequence diversity can be easily prepared. Examples of codons using mixed bases are, for example, NNN (where N represents a mixture of 4 bases A, T, G and C), NNW (where W represents a mixture of 2 bases A and T), NNM (where W represents a mixture of two bases A and C), NNK (where K represents a mixture of two bases G and T) and NNS (where S represents a mixture of two bases C and G). Alternatively, by limiting the base used in the third letter of the codon to any one of A, T, G and C, a nucleic acid library in which only some specific amino acids are encoded can be synthesized. In addition, when preparing codons containing mixed bases, the frequency of occurrence of amino acids obtainable by codons can be arbitrarily adjusted by mixing multiple bases in different proportions rather than in equal proportions. By taking the above codon as a unit, preparing a plurality of different codon units, and then connecting them in the desired order, a library can be designed in which the occurrence positions and frequencies of the contained amino acids are controlled.

[0613] In some embodiments, the peptide library described in the present disclosure is a library in which peptides are displayed on nucleic acids (nucleic acid display library, or simply display library). Display libraries are libraries in which a single complex is formed by connecting a peptide to a nucleic acid encoding the peptide, and phenotype and genotype are associated with each other. Examples of major display libraries include mRNA display methods (Roberts and Szostak, Proc Natl Acad Sci USA (1997) 94: 12297-12302), in vitro viral methods (Nemoto et al., FEBS Lett (1997) 414: 405-408), cDNA display methods (Yamaguchi et al., Nucleic Acids Res (2009) 37: e108), ribosome display methods (Mattheakis et al., Proc Natl Acad Sci USA (1994) 91: 9022-9026), covalent display methods (Reiersen et al., Nucleic Acids Res (2005) 33: e10), CIS display methods (Odegrip et al., Proc Natl Acad Sci USA (2004) 101: 2806-2810) etc. Alternatively, a library prepared by using an in vitro compartmentalization method (Tawfik and Griffiths, Nat Biotechnol (1998) 16: 652-656) can be mentioned as one embodiment of the display library.

[0614] In another aspect, the present disclosure provides a peptide library produced by the method for producing a peptide library described in the present disclosure.

[0615] On the one hand, the present disclosure provides a method for identifying peptides with binding activity to a target molecule, including contacting the target molecule with a peptide library described in the present disclosure. The target molecule is not particularly limited and can be appropriately selected from, for example, low molecular weight compounds, high molecular weight compounds, nucleic acids, peptides, proteins, sugars and lipids. The target molecule can be a molecule present outside the cell or a molecule present inside the cell. Alternatively, it can be a molecule present in the cell membrane, in which case any one of the extracellular domain, the transmembrane domain and the intracellular domain can be a target. In the step where the target molecule contacts the peptide library, the target molecule is usually fixed on a certain solid phase carrier (e.g., a microtiter plate or microbeads). Then, by removing the peptides that are not connected to the target molecule and only recovering the peptides that are connected to the target molecule, the peptides with binding activity to the target molecule can be selectively concentrated (panning method). When the peptide library used is a nucleic acid display library, the recovered peptides have nucleic acids encoding their respective genetic information connected thereto; therefore, the nucleic acid sequence and amino acid sequence encoding the recovered peptides can be easily identified by separating and analyzing them. Furthermore, based on the obtained nucleic acid sequence or amino acid sequence, the identified peptides can be individually produced by chemical synthesis or gene recombination technology.

[0616] In one aspect, the present disclosure provides a nucleic acid-peptide complex comprising a peptide and a nucleic acid encoding the peptide, wherein the complex has the following characteristics:

[0617] (i) The nucleic acid sequence encoding the peptide contains two codons, M 1 M 2 A and M 1 M 2 G; and

[0618] (ii) In the amino acid sequence of the peptide, M 1 M 2 The amino acid corresponding to the A codon is 1 M 2 The G codon corresponds to a different amino acid.

[0619] In this paper, M 1 and M 2 Represents the first and second letters of a specific codon (but not including M 1 For A and M 2 is the codon for U).

[0620] In another aspect, the present disclosure provides a nucleic acid-peptide complex comprising a peptide and a nucleic acid encoding the peptide, wherein the complex has the following characteristics:

[0621] (i) The nucleic acid sequence encoding the peptide contains three codons, M 1 M 2 U, M 1 M 2 A and M1 M 2 G; and

[0622] (ii) In the amino acid sequence of the peptide, M 1 M 2 The amino acid corresponding to the U codon, 1 M 2 The amino acid corresponding to the A codon, 1 M 2 The amino acids corresponding to the G codons are all different.

[0623] In this article, M 1 and M 2 Represents the first and second letters of a specific codon, respectively.

[0624] In another aspect, the present disclosure provides a nucleic acid-peptide complex comprising a peptide and a nucleic acid encoding the peptide, wherein the complex has the following characteristics:

[0625] (i) The nucleic acid sequence encoding the peptide contains three codons, M 1 M 2 C.M. 1 M 2 A and M 1 M 2 G; and

[0626] (ii) In the amino acid sequence of the peptide, M 1 M 2 The amino acid corresponding to the C codon, 1 M 2 The amino acid corresponding to the A codon, 1 M 2 The amino acids corresponding to the G codons are different from each other.

[0627] In this article, M 1 and M 2 Represents the first and second letters of a specific codon, respectively.

[0628] In some embodiments, the above-mentioned nucleic acid-peptide complex can be included in a peptide library as one of the elements constituting the library (particularly a nucleic acid display library). In one aspect, the present disclosure provides a library (peptide library or nucleic acid display library) comprising the nucleic acid-peptide complex described in the present disclosure. In certain embodiments, the above-mentioned nucleic acid-peptide complex and library can be prepared using the mutant tRNA described in the present disclosure or the translation system described in the present disclosure.

[0629] In one aspect, the present disclosure provides a compound that is cytolysine diphosphate (pLp) or a salt thereof.

[0630]

[0631] This compound can be used to prepare a mutant tRNA into which cytidine is introduced. Therefore, the present disclosure relates to a method for producing a mutant tRNA into which cytidine is introduced using cytidine diphosphate, and a mutant tRNA produced by the method. The present disclosure also relates to a method for producing a mutant tRNA into which cytidine is introduced using cytidine diphosphate, wherein the mutant tRNA has an amino acid or an amino acid analog (aminoacyl mutant tRNA) connected thereto, and the aminoacyl mutant tRNA produced by the method. Such mutant tRNA and / or aminoacyl mutant tRNA can be used in the translation system of the present disclosure. Therefore, the present disclosure relates to a translation system comprising such mutant tRNA and / or aminoacyl mutant tRNA. The present disclosure also provides a method for producing a peptide or a peptide library using the translation system. The present disclosure also provides a peptide or a peptide library produced by the method.

[0632] In the present disclosure, cytosine can be introduced at position 34 of tRNA (based on the tRNA numbering rule). In one embodiment, a mutant tRNA that introduces cytosine at position 34 according to the tRNA numbering rule can be obtained by preparing one or more (e.g., 2, 3, 4, 5 or more) tRNA nucleic acid fragments and cytosine-diphosphate, and connecting them by methods known to those skilled in the art. Specifically, for example, a nucleic acid fragment consisting of bases at positions 1 to 33 of tRNA cytosine diphosphate, and a nucleic acid fragment consisting of bases at positions 35 to 76 of tRNA (or positions 35 to 75 of tRNA, or positions 35 to 74 of tRNA) are connected from the 5' side in this order. The CA sequence at the 3' end can be removed.

[0633] In one aspect, the present disclosure provides a compound that is agmatine-diphosphate (p(Agm)p) or a salt thereof.

[0634]

[0635] This compound can be used to prepare a mutant tRNA introduced with agmatine. Therefore, the present disclosure relates to a method for producing a mutant tRNA introduced with agmatine using agmatine diphosphate, and a mutant tRNA produced by the method. The present disclosure also relates to a method for producing a mutant tRNA introduced with agmatine using agmatine diphosphate, wherein the mutant tRNA has an amino acid or an amino acid analog (aminoacyl mutant tRNA) connected thereto, and the tRNA of aminoacyl mutation produced by the method. Such mutant tRNA and / or aminoacyl mutant tRNA can be used in the translation system of the present disclosure. Therefore, the present disclosure relates to a translation system comprising such mutant tRNA and / or aminoacyl mutant tRNA. The present disclosure also provides a method for producing a peptide or a peptide library using the translation system. The present disclosure also provides a peptide or a peptide library produced by the method.

[0636] In the present disclosure, agmatine can be introduced at position 34 of tRNA (based on the tRNA numbering rule). In one embodiment, a mutant tRNA that introduces agmatine at position 34 according to the tRNA numbering rule can be obtained by preparing one or more (e.g., 2, 3, 4, 5 or more) tRNA nucleic acid fragments and agmatine-diphosphate, and connecting them by methods known to those skilled in the art. Specifically, for example, a nucleic acid fragment consisting of bases at positions 1 to 33 of tRNA agmatine diphosphate, and a nucleic acid fragment consisting of bases at positions 35 to 76 of tRNA (or positions 35 to 75 of tRNA, or positions 35 to 74 of tRNA) are connected from the 5' side in this order. The CA sequence at the 3' end can be removed.

[0637] The compounds of the present disclosure may be free bodies or salts. Examples of salts of compounds of the present disclosure include the following: hydrochlorides; hydrobromides; hydroiodides; phosphates; phosphonates; sulfates; sulfonates such as methanesulfonates, p-toluenesulfonates; carboxylates such as acetates, citrates, malates, tartrates, succinates, salicylates; alkali metal salts such as sodium and potassium salts; alkaline earth metal salts such as magnesium salts, calcium salts; ammonium salts such as ammonium salts, alkylammonium salts, dialkylammonium salts, trialkylammonium salts and tetraalkylammonium salts. The salts of compounds of the present disclosure are prepared, for example, by contacting the compounds of the present disclosure with an acid or a base. The compounds of the present disclosure may be hydrates, and such hydrates are also included in the salts of the compounds of the present disclosure. In addition, the compounds of the present invention may be solvates, and such solvates are also included in the salts of the compounds of the present disclosure.

[0638] In one aspect, the present invention relates to a method for preparing lysine diphosphate or a derivative thereof, or agmatine diphosphate or a derivative thereof represented by the following formula A.

[0639]

[0640] In formula A, R 1 and R 2 Each independently is H or C 1 -C 3 Alkyl, preferably R 1 and R 2 Both are H.

[0641] In formula A, L is C 2 -C 6 Straight chain alkylene or C 2 -C 6 Straight chain alkenylene, optionally substituted by one or more selected from hydroxyl and C 1 -C 3 The alkyl group is substituted with a substituent, wherein C 2 -C6 The carbon atoms of the straight chain alkylene group are optionally substituted by an oxygen atom or a sulfur atom. 2 -C 6 The straight chain alkylene group is preferably C 4 -C 5 Straight chain alkylene, C 2 -C 6 The straight chain alkenylene group is preferably C 4 -C 5 Straight chain alkenylene. Specific examples of such L include -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 、-(CH 2 ) 2 -O-CH 2 -、-(CH 2 ) 2 -S-CH 2 -、-CH 2 CH(OH)(CH 2 ) 2 -and-CH 2 CH=CH- (cis or trans).

[0642] In formula A, M is a single bond,

[0643]

[0644] The wavy line indicates the connection point to the carbon atom, the * indicates the connection point to the hydrogen atom, and the ** indicates the connection point to the nitrogen atom. When M is a single bond, the H connected to M does not exist. For example, when M is

[0645]

[0646] The compound of formula A can be represented as follows:

[0647]

[0648] When M is

[0649]

[0650] The compound of formula A can be represented as follows:

[0651]

[0652] When M is a single bond, the compound of formula A can be represented as:

[0653]

[0654] The compound represented by formula A is preferably lysine diphosphate, agmatine diphosphate or a salt thereof.

[0655] In some embodiments, compounds of Formula A can be prepared according to Scheme 1 as shown below.

[0656] Option I:

[0657]

[0658]

[0659]

[0660] Step 1 of Scheme 1 is a step of intramolecularly cyclizing the compound represented by Formula B1 to obtain the compound represented by Formula C1. This step can be carried out by stirring the reaction mixture in the presence of an intramolecular cyclization agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours.

[0661] The compounds represented by formula B1 are available from commercial suppliers or they can be produced using methods known in the literature. 11 PG is a protecting group for the amino group, and any protecting group may be used as long as it does not interfere with the reaction process according to the above scheme 1; for example, a protecting group that is not deprotected by acid or fluoride ion is preferred. 11 Specific examples include p-bromobenzoyl, optionally substituted benzoyl, pyridinecarbonyl and acetyl.

[0662] The intramolecular cyclization agent is not particularly limited, but diisopropyl azodicarboxylate and triphenylphosphine can be preferably used.

[0663] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, and ketone solvents, and dichloromethane may be preferably used.

[0664] Step 2 of Scheme 1 is a step of introducing an amine represented by formula D1 into a compound represented by formula C1 to obtain a compound represented by formula E1. This step can be carried out by stirring the reaction mixture in the presence of an amine-introducing agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours.

[0665] The amine-introducing reagent is not particularly limited, but lithium chloride and DBU can be preferably used.

[0666] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents and ketone solvents, and tetrahydrofuran is preferably used in this step.

[0667] Steps 3A and 3B of Scheme 1 are to convert PG 12 and / or PG 13 The step of introducing into the compound represented by formula E1 to obtain the compound represented by formula F1A or F1B. 2 When it is an alkyl group, only PG is introduced 13 Formula F1A is obtained; when R of formula E1 2 When hydrogen is used, PG is introduced 12 and PG 13 Formula F1B is obtained. This step can be carried out by stirring the reaction mixture in the presence of a reagent for introducing a protecting group in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably at 0°C to 180°C, for 15 minutes to 48 hours.

[0668] PG 12 PG is the protecting group of amino group. 13 is a protecting group for a carboxyl group or an imino group. Any protecting group may be used as long as it does not interfere with the reaction process according to the above scheme 1; for example, a protecting group that is not deprotected by acid or fluoride ion is preferred. Fmoc is preferably used as PG 12 ; When M is

[0669]

[0670] Methyl, ethyl or optionally substituted benzyl is preferably used as PG 13 , and when M is

[0671]

[0672] Optionally substituted benzyl, Cbz or optionally substituted benzyloxycarbonyl is preferably used as PG 13 PG 12 and PG 13 They can be introduced simultaneously or sequentially. When they are introduced sequentially, PG can be introduced first. 12 or PG 13 , but it is preferred to introduce PG first 12 , then introduce PG 13 For the introduction of the protecting group, for example, the method described in "Greene's, "Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)" can be used; and when PG 12 When Fmoc is used, it is preferred to use (2,5-dioxopyrrolidin-1-yl)(9H-fluorene-9-yl)methyl carbonate and sodium carbonate to introduce Fmoc. 13 In the case of a methyl group, it is preferred to introduce the methyl group using N,N'-diisopropylcarbodiimide, methanol and N,N-dimethyl-4-aminopyridine.

[0673] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents and ketone solvents. Dioxane is preferably used when Fmoc is introduced, and dichloromethane is preferably used when a methyl group is introduced.

[0674] Steps 4A and 4B of Scheme 1 are to remove the acetone compound from the compound represented by Formula F1A or F1B and introduce PG 14 and PG 15 A step of obtaining a compound represented by formula G1A or G1B. The acetonide may be removed in the presence of an acid, and the protective group may be introduced by stirring the reaction mixture in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours in the presence of a reagent for introducing a protective group.

[0675] PG 14 and PG 15 Each is independently a protecting group for a hydroxyl group, and any protecting group may be used as long as it does not interfere with the reaction process according to the above scheme 1; for example, a silyl protecting group that is deprotected by fluoride ion is preferably used. Preferably PG 14 and PG 15 Together, they form a divalent protecting group, and specific examples of such protecting groups include di-tert-butylsilyl. For the removal of acetone compounds and the introduction of protecting groups, for example, the method described in "Greene's, "Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)" can be used; the acid used to remove acetone compounds is preferably TFA. When PG 14 and PG 15 When a di-tert-butylsilyl group is formed together, it is preferred to introduce the di-tert-butylsilyl group by using di-tert-butylsilylbis(trifluoromethanesulfonate).

[0676] As the solvent for removing the acetone compound, examples include water and carboxylic acid solvents, and preferably a mixed solvent of water and TFA is used. 14 and PG 15 Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and amide solvents, and DMF is preferably used.

[0677] Steps 5A and 5B of Scheme 1 are to convert PG 16 A step of introducing PG into a compound represented by formula G1A or G1B to obtain a compound represented by formula H1A or H1B. 16The introduction can be carried out by stirring the reaction mixture in the presence of a reagent for introducing a protecting group in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably at a temperature of 0°C to 180°C, for 15 minutes to 48 hours.

[0678] PG 16 is a protecting group for hydroxyl and / or amino groups, and any protecting group may be used as long as it does not interfere with the reaction process according to the above scheme 1; for example, it is preferred to use a protecting group that is not deprotected by fluoride ions. TOM is preferably used for PG 16 For the introduction of protecting groups, for example, the method described in "Greene's, "Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)" can be used; when PG 16 In the case of TOM, it is preferred to use DIPEA and (triisopropylsiloxy)methyl chloride to introduce TOM.

[0679] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and amide solvents, and dichloromethane is preferably used.

[0680] Steps 6A and 6B of Scheme 1 are to remove PG from the compound represented by formula G1A or G1B. 14 and PG 15 Steps for obtaining a compound represented by formula I1A or I1B. 14 and PG 15 The removal can be carried out by stirring the reaction mixture in the presence of a deprotecting agent in a solvent at a temperature from -20°C to about the boiling point of the solvent, preferably at 0°C to 180°C, for 15 minutes to 48 hours.

[0681] Any reagent can be used as a deprotection reagent as long as it can selectively remove only PG 14 and PG 15 However, when PG 14 and PG 15 When a di-tert-butylsilyl group is formed together, it is preferably removed using a fluoride ion generating agent, or more specifically, such as a hydrogen fluoride pyridine complex.

[0682] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and amide solvents, and THF is preferably used.

[0683] Steps 7A and 7B of Scheme 1 are steps of phosphitylation of a compound represented by Formula I1A or I1B, followed by oxidation to obtain a compound represented by Formula J1A or J1B. Phosphitylation can be carried out by stirring the reaction mixture in the presence of a phosphitylation agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours. Oxidation can be carried out by stirring the reaction mixture in the presence of an oxidizing agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours. The compound may be isolated after phosphitylation, but it is preferred to carry out the phosphitylation reaction and oxidation reaction in one pot.

[0684] In formula J1A or J1B, PG 17 is a protecting group for the hydroxyl group, and any protecting group may be used as long as it does not interfere with the reaction process according to the above scheme 1; for example, it may be combined with PG 11 PG 12 and PG 13 Simultaneous deprotection of protecting groups is preferred. 17 The specific example includes cyanoethyl. The phosphitylation reagent in which the hydroxyl group is protected by a protecting group can be used, or an unprotected phosphitylation reagent can be used, and then the protecting group can be introduced into the hydroxyl group. For the introduction of the protecting group, for example, the method described in "Greene's, "Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)" can be used. When using a phosphitylation reagent with a hydroxyl group protected by cyanoethyl, preferably bis (2-cyanoethyl) -N, N- diisopropyl amino phosphoramidite is used as the phosphitylation reagent. The oxidant used in the oxidation after phosphitylation is not particularly limited, and preferably tert-butyl hydroperoxide is used.

[0685] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and nitrile solvents, and acetonitrile is preferably used.

[0686] Steps 8A and 8B of Scheme 1 are to remove PG from the compound represented by Formula J1A. 11 PG 12 PG 13 and PG 17 , or removing PG from the compound represented by formula J1B 11 PG 13 and PG 17 , a step of obtaining a compound represented by formula K1. These protecting groups can be removed by stirring the reaction mixture in the presence of a deprotecting agent in a solvent at a temperature from -20°C to about the boiling point of the solvent, preferably from 0°C to 180°C, for 15 minutes to 48 hours.

[0687] Any reagent can be used as the deprotecting reagent as long as it can selectively remove the above-mentioned protecting group. Specific examples of such a reagent include combined use of bis-(trimethylsilyl)acetamide and DBU.

[0688] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents, nitrile solvents and amine solvents, and pyridine is preferably used.

[0689] Step 9 of Scheme 1 is to remove PG from the compound represented by Formula K1. 16 Steps for obtaining a compound represented by formula A. PG 16 The removal can be carried out by stirring the reaction mixture in the presence of a deprotecting agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours.

[0690] Any deprotection reagent can be used as long as it can selectively remove only PG. 16 That is, ammonium fluoride is preferably used.

[0691] Examples of the solvent include water, halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents, and nitrile solvents, and a combined solvent consisting of water and acetonitrile may be preferably used.

[0692] In one embodiment, compounds of Formula A can be prepared according to Scheme 2 as shown below.

[0693] Scenario 2:

[0694]

[0695]

[0696] Step 1 of Scheme 2 is a step of intramolecularly cyclizing the compound represented by Formula B2 to obtain a compound represented by Formula C2. This step can be carried out by stirring the reaction mixture in the presence of an intramolecular cyclization agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours.

[0697] Compounds represented by formula B2 are available from commercial suppliers or they can be produced using methods known in the literature. 21 PG is a protecting group for the amino group, and any protecting group may be used as long as it does not affect the reaction process according to the above scheme 2; for example, a protecting group that is not deprotected by acid or fluoride ion is preferred. 21 Specific examples include Cbz, optionally substituted benzyloxycarbonyl and optionally substituted benzyl.

[0698] The intramolecular cyclization agent is not particularly limited, but diisopropyl azodicarboxylate and triphenylphosphine can be preferably used.

[0699] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, and ketone solvents, and dichloromethane may be preferably used.

[0700] Step 2 of Scheme 2 is a step of introducing an amine represented by formula D2A or D2B into a compound represented by formula C2 to obtain a compound represented by formula E2A or E2B. This step can be carried out by stirring the reaction mixture in the presence of an amine-introducing agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours.

[0701] The amine-introducing reagent is not particularly limited, but lithium chloride and DBU can be preferably used.

[0702] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, and ketone solvents, and THF is preferably used in this step.

[0703] Steps 3A and 3B of Scheme 2 are to remove the acetone compound from the compound represented by Formula E2A or E2B and introduce PG 24 and PG 25 The step of obtaining a compound represented by formula F2A or F2B. The acetone compound may be removed in the presence of an acid, and the protective group may be introduced by stirring the reaction mixture in the presence of a reagent for introducing a protective group in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours.

[0704] PG 24 and PG 25 Each is independently a protecting group for a hydroxyl group, and any protecting group may be used as long as it does not interfere with the reaction process according to the above scheme 2; for example, a silyl protecting group that is deprotected by fluoride ion is preferably used. Preferably PG 24 and PG 25 Together, they form a divalent protecting group, and specific examples of such protecting groups include di-tert-butylsilyl. For the removal of acetone compounds and the introduction of protecting groups, for example, the method described in "Greene's, "Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)" can be used; the acid used to remove acetone compounds is preferably TFA. When PG 24 and PG 25 When a di-tert-butylsilyl group is formed together, it is preferred to introduce the di-tert-butylsilyl group by using di-tert-butylsilylbis(trifluoromethanesulfonate).

[0705] As the solvent for removing the acetone compound, examples include water and carboxylic acid solvents, and preferably a mixed solvent of water and TFA is used. 24 and PG 25 Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and amide solvents, and DMF is preferably used.

[0706] Steps 4A and 4B of Scheme 2 are to convert PG 26 A step of introducing a compound represented by formula F2A or F2B to obtain a compound represented by formula G2A or G2B. 26 The introduction can be carried out by stirring the reaction mixture in the presence of a reagent for introducing a protecting group in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours.

[0707] PG 26 is a protecting group for the hydroxyl group, and any protecting group may be used as long as it does not affect the progress of the reaction according to the above Scheme 2; for example, a protecting group that is not deprotected by fluoride ion is preferred. PG 26 Preferably, tetrahydropyranyl, tetrahydrofuranyl or methoxymethyl is used. For the introduction of the protecting group, for example, the method described in "Greene's, "Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)" can be used; when PG 16 In the case of tetrahydropyranyl, it is preferred to introduce the tetrahydropyranyl group using TFA and 3,4-dihydro-2H-pyran.

[0708] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and amide solvents, and dichloromethane is preferably used.

[0709] Steps 5A and 5B of Scheme 2 are to remove PG from the compound represented by formula G2A or G2B. 24 and PG 25 Step of obtaining a compound represented by formula H2A or H2B. 24 and PG 25 The removal can be carried out by stirring the reaction mixture in the presence of a solvent deprotecting agent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours.

[0710] Any deprotection reagent can be used as long as it can selectively remove only PG. 24 and PG 25 ; However, when PG 24 and PG 25When a di-tert-butylsilyl group is formed together, it is preferably removed using a fluoride ion generating agent, or more specifically, tetrabutylammonium fluoride, for example.

[0711] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and amide solvents, and THF is preferably used.

[0712] Steps 6A and 6B of Scheme 2 are steps of phosphitylation of a compound represented by formula H2A or H2B, followed by oxidation to obtain a compound represented by formula I2A or I2B. Phosphitylation can be carried out by stirring the reaction mixture in the presence of a phosphitylation agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours. Oxidation can be carried out by stirring the reaction mixture in the presence of an oxidizing agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours. The compound can be isolated after phosphitylation, but it is preferred to carry out the phosphitylation reaction and oxidation reaction in one pot.

[0713] In formula I2A or I2B, PG 27 Any protective group can be used as long as it does not interfere with the reaction process according to the above scheme 2, preferably a protective group that can be used with PG 21 PG 22 and PG 23 Simultaneous deprotection of protecting groups. PG 27 Specific examples include benzyl. A phosphitylation reagent in which a hydroxyl group is protected by a protecting group can be used, or an unprotected phosphitylation reagent can be used, and then the protecting group can be introduced into the hydroxyl group. For the introduction of the protecting group, for example, the method described in "Greene's, "Protective Groups in Organic Synthesis" (5th edition, John Wiley & Sons 2014)" can be used. When a phosphitylation reagent having a hydroxyl group protected by a benzyl group is used, dibenzyl-N, N-diisopropylphosphoramidite is preferably used as the phosphitylation reagent. The oxidant used in the oxidation after phosphitylation is not particularly limited, but Dess-Martin periodinane is preferably used.

[0714] Examples of the solvent include halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents and nitrile solvents, and acetonitrile is preferably used.

[0715] Steps 7A and 7B of Scheme 2 are to remove PG from the compound represented by Formula I2A. 21 PG 22 PG 23 and PG27 , or removing PG from the compound represented by formula I2B 21 PG 23 and PG 27 , a step of obtaining a compound represented by formula J2. These protecting groups can be removed by stirring the reaction mixture in the presence of a deprotecting agent in a solvent at a temperature from -20°C to about the boiling point of the solvent, preferably at 0°C to 180°C, for 15 minutes to 48 hours.

[0716] Any method can be used for deprotection, as long as the above-mentioned protecting group can be selectively removed. Specific examples of this method include catalytic hydrogenation. For catalytic hydrogenation, Pd catalysts such as palladium-carbon can be preferably used.

[0717] Examples of the solvent include water, alcohol solvents, halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents, nitrile solvents, and amine solvents, and a combined solvent consisting of water and methanol is preferably used.

[0718] Step 8 of Scheme 2 is to remove PG from the compound represented by Formula J2. 26 Steps for obtaining a compound represented by formula A. PG 26 The removal can be carried out by stirring the reaction mixture in the presence of a deprotecting agent in a solvent at a temperature of -20°C to about the boiling point of the solvent, preferably 0°C to 180°C, for 15 minutes to 48 hours.

[0719] Any reagent can be used as the deprotection reagent as long as it can selectively remove PG. 26 That is, hydrochloric acid is preferably used.

[0720] Examples of the solvent include water, halogenated solvents, ether solvents, benzene solvents, ester solvents, ketone solvents, and nitrile solvents, and water can be preferably used.

[0721] All prior art documents cited in this specification are incorporated herein by reference.

[0722] Example

[0723] The present invention is further illustrated by the following examples, but is not limited thereto.

[0724] The following abbreviations are used in the examples.

[0725] AA: Ammonium acetate

[0726] CH 2 CN:Cyanomethoxy

[0727] DBU: 1,8-diazabicyclo[5.4.0]-7-undecene

[0728] DCM: dichloromethane

[0729] DIC: N,N-diisopropylcarbodiimide

[0730] DIPEA: N,N-diisopropylethylamine

[0731] DMF: dimethylformamide

[0732] DMSO: dimethyl sulfoxide

[0733] FA: Formic acid

[0734] Fmoc: 9-fluorenylmethoxycarbonyl group

[0735] F-Pnaz: 4-(2-(4-fluorophenyl)acetylamino)benzyloxycarbonyl group

[0736]

[0737] HFIP: 1,1,1,3,3,3-hexafluoro-2-propanol

[0738] MeCN: Acetonitrile

[0739] NMP: N-methyl-2-pyrrolidone

[0740] TEA: triethylamine

[0741] TFA: trifluoroacetic acid

[0742] TFE: 2,2,2-trifluoroethanol

[0743] THF: Tetrahydrofuran

[0744] The following abbreviations are used in this example. Gly or G (glycine), Ile or I (isoleucine), Leu or L (leucine), Phe or F (phenylalanine), Pro or P (proline), Thr or T (threonine). In addition, the abbreviations shown in Table 2 are also used.

[0745] [Table 2]

[0746]

[0747] The LCMS analysis conditions are shown in Table 3 below.

[0748] [Table 3]

[0749]

[0750]

[0751] Example 1 Synthesis of uridine diphosphate by introducing uridine units at the 3' end of tRNA fragments by ligation

[0752] In order to introduce a uridine unit into the 3' end of the tRNA fragment by ligation, uridine diphosphate (SS01, pUp) was synthesized according to the method described in the reference (Nucleic Acids Research 2003, 31(22), e145).

[0753] ((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-3-(phosphonooxy) Tetrahydrofuran-2-yl)methyl dihydrogen phosphate (compound SS02) and ((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydrogen Pyrimidin-1(2H)-yl)-3-hydroxy-4-(phosphonooxy)tetrahydrofuran-2-yl)methyl di Synthesis of a mixture of hydrogen phosphates (compound SS03) (compound SS01, pUp)

[0754]

[0755] 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (10 mg, 0.041 mmol) and pyrophosphate tetrachloride (56.6 μL, 0.409 mmol) were mixed in an ice bath. After the reaction mixture was stirred at 0°C for 5 hours, ice-cooled pure water (38 mL) and triethylammonium bicarbonate buffer (1 M, 2 mL) were added under ice cooling. The mixture was purified by DEAE-Sephadex A-25 column chromatography (0.05 M triethylammonium bicarbonate buffer → 1 M triethylammonium bicarbonate buffer), and the collected solution was concentrated under reduced pressure. The obtained residue was purified by reverse phase silica gel column chromatography (15 mM TEA and 400 mM HFIP aqueous solution / 15 mM TEA and 400 mM HFIP methanol solution) to obtain an aqueous solution of a mixture of ((2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methyl dihydrogen phosphate (compound SS02) and ((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxy-4-(phosphonooxy)tetrahydrofuran-2-yl)methyl dihydrogen phosphate (compound SS03) (100 μL, 40.30 mM) (compound SS01, pUp).

[0756] LCMS (ESI) m / z = 403 (MH) -

[0757] Retention time: 1.79 minutes, 1.89 minutes (analysis conditions LTQTEA / HFIP05_01)

[0758] Example 2 Synthesis of Lysine Diphosphate by Introducing Lysine Units at the 3' End of tRNA Fragments by Ligation

[0759] In order to introduce a lysine unit at the 3' end of the tRNA fragment by a ligation method, lysine diphosphate was synthesized. More specifically, lysine diphosphate (SS04, pLp) was synthesized according to the following scheme.

[0760]

[0761] N6-(4-(4-bromobenzamido)-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuran Furo[3,4-d][1,3]dioxolan-4-yl)pyrimidin-2(1H)-ylidene)-L-lysine 2,2,2-trifluoroacetate Synthesis of (Compound SS05)

[0762]

[0763] Under nitrogen atmosphere, THF (6.7 mL) was added to (((9H-fluoren-9-yl)methoxy)carbonyl)-L-lysine hydrochloride (813 mg, 2.01 mmol), lithium chloride (213 mg, 5.02 mmol) and N synthesized by the method described in the literature (Org. Lett. 2012, 14 (16), 4118-4121) at room temperature. 4 -4-bromobenzoyl-2',3'-O-isopropylidene-O2,5'-cyclocytidine (300 mg, 0.067 mmol). After cooling the mixture in an ice bath, DBU (1.50 mL, 10.04 mmol) was added. The reaction mixture was stirred at 0°C for 1 hour and then purified by reverse phase silica gel column chromatography (0.1% FA aqueous solution / 0.1% FA-acetonitrile solution) to give N 6 -(4-(4-bromobenzamido)-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolan-4-yl)pyrimidin-2(1H)-ylidene)-L-lysine 2,2,2-trifluoroacetate (Compound SS05) (335.6 mg, 71%).

[0764] LCMS (ESI) m / z = 594 (M + H) +

[0765] Retention time: 0.41 minutes (analysis conditions SQDFA05_01)

[0766] N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromobenzamido)-1-((3aR,4R,6R, 6aR)-6-(Hydroxymethyl)2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolan-4-yl)pyrimidine-2 Synthesis of (1H)-L-lysine 2,2,2-trifluoroacetate (Compound SS06)

[0767]

[0768] N 6-(4-(4-bromobenzamido)-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolan-4-yl)pyrimidin-2(1H)-ylidene)-L-lysine 2,2,2-trifluoroacetate (Compound SS05) (311.12 mg, 0.44 mmol) and (2,5-dioxopyrrolidin-1-yl)(9H-fluoren-9-yl)methyl carbonate (148.09 mg, 0.44 mmol) were dissolved in a mixed solvent of 1,4-dioxane (2.75 mL) and ultrapure water (1.65 mL) at room temperature. After cooling the mixture with an ice bath, sodium carbonate (186.22 mg, 1.76 mmol) was added, and then the mixture was warmed to room temperature and stirred at room temperature for 2 hours. The reaction solution was concentrated, and the residue was purified by reverse phase silica gel column chromatography (0.05% TFA aqueous solution / 0.05% TFA-acetonitrile solution) to obtain N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-(4-(4-bromobenzamido)-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolan-4-yl)pyrimidin-2(1H)-ylidene)-L-lysine 2,2,2-trifluoroacetate (Compound SS06) (328.78 mg, 80%).

[0769] LCMS (ESI) m / z = 816 (M + H) +

[0770] Retention time: 0.68 minutes (Analysis conditions SQDFA05_01)

[0771] N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromobenzamido)-1-((3aR,4R,6R, 6aR)-6-(Hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolan-4-yl)pyrimidine-2 Synthesis of (1H)-Lysine methyl ester 2,2,2-trifluoroacetate (Compound SS07)

[0772]

[0773] In a nitrogen atmosphere, N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6-(4-(4-bromobenzamido)-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl))-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolan-4-yl)pyrimidin-2(1H)-ylidene)-L-lysine 2,2,2-trifluoroacetate (Compound SS06) (438.60 mg, 0.47 mmol) was dissolved in DCM (4.71 mL) at room temperature. After cooling the mixture in an ice bath, N,N'-diisopropylcarbodiimide (221.40 μL, 1.41 mmol), methanol (382.07 μL, 9.42 mmol) and N,N-dimethyl-4-aminopyridine (11.51 mg, 0.09 mmol) were added, and then the mixture was warmed to room temperature and stirred at room temperature for 2 hours. The reaction solution was concentrated, and the residue was purified by reverse phase silica gel column chromatography (0.05% TFA aqueous solution / 0.05% TFA-acetonitrile solution) to obtain N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromobenzamido)-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolan-4-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester 2,2,2-trifluoroacetate (Compound SS07) (405.00 mg, 91%).

[0774] LCMS (ESI) m / z = 828 (MH) -

[0775] Retention time: 0.76 minutes (Analysis conditions SQDFA05_02)

[0776] N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromobenzamido)-1-((2R,3R,4S,5R)- 3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester 2,2,2-trifluoroethyl Synthesis of acid salt (compound SS08)

[0777]

[0778] N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6-(4-(4-bromobenzamido)-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolan-4-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester 2,2,2-trifluoroacetate (Compound SS07) (308.70 mg, 0.33 mmol) was dissolved in a mixed solvent of TFA (8.71 mL) and ultrapure water (4.36 mL) while cooling in an ice bath, and the mixture was stirred at room temperature for 45 minutes. The reaction solution was concentrated to obtain a crude product, N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromobenzamido)-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester 2,2,2-trifluoroacetate (Compound SS08) (296.00 mg). The obtained crude product N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-Bromobenzamido)-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester 2,2,2-trifluoroacetate (Compound SS08) was used directly in the next step.

[0779] LCMS (ESI) m / z = 790 (M + H) +

[0780] Retention time: 0.70 minutes (Analysis conditions SQDFA05_02)

[0781] N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromobenzamido)-1-((4aR,6R,7R, 7aS)-2,2-di-tert-butyl-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxasilane (dioxasilin)-6-yl)pyrimidine-2(1H)-ylidene)-L-lysine Methyl ester Synthesis of (Compound SS09)

[0782]

[0783] Under nitrogen atmosphere, the crude product obtained in the previous step was 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6-(4-(4-bromobenzamido)-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl 2,2,2-trifluoroacetate (Compound SS08) (296.00 mg (0.33 mmol) was dissolved in DMF (3.27 mL) at room temperature. After cooling the mixture in an ice bath, di-tert-butylsilyl bis(trifluoromethanesulfonate) (211.80 μL, 0.65 mm ol), and the mixture was stirred in an ice bath for 1 hour. Di-tert-butylsilyl bis(trifluoromethanesulfonate) (158.85 μL, 0.49 mmol) was further added, and the mixture was stirred in an ice bath for 30 minutes. Saturated aqueous sodium bicarbonate solution was added to the reaction solution, the resulting mixture was extracted with DCM, and the organic layer was washed with saturated brine. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure. The obtained residue was purified by normal phase silica gel column chromatography (n-hexane / ethyl acetate, dichloromethane / methanol) to obtain N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromobenzamido)-1-((4aR,6R,7R,7aS)-2,2-di-tert-butyl-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxasilin-6-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS09) (273.80 mg, 90%, 2 steps).

[0784] LCMS (ESI) m / z = 928.5 (MH) -

[0785] Retention time: 0.92 minutes (analysis conditions SQDFA05_02)

[0786] N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromo-N-(((triisopropylsilyl)oxy) methyl)benzamido)-1-((4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-((((triisopropylsilyl)oxy) 2-((methoxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilin-6-yl)pyrimidine Synthesis of (1H)-L-lysine methyl ester (Compound SS10)

[0787]

[0788] In a nitrogen atmosphere, N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6-(4-(4-Bromobenzamido)-1-((4aR,6R,7R,7aS)-2,2-di-tert-butyl-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxasilin-6-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS09) (386.15 mg, 0.42 mmol) was dissolved in DCM (8.30 mL) at room temperature, and DIPEA (722.88 μL, 4.15 mmol) and (triisopropylsiloxy)methyl chloride (481.40 μL, 2.07 mmol) were added. The reaction mixture was stirred at 45°C for three hours, then returned to room temperature, DIPEA (722.88 μL, 4.15 mmol) and (triisopropylsilyloxy)methyl chloride (481.40 μL, 2.07 mmol) were added, and the reaction mixture was stirred at 45°C for four hours. After the mixture was returned to room temperature, DMSO was added, and DCM was removed by nitrogen. The resulting DMSO solution was purified by reverse phase silica gel column chromatography (0.05% TFA aqueous solution / 0.05% TFA-acetonitrile solution). The obtained fraction was neutralized with saturated sodium bicarbonate, and the target compound was extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure to obtain N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromo-N-((((triisopropylsilyl)oxy)methyl)benzamido)-1-((4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-(((triisopropylsilyl)oxy)methoxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilin-6-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS10) (291.55 mg, 54%).

[0789] LCMS (ESI) m / z = 1303 (M + H) +

[0790] Retention time: 0.84 minutes (analysis conditions SQDFA50)

[0791] N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromo-N-(((triisopropylsilyl)oxy) methyl)benzoylamino)-1-((2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-(((triisopropylsilyl)oxy (1H)-ylidene)-L-lysine methyl ester Synthesis of (Compound SS11)

[0792]

[0793] In a nitrogen atmosphere, N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6-(4-(4-bromo-N-((((triisopropylsilyl)oxy)methyl)benzamido)-1-((4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-(((triisopropylsilyl)oxy)methoxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilin-6-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS10)(14 1.55mg, 0.11mmol) was dissolved in THF (2.17mL) and cooled to -80°C. Hydrogen fluoride pyridine complex (about 30% pyridine, about 70% hydrogen fluoride) (9.85μL) diluted with pyridine (134.41μL) was added at -80°C, and the reaction mixture was stirred at -15°C for 15 minutes. After cooling to -80°C, methoxytrimethylsilane (7.0mL) was added, and the resulting mixture was purified by reverse phase silica gel column chromatography (0.05% TFA aqueous solution / 0.05% TFA-acetonitrile solution). The obtained fraction was neutralized with saturated sodium bicarbonate, and the target compound was extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and then toluene was added, and the mixture was concentrated under reduced pressure to obtain a crude product, N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromo-N-(((triisopropylsilyl)oxy)methyl)benzamido)-1-((2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-((((triisopropylsilyl)oxy)methoxy)tetrahydrofuran-2-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS11) (61.53 mg). The crude product N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromo-N-(((triisopropylsilyl)oxy)methyl)benzamido)-1-((2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-((((triisopropylsilyl)oxy)methoxy)tetrahydrofuran-2-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS11) was used directly in the next step.

[0794] LCMS (ESI) m / z = 1162.8 (M+H) +

[0795] Retention time: 3.69 minutes (analysis conditions SQDFA05long)

[0796] N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(1-((2R,3R,4R,5R)-4-((bis(2-cyanoethoxy (((((bis(2-cyanoethoxy)phosphoryl)oxy)methyl)-3-((((triisopropylsilane (((triisopropylsilyl)oxy)methyl)benzoyl)-4-(4-bromo-N-(((triisopropylsilyl)oxy)methyl)-2-(tetrahydrofuran-2-yl)-4-(4-bromo-N-(((triisopropylsilyl)oxy)methyl)benzoyl) Synthesis of (amino)pyrimidine-2(1H)-ylidene)-L-lysine methyl ester (compound SS12)

[0797]

[0798] Under nitrogen atmosphere, the crude product N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(4-(4-bromo-N-(((triisopropylsilyl)oxy)methyl)benzamido)-1-((2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-((((triisopropylsilyl)oxy)methoxy)tetrahydrofuran-2-yl)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS11) (61.53 mg, 0.053 mmol) and 1H-tetrazole (44.48 mg, 0.64 mmol) were dissolved in ethyl acetate at room temperature. nitrile (3.53mL). After cooling the mixture in an ice bath, bis(2-cyanoethyl)-N,N-diisopropylaminophosphoramidite (82.77μL, 0.32mmol) was added, the mixture was warmed to room temperature, and stirred at room temperature for 3 hours. At room temperature, tert-butyl hydroperoxide 5-6M decane solution (303.92μL, 3.17mmol) was added, stirred for 10 minutes, and the reaction solution was concentrated. The residue was purified by normal phase silica gel column chromatography (n-hexane / ethyl acetate, dichloromethane / methanol) to obtain a crude product, N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(1-((2R,3R,4R,5R)-4-(((bis(2-cyanoethoxy)phosphoryl)oxy)-5-((((bis(2-cyanoethoxy)phosphoryl)oxy)methyl)-3-((((triisopropylsilyl)oxy)methoxy)tetrahydrofuran-2-yl)-4-(4-bromo-N-(((triisopropylsilyl)oxy)methyl)benzamido)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS12) (54.33 mg). The crude product N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(1-((2R,3R,4R,5R)-4-((bis(2-cyanoethoxy)phosphoryl)oxy)-5-(((bis(2-cyanoethoxy)phosphoryl)oxy)methyl)-3-((((triisopropylsilyl)oxy)methoxy)tetrahydrofuran-2-yl)-4-(4-bromo-N-(((triisopropylsilyl)oxy)methyl)benzamido)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS12) was used directly in the next step.

[0799] LCMS (ESI) m / z = 1534.9 (M + H) +

[0800] Retention time: 3.62 minutes (analysis conditions SQDFA05long)

[0801] N 6 -(1-((2R,3R,4R,5R)-4-(phosphonooxy)-5-((phosphonooxy)methyl)-3-(((triisopropylmethyl) ((((triisopropylsilyl)oxy)methyl) Synthesis of (amino)pyrimidine-2(1H)-ylidene)-L-lysine (Compound SS13)

[0802]

[0803] Under nitrogen atmosphere, the crude product N 2 -(((9H-fluoren-9-yl)methoxy)carbonyl)-N 6 -(1-((2R,3R,4R,5R)-4-((bis(2-cyanoethoxy)phosphoryl)oxy)-5-((((bis(2-cyanoethoxy)phosphoryl)oxy)methyl)-3-((((triisopropylsilyl)oxy)methoxy)tetrahydrofuran-2-yl)-4-(4-bromo-N-(((triisopropylsilyl)oxy)methyl)benzamido)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS 12) (54.33 mg, 0.035 mmol) was dissolved in pyridine (2.36 mL) at room temperature, bis (trimethylsilyl) acetamide (345.98 μL, 1.42 mmol) and DBU (84.64 μL, 0.57 mmol) were added, and the mixture was stirred at room temperature for 45 minutes. Ultrapure water was added to the reaction solution, and it was washed with ether and n-hexane. Toluene and acetonitrile were added to the obtained aqueous layer, and it was concentrated under reduced pressure to obtain a crude product, N 6 -(1-((2R,3R,4R,5R)-4-(phosphonooxy)-5-((phosphonooxy)methyl)-3-((((triisopropylsilyl)oxy)methoxy)tetrahydrofuran-2-yl)-4-(((((triisopropylsilyl)oxy)methyl)amino)pyrimidin-2(1H)-ylidene)-L-lysine (Compound SS13). The crude product N 6 -(1-((2R,3R,4R,5R)-4-(phosphonooxy)-5-((phosphonooxy)methyl)-3-((((triisopropylsilyl)oxy)methoxy)tetrahydrofuran-2)-yl)-4-(((((triisopropylsilyl)oxy)methyl)amino)pyrimidin-2(1H)-ylidene)-L-lysine (Compound SS13) was used directly in the next step.

[0804] LCMS (ESI) m / z = 904.7 (M + H) +

[0805] Retention time: 0.79 minutes (Analysis conditions SQDFA05_02)

[0806] N 6 -(4-amino-1-((2R,3R,4S,5R)-3-hydroxy-4-(phosphonooxy)-5-((phosphonooxy)methyl)tetrakis Synthesis of 2-(1H)-pyrimidine-2-yl)-L-lysine (compound SS04, pLp)

[0807]

[0808] The crude product N 6 -(1-((2R,3R,4R,5R)-4-(phosphonooxy)-5-((phosphonooxy)methyl)-3-((((triisopropylsilyl)oxy)methoxy)tetrahydrofuran-2-yl)-4-(((((triisopropylsilyl)oxy)methyl)amino)pyrimidin-2(1H)-ylidene)-L-lysine methyl ester (Compound SS13) was dissolved in a mixed solvent of acetonitrile (885 μL) and ultrapure water (885 μL) at room temperature, ammonium fluoride (15.73 mg, 0.43 mmol) was added, and the mixture was stirred at 60°C for 2.5 hours. After the mixture was returned to room temperature, additional ammonium fluoride (15.73 mg, 0.43 mmol) was added, and the mixture was stirred at 60°C for 1 hour. After returning to room temperature, acetonitrile was removed by nitrogen, and the resulting aqueous solution was purified by reverse phase silica gel column chromatography (15 mM TEA and 400 mM HFIP aqueous solution / 15mM TEA and 400mM HFIP methanol solution) to obtain N 6 -(4-amino-1-((2R,3R,4S,5R)-3-hydroxy-4-(phosphonooxy)-5-((phosphonooxy)methyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-ylidene)-L-lysine (Compound SS04, pLp) (100 μL, 17.20 mM) in water.

[0809] LCMS (ESI) m / z = 530 (MH) -

[0810] Retention time: 1.64 minutes (analysis conditions LTQTEA / HFIP05_02)

[0811] Example 3 Synthesis of lysine diphosphate by introducing lysine units at the 3' end of tRNA fragments by ligation Alternative methods

[0812] The method for synthesizing lysine diphosphate for introducing a lysine unit at the 3' end of a tRNA fragment by a ligation method was improved. More specifically, lysine diphosphate (SS04, pLp) was synthesized according to the following scheme.

[0813]

[0814] Benzyl ((3aR,4R,12R,12aR)-2,2-dimethyl-3a,4,12,12a-tetrahydro-5H,8H-4,12-epoxy[1, 3]dioxolane[4,5-e]pyrimido[2,1-b][1,3]oxocane Synthesis of (oxazocin)-8-yl)carbamate (Compound SS24)

[0815]

[0816] Under nitrogen atmosphere, DCM (17.2 mL) was added to a mixture of 2',3'-O-isopropylidene-4-N-(benzyl-oxy-carbonyl)-cytidine (718.2 mg, 1.72 mmol) and triphenylphosphine (474 ​​mg, 1.81 mmol) at room temperature. 2',3'-O-isopropylidene-4-N-(benzyl-oxy-carbonyl)-cytidine is a known compound from the literature (Antiviral Chemistry & Chemotherapy, 2003, 14 (4), 183-194). After cooling the mixture in an ice bath, diisopropyl azodicarbonate (385 μL, 1.98 mmol) was added, and the mixture was then warmed to room temperature and stirred at room temperature for 1.5 hours. The reaction solution was concentrated, toluene (20 mL) was added, and the resulting precipitate was recovered by filtration. The obtained solid was washed with toluene three times to give benzyl ((3aR,4R,12R,12aR)-2,2-dimethyl-3a,4,12,12a-tetrahydro-5H,8H-4,12-epoxy[1,3]dioxolano[4,5-e]pyrimido[2,1-b][1,3]oxazocin-8-ylidene)carbamate (Compound SS24) (525.7 mg, 76%).

[0817] LCMS (ESI) m / z = 400.3 (M + H) +

[0818] Retention time: 0.48 minutes (Analysis conditions SQDFA05_02)

[0819] Benzyl (2S)-6-[[1-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydro Furo[3,4-d][1,3]dioxolan-4-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(benzyl Synthesis of 2,2,2-trifluoroacetic acid (compound SS25)

[0820]

[0821] Under nitrogen atmosphere, THF (7.5) was added to a mixture of benzyl ((3aR,4R,12R,12aR)-2,2-dimethyl-3a,4,12,12a-tetrahydro-5H,8H-4,12-epoxy[1,3]dioxolo[4,5-e]pyrimido[2,1-b][1,3]oxazocin-8-ylidene)carbamate (compound SS24) (300 mg, 0.75 mmol) and lithium chloride (159 mg, 3.76 mmol) at room temperature, and the mixture was cooled in an ice bath. To the mixture were added a mixture of ((benzyloxy)carbonyl)-L-lysine benzenesulfonate (813 mg, 2.01 mmol) and DBU (673 μL, 4.51 mmol) added with THF (7.5 mL) in an ice bath, and the reaction mixture was stirred for 30 minutes at 0° C. DMSO was added to the reaction solution in an ice bath, the mixture was warmed to room temperature, and then the reaction solution was concentrated to remove THF. The residue was purified by reverse phase silica gel column chromatography (0.05% TFA aqueous solution / 0.05% TFA-acetonitrile solution) to obtain benzyl (2S)-6-[[1-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxolan-4-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(benzyloxycarbonylamino)hexanoate; 2,2,2-trifluoroacetic acid (Compound SS25) (726.6 mg) quantitatively.

[0822] LCMS (ESI) m / z = 768.6 (MH) -

[0823] Retention time: 0.74 minutes (Analysis conditions SQDFA05_02)

[0824] Benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4S,5R)-3, 4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]hexanoate; 2,2,2-trifluoroacetic acid (compound Synthesis of SS26

[0825]

[0826] Benzyl (2S)-6-[[1-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxolan-4-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(benzyloxycarbonylamino)hexanoate; 2,2,2-trifluoroacetic acid (Compound SS25) (281.1 mg, 0.318 mmol) was dissolved in a mixed solvent of TFA (4.24 mL) and ultrapure water (2.12 mL), cooled in an ice bath, and the mixture was stirred at room temperature for 50 minutes. Toluene and acetonitrile were added, and the reaction solution was concentrated. This operation was repeated several times, and water and TFA were distilled off to obtain a crude product of benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]hexanoate; 2,2,2-trifluoroacetic acid (Compound SS26) (272.6 mg). The obtained crude product of benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]hexanoate; 2,2,2-trifluoroacetic acid (Compound SS26) was used directly in the next step.

[0827] LCMS (ESI) m / z = 728.5 (MH) -

[0828] Retention time: 0.69 minutes (Analysis conditions SQDFA05_02)

[0829] Benzyl (2S)-6-[[1-[(4aR,6R,7R,7aS)-2,2-di-tert-butyl-7-hydroxy-4a,6,7,7a-tetrahydro- 4H-furo[3,2-d][1,3,2]dioxasilin-6-yl]-4-benzyloxycarbonylamino)pyrimidine Synthesis of [2-pyridin-2-ylidene]amino]-2-(benzyloxycarbonylamino)hexanoate; 2,2,2-trifluoroacetic acid (Compound SS27)

[0830]

[0831] Under nitrogen atmosphere, the crude product obtained in the previous step, benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]hexanoate; 2,2,2-trifluoroacetic acid (compound SS26) (258 mg, 0.306 mmol) was dissolved in DMF (3.06 mL). After the mixture was cooled in an ice bath, di-tert-butylsilyl bis(trifluoromethanesulfonate) (396 μL, 1.22 mmol) was added, and the mixture was stirred in an ice bath for 2 hours. In an ice bath, saturated aqueous sodium bicarbonate solution was added to the reaction solution, and the resulting mixture was purified by reverse phase silica gel column chromatography (0.05% aqueous TFA solution / 0.05% TFA-acetonitrile solution) to give benzyl (2S)-6-[[1-[(4aR,6R,7R,7aS)-2,2-di-tert-butyl-7-hydroxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilin-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(benzyloxycarbonylamino)hexanoate; 2,2,2-trifluoroacetic acid (Compound SS27) (234.0 mg, 78%, two steps).

[0832] LCMS (ESI) m / z = 868.8 (MH) -

[0833] Retention time: 0.88 minutes (Analysis conditions SQDFA05_02)

[0834] Benzyl (2S)-6-[[1-[(4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-tetrahydropyran-2-yloxy-4a, 6,7,7a-Tetrahydro-4H-furo[3,2-d][1,3,2]dioxacillin-6-yl]-4-(benzyl)- [(2-(Benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(benzyloxycarbonylamino)hexanoate; 2,2,2-trifluoroacetic acid (compound Synthesis of SS28

[0835]

[0836] Under nitrogen atmosphere, at room temperature, benzyl (2S)-6-[[1-[(4aR,6R,7R,7aS)-2,2-di-tert-butyl-7-hydroxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilin-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(benzyloxycarbonylamino)hexanoate; 2,2,2-trifluoroacetic acid (Compound SS27) (30 mg, 0.03 mmol) and TFA (6.98 μL, 0.09 mmol) were dissolved in DCM (610 μL), and 3,4-dihydro-2H-pyran (83 μL, 0.915 mmol) was added. After the reaction mixture was stirred at room temperature for 13 hours, toluene was added and the reaction solution was concentrated to give a crude product, benzyl (2S)-6-[[1-[(4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-tetrahydropyran-2-yloxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilan-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(benzyloxycarbonylamino)hexanoate; 2,2,2-trifluoroacetic acid (Compound SS28), as a mixture of diastereomers derived from the asymmetric carbon on the THP protecting group. The obtained crude product, benzyl (2S)-6-[[1-[(4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-tetrahydropyran-2-yloxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxacillin-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(benzyloxycarbonylamino)hexanoate; 2,2,2-trifluoroacetic acid (Compound SS28), was used directly in the next step.

[0837] LCMS (ESI) m / z = 952.8 (MH) -

[0838] Retention time: 3.17 minutes, 3.38 minutes (analysis conditions SQDAA05long)

[0839] Benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-hydroxy [5-(hydroxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]hexanoate (compound Synthesis of SS29

[0840]

[0841] Under nitrogen atmosphere, the crude product benzyl (2S)-6-[[1-[(4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-tetrahydropyran-2-yloxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxacillin-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]-2-(benzyloxycarbonylamino)hexanoate; 2,2,2-trifluoroacetic acid (Compound SS28) obtained in the previous step was dissolved in THF (610 μL) at room temperature, and tetrabutylammonium fluoride (about 1 mol / L tetrahydrofuran solution) (305 μL, about 0.305 mmol) was added at room temperature, and the reaction mixture was stirred at room temperature for 30 minutes. DMSO was added to the reaction solution, and then concentrated to distill off THF. The residue was purified by reverse phase silica gel column chromatography (10 mM AA aqueous solution / 10 mM AA-acetonitrile solution) to obtain Benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R, 4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino] Hexanoate (Compound SS29) (21.51 mg, 87% over two steps) as a mixture of diastereomers derived from the asymmetric carbon on the THP protecting group.

[0842] LCMS (ESI) m / z = 812.7 (MH) -

[0843] Retention time: 1.74 minutes (analysis conditions SQDAA05long)

[0844] Benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-dicarboxylic acid Benzyloxyphosphoryloxy-5-(dibenzyloxyphosphoryloxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidine Synthesis of [2-pyridin-2-ylidene]amino]hexanoate (Compound SS30)

[0845]

[0846] Under nitrogen atmosphere, Benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R, 3R,4R,5R)-4-Hydroxy-5-(hydroxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino [C]hexanoate (Compound SS29)(21.51 mg, 0.026 mmol) and 1H-tetrazole (22.22 mg, 0.317 mmol) were dissolved in acetonitrile (1.06 mL) at room temperature, dibenzyl N,N-diisopropylphosphoramidite (53.2 μL, 0.159 mmol) was added, and the mixture was stirred at room temperature for 1 hr. Dess-Martin Periodinane (135 mg, 0.317 mmol) was added to the mixture and stirred at room temperature for 15 minutes. The reaction solution was purified by reverse phase silica gel column chromatography (10 mM AA aqueous solution / 10 mM AA solution in acetonitrile) to quantitatively give benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-dibenzyloxyphosphoryloxy-5-(dibenzyloxyphosphoryloxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]hexanoate (Compound SS30) (36.59 mg, two steps) as a mixture of diastereomers derived from the asymmetric carbon on the THP protecting group.

[0847] LCMS (ESI) m / z = 1332.8 (MH) -

[0848] Retention time: 3.08 minutes, 3.11 minutes (analysis conditions SQDAA05long)

[0849] (2S)-2-amino-6-[[4-amino-1-[(2R,3R,4S,5R)-3-hydroxy-4-phosphonooxy-5-(phosphono Synthesis of [(1-(2-( ...

[0850]

[0851] Benzyl (2S)-2-(benzyloxycarbonylamino)-6-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-dibenzyloxyphosphoryloxy-5-(dibenzyloxyphosphoryloxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]hexanoate (Compound SS30) (36.59 mg, 0.027 mmol) was dissolved in a mixed solvent of methanol (649 μL) and ultrapure water (152 μL) at room temperature, and palladium carbon (10% Pd) (5.84 mg, 5.48 μmol) was added under a nitrogen atmosphere. The mixture was stirred at room temperature for 18 hours under a hydrogen atmosphere. The reaction solution was filtered through celite and washed several times with ultrapure water. 1 mol / L hydrogen chloride (2.74 mL, 2.74 mmol) was added to the obtained filtrate (24.66 mL) and allowed to stand at room temperature for 1 hour. The reaction solution was filtered through diatomaceous earth and washed several times with ultrapure water. After the filtrate was freeze-dried, the obtained powder was redissolved with ultrapure water (1.52 mL), and then centrifuged to recover the supernatant to obtain (2S)-2-amino-6-[[4-amino-1-[(2R,3R,4S,5R)- 3-Hydroxy-4-phosphonooxy-5-(phosphonooxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]hexanoic acid (compound SS04, pLp) aqueous solution (1.37 mL, 17.47 mM, 87%, two steps).

[0852] LCMS (ESI) m / z = 530.1 (MH) -

[0853] Retention time: 1.60 minutes (analysis conditions LTQTEA / HFIP05_02)

[0854] The column exchange was performed after the analysis of the compound SS04 synthesized in Example 2 and before the analysis of the compound SS04 synthesized in Example 3. The compound SS04 synthesized in Example 2 was analyzed again after the column exchange, and it was confirmed that it was the same as the compound SS04 synthesized in Example 3. The results are shown below.

[0855] LCMS (ESI) m / z = 530.1 (MH) -

[0856] Retention time: 1.60 minutes (analysis conditions LTQTEA / HFIP05_02)

[0857] Example 4: Introduction of agmatine diphosphate into the 3' end of a tRNA fragment by ligation synthesis

[0858] In order to introduce an agmatine unit at the 3' end of the tRNA fragment by ligation, guanidinyl cytidine diphosphate was synthesized. More specifically, agmatine-diphosphate (SS31, p(Agm)p) was synthesized according to the following scheme.

[0859]

[0860] Benzyl N-[(4-aminobutylamino)-(benzyloxycarbonylamino)methylene]carbamate; hydrochloride (compound Synthesis of SS32

[0861]

[0862] Under nitrogen atmosphere, benzyl N-[benzyloxycarbonylamino-[4-(tert-butoxycarbonylamino)butylamino]methylene]carbamate (241 mg, 0.483 mmol) (this is a known compound in the literature (Chemistry A European Journal, 2015, 21 (26), 9370-9379)) was added to 4N-HCl / 1,4-dioxane (3.63 mL) in an ice bath, warmed to room temperature, and then stirred for 20 minutes. After adding n-hexane, the reaction solution was concentrated to quantitatively obtain benzyl N-[(4-aminobutylamino)-(benzyloxycarbonylamino)methylene]carbamate; hydrochloride (compound SS32) (256.5 mg).

[0863] LCMS (ESI) m / z = 399.4 (M+H) +

[0864] Retention time: 0.61 minutes (Analysis conditions SQDFA05_02)

[0865] Benzyl N-[[4-[[1-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuran Furo[3,4-d][1,3]dioxolan-4-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]butylamino [Benzyl]-(benzyloxycarbonylamino)methylene]carbamate; 2,2,2-trifluoroacetic acid (compound Synthesis of SS33

[0866]

[0867] Under nitrogen atmosphere, THF (0.998 mL) was added to a mixture of benzyl N-[(4-aminobutylamino)-(benzyloxycarbonylamino)methylene]carbamate; hydrochloride (SS32) (65.1 mg, 0.150 mmol) and DBU (112 μL, 0.748 mmol) at room temperature, and then cooled in an ice bath. To the mixture, a mixture of benzyl ((3aR, 4R, 12R, 12aR) -2,2-dimethyl-3a, 4, 12, 12a-tetrahydro-5H, 8H-4, 12-epoxy [1, 3] dioxolano (dioxolo) [4, 5-e] pyrimido [2, 1-b] [1, 3] oxazocin-8-ylidene) carbamate (compound SS24) (49.8 mg, 0.125 mmol) and lithium chloride (26.4 mg, 0.624 mmol) added with THF (1.497 mL) was added in an ice bath, and the reaction mixture was pulverized with an ultrasonic cleaner and then stirred in an ice bath for 60 minutes. DMSO was added to the reaction solution in an ice bath, the temperature was raised to room temperature, and then the reaction solution was concentrated to remove THF. The residue was purified by reverse phase silica gel column chromatography (0.05% aqueous TFA / 0.05% TFA-acetonitrile solution) to give benzyl N-[[4-[[1-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxolan-4-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]butylamino]-(benzyloxycarbonylamino)methylene]carbamate; 2,2,2-trifluoroacetic acid (Compound SS33) (74.0 mg, 65%).

[0868] LCMS (ESI) m / z = 796.6 (MH) -

[0869] Retention time: 0.78 minutes (Analysis conditions SQDFA05_02)

[0870] Benzyl N-(benzyloxycarbonylamino)-[4-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4S,5R)-3,4- dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]butylamino]methylene] Synthesis of carbamate; 2,2,2-trifluoroacetic acid (compound SS34)

[0871]

[0872] Benzyl N-[[4-[[1-[(3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofurano[3,4-d][1,3]dioxolan-4-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]butylamino]-(benzyloxycarbonylamino)methylene]carbamate; 2,2,2-trifluoroacetic acid (compound SS33) (109.5 mg, 0.120 mmol) were dissolved in a mixed solvent of TFA (1.60 mL) and ultrapure water (0.80 mL), cooled in an ice bath, and the mixture was stirred at room temperature for 45 minutes. The operation of adding toluene and concentrating the reaction solution was repeated several times, and water and TFA were evaporated to obtain a crude product. Benzyl N-(Benzyloxycarbonylamino)-[4-[[4-(Benzyloxycarbonylamino)-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxy [methyl]tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]butylamino]methylene]carbamate; 2,2,2-trifluoroacetic acid (Compound SS34) (105 mg). The crude product obtained Benzyl N-(benzyloxycarbonylamino)-[4-[[4-(benzyloxycarbonylamino)- 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]butylamino 2,2,2-Trifluoroacetic acid (Compound SS34) Use directly in the next step.

[0873] LCMS (ESI) m / z = 756.5 (MH) -

[0874] Retention time: 0.71 minutes (Analysis conditions SQDFA05_02)

[0875] Benzyl N-[[4-[[1-[(4aR,6R,7R,7aS)-2,2-di-tert-butyl-7-hydroxy-4a,6,7,7a-tetrahydro-4H- Furo[3,2-d][1,3,2]dioxasilane-6-yl]-4-(benzyloxycarbonylamino)pyrimidine [2-pyridin-2-ylidene]amino]butylamino]-(benzyloxycarbonylamino)methylene]carbamate; Synthesis of 2,2,2-trifluoroacetic acid (Compound SS35)

[0876]

[0877] Under nitrogen atmosphere, the crude product obtained in the previous step, benzyl N-[benzyloxycarbonylamino-[4-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]butylamino]methylene]carbamate; 2,2,2-trifluoroacetic acid (compound SS34) (105 mg, 0.120 mmol) was dissolved in DMF (1.20 mL), the mixture was cooled in an ice bath, di-tert-butylsilylbis(trifluoromethanesulfonate) (78 μL, 0.241 mmol) was added, and the mixture was stirred in an ice bath for 1 hour. Additional di-tert-butylsilylbis(trifluoromethanesulfonate) (78 μL, 0.241 mmol) was added, and the mixture was stirred in an ice bath for 30 minutes. Additional di-tert-butylsilyl bis(trifluoromethanesulfonate) (19.5 μL, 0.060 mmol) was further added and stirred in an ice bath for 15 minutes. In an ice bath, saturated aqueous sodium bicarbonate solution was added to the reaction solution, and the resulting mixture was purified by reverse phase silica gel column chromatography (0.05% aqueous TFA solution / 0.05% TFA-acetonitrile solution) to give benzyl N-[[4-[[1-[(4aR,6R,7R,7aS)-2,2-di-tert-butyl-7-hydroxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxacillin-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]butylamino]-(benzyloxycarbonylamino)methylene]carbamate; 2,2,2-trifluoroacetic acid (Compound SS35) (108.02 mg, 89%, two steps).

[0878] LCMS (ESI) m / z = 896.7 (MH) -

[0879] Retention time: 0.91 minutes (analysis conditions SQDFA05_02)

[0880] Benzyl N-[[4-[[1-[(4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-tetrahydropyran-2-yloxy-4a,6, 7,7a-Tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilan-6-yl]-4-(benzyloxycarbonylamino)pyrimidine [2-pyridin-2-ylidene]amino]butylamino]-(benzyloxycarbonylamino)methylene]carbamic acid Synthesis of ester; 2,2,2-trifluoroacetic acid (Compound SS36)

[0881]

[0882] Under nitrogen atmosphere, benzyl N-[[4-[[1-[(4aR,6R,7R,7aS)-2,2-di-tert-butyl-7-hydroxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxacillin-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]butylamino]-(benzyloxycarbonylamino)methylene]carbamate; 2,2,2-trifluoroacetic acid (compound SS35) (64.51 mg, 0.064 mmol) and 3,4-dihydro-2H-pyran (173 μL, 1.912 mmol) were dissolved in DCM (1.28 mL), and after cooling the mixture in an ice bath, TFA (14.60 μL, 0.191 mmol) was added. The reaction mixture was warmed to room temperature and stirred for 22.5 hours, then toluene was added and the reaction solution was concentrated to give a crude product of benzyl N-[[4-[[1-[(4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-tetrahydropyran-2-yloxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilan-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]butylamino]-(benzyloxycarbonylamino)methylene]carbamate; 2,2,2-trifluoroacetic acid (Compound SS36) as a mixture of diastereomers derived from the asymmetric carbon on the THP protecting group. The crude product benzyl N-[[4-[[1-[(4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-tetrahydropyran-2-yloxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilan-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]butylamino]-(benzyloxycarbonylamino)methylene]carbamate; 2,2,2-trifluoroacetic acid (Compound SS36) was used directly in the next step.

[0883] LCMS (ESI) m / z = 980.9 (MH) -

[0884] Retention time: 3.51 minutes, 3.72 minutes (analysis conditions SQDAA50long)

[0885] Benzyl N-[benzyloxycarbonylamino-[4-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-hydroxy [5-(hydroxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]butylamino] Synthesis of [methyl] carbamate (compound SS37)

[0886]

[0887] Under nitrogen atmosphere, the crude product benzyl N-[[4-[[1-[(4aR,6R,7R,7aR)-2,2-di-tert-butyl-7-tetrahydropyran-2-yloxy-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilan-6-yl]-4-(benzyloxycarbonylamino)pyrimidin-2-ylidene]amino]butylamino]-(benzyloxycarbonylamino)methylene]carbamate; 2,2,2-trifluoroacetic acid (compound SS36) obtained in the previous step was dissolved in THF (1.28 mL) at room temperature, the mixture was cooled in an ice bath, and tetrabutylammonium fluoride (about 1 mol / L solution in tetrahydrofuran) (638 μL, about 0.638 mmol) was added. The reaction mixture was warmed to room temperature and stirred for 30 minutes, and then DMSO was added to the reaction solution, and concentrated to distill off THF. The residue was purified by reverse phase silica gel column chromatography (10 mM AA aqueous solution / 10 mM AA-acetonitrile solution) to give benzyl N-[benzyloxycarbonylamino-[4-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]butylamino]methylene]carbamate (Compound SS37) (40.62 mg, 76%, two steps) as a mixture of diastereomers derived from the asymmetric carbon on the THP protecting group.

[0888] LCMS (ESI) m / z = 840.7 (MH) -

[0889] Retention time: 2.27 minutes (analysis conditions SQDAA50long)

[0890] Benzyl N-[benzyloxycarbonylamino-[4-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-dibenzyl Oxyphosphoryloxy-5-(dibenzyloxyphosphoryloxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidine- Synthesis of 2-[2-[(2-amino]butylamino]methylene]carbamate (Compound SS38)

[0891]

[0892] Under nitrogen atmosphere, benzyl N-[benzyloxycarbonylamino-[4-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]butylamino]methylene]carbamate (compound SS37) (40.62 mg, 0.048 mmol) and 1H-tetrazole (40.6 mg, 0.579 mmol) were dissolved in toluene. The residue was dissolved in acetonitrile (1.93 mL) at room temperature, the mixture was cooled in an ice bath, and then dibenzyl N,N-diisopropylphosphoramidite (97 μL, 0.289 mmol) was added, and the reaction mixture was warmed to room temperature and stirred for 2.5 hours. Dess-Martin Periodinane (246 mg, 0.579 mmol) was added and stirred at room temperature for 15 minutes. The reaction solution was purified by reverse phase silica gel column chromatography (10 mM AA aqueous solution / 10 mM AA-acetonitrile solution) to give benzyl N-[benzyloxycarbonylamino-[4-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-dibenzyloxyphosphoryloxy-5-(dibenzyloxyphosphoryloxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]butylamino]methylene]carbamate (Compound SS38) (59.66 mg, 91%, two steps) as a mixture of diastereomers derived from the asymmetric carbon on the THP protecting group.

[0893] LCMS (ESI) m / z = 1363.0 (M + H) +

[0894] Retention time: 4.11 minutes, 4.14 minutes (analysis conditions SQDAA05long)

[0895] [(2R,3S,4R,5R)-5-[4-amino-2-(4-guanidine imino)pyrimidin-1-yl]-4-hydroxy-2-(phosphono) Synthesis of [( ...

[0896]

[0897] Benzyl N-[benzyloxycarbonylamino-[4-[[4-(benzyloxycarbonylamino)-1-[(2R,3R,4R,5R)-4-dibenzyloxyphosphoryloxy-5-(dibenzyloxyphosphoryloxymethyl)-3-tetrahydropyran-2-yloxy-tetrahydrofuran-2-yl]pyrimidin-2-ylidene]amino]butylamino]methylene]carbamate (Compound SS38) (30.59 mg, 0.022 mmol) was dissolved in a mixed solvent of methanol (727 μL) and ultrapure water (171 μL) at room temperature, and palladium carbon (10% Pd) (4.78 mg, 4.49 μmol) was added under a nitrogen atmosphere. The mixture was stirred at room temperature for seven hours under a hydrogen atmosphere. The reaction solution was filtered through celite and washed several times with ultrapure water. 1 mol / L hydrogen chloride (2.78 mL, 2.78 mmol) was added to the obtained filtrate (25 mL) and allowed to stand at room temperature for 45 minutes. The reaction solution was freeze-dried, and then the obtained powder was dissolved in ultrapure water, filtered through diatomaceous earth, and washed several times with ultrapure water. After the filtrate was freeze-dried, the obtained powder was dissolved in ultrapure water (1.7 mL), the solution was centrifuged, and the supernatant was recovered to obtain [(2R,3S,4R,5R)-5-[4-amino-2-(4-guanidine imino)pyrimidin-1-yl]-4-hydroxy-2-(phosphonooxy [( ... Aqueous solution (1.61 mL, 12.11 mM, 87%, two steps).

[0898] LCMS (ESI) m / z = 514.1 (MH) -

[0899] Retention time: 1.58 minutes (analysis conditions LTQTEA / HFIP05_02)

[0900] Example 5 Synthesis of pCpA-amino acids for cell-free translation system

[0901] Aminoacylated pCpAs (SS14, SS15, SS16, SS39, and SS40) were synthesized according to the following scheme.

[0902]

[0903] (S)-1-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)piperidine-2-carboxylic acid (Compound Synthesis of SS17, F-Pnaz-Pic2-OH)

[0904]

[0905] Under nitrogen atmosphere, DMF (330 μL) was added to a mixture of (S)-piperidine-2-carboxylic acid (42.6 mg, 0.33 mmol) and (4-nitrophenyl)-4-(2-(4-fluorophenyl)acetylamino)benzyl carbonate (compound ts11) (140 mg, 0.44 mmol) (synthesized at room temperature by the method of patent document (WO2018143145A1)). After stirring the mixture at room temperature for five minutes, triethylamine (105.6 μL, 2.25 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 30 minutes and then purified by reverse phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid-acetonitrile solution) to obtain (S)-1-(((4-(2-(4- (Fluorophenyl)acetylamino)benzyl)oxy)carbonyl)piperidine-2-carboxylic acid (Compound SS17, F-Pnaz-Pic2-OH) (92 mg, 67%).

[0906] LCMS (ESI) m / z = 413 (MH) -

[0907] Retention time: 0.70 minutes (analysis conditions SQDFA05_01)

[0908] 1-(4-(2-(4-fluorophenyl)acetylamino)benzyl)2-(cyanomethyl)(S)-piperidine-1,2-dicarboxylate (Mixture SS18, F-Pnaz-Pic2-OCH 2 Synthesis of CN)

[0909]

[0910] Under nitrogen atmosphere, (S)-1-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)piperidin-2-yl Carboxylic acid (Compound SS17, F-Pnaz-Pic2-OH) (30 mg, 0.072 mmol) and N-ethyl-isopropylpropan-2-amine (DIPEA) (20.23 μL, 0.116 mmol) were dissolved in acetonitrile (90 μL), 2-bromoacetonitrile (5.34 μL, 0.080 mmol) was added at 0°C, and the mixture was stirred at room temperature for two hours. The reaction solution was concentrated to obtain a crude product of 1-(4-(2-(4-fluorophenyl)acetylamino)benzyl)2-(cyanomethyl) (S)-piperidine-1,2-dicarboxylate (mixture SS18, F-Pnaz-Pic2-OCH 2 CN). The obtained crude product was dissolved in acetonitrile (2.00 mL) and used directly in the next step.

[0911] LCMS (ESI) m / z = 452 (MH) -

[0912] Retention time: 0.79 minutes (Analysis conditions SQDFA05_01)

[0913] 1-(4-(2-(4-fluorophenyl)acetylamino)benzyl)2-((2R,3S,4R,5R)-2-(((((2R,3S,4R, 5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy-2-(((phosphonooxy)methyl)tetrahydrofuran-3-yl)oxy (2S)-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-3-yl)-(2-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-3-yl)-(2S)- Synthesis of piperidine-1,2-dicarboxylate (Compound SS14, F-Pnaz-Pic2-pCpA)

[0914]

[0915] The ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-((((((2R,3S,4R,5R)-5-(6)-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl) 4-((tetrahydrofuran-2-yl)oxy)tetrahydrofuran-2-yl)methyl dihydrogen phosphate (Compound PC01) (113 mg, 0.156 mmol) was dissolved in buffer A (40 mL), and 1-(4-(2-(4-fluorophenyl)acetamido)benzyl)2-(cyanomethyl) (S)-piperidine-1,2-dicarboxylate (Compound SS18, F-Pnaz-Pic2-OCH 2 CN) (35.4 mg, 0.078 mmol) in acetonitrile (2.00 mL), and the mixture was stirred at room temperature for 150 minutes. The reaction solution was cooled to 0°C, and trifluoroacetic acid (2.00 mL) was then added. The reaction solution was stirred at 0°C for 45 minutes and purified by reverse phase silica gel column chromatography (0.05% trifluoroacetic acid aqueous solution / 0.05% trifluoroacetic acid-acetonitrile) to give the title compound (Compound SS14, F-Pnaz-Pic2-pCpA) (6.0 mg, 7.3%).

[0916] LCMS (ESI) m / z = 1047.5 (MH) -

[0917] Retention time: 0.50 minutes (analysis conditions SQDFA05_01)

[0918] Buffer A was prepared as follows.

[0919] Acetic acid was added to an aqueous solution of N,N,N-trimethylhexadecyl-1-ammonium chloride (6.40 g, 20 mmol) and imidazole (6.81 g, 100 mmol) to obtain buffer A (1 L), pH 8, of 20 mM N,N,N-trimethylhexadecyl-1-ammonium chloride and 100 mM imidazole.

[0920] O-(2-Chlorophenyl)-N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-L-serine Synthesis of acid (compound SS19, F-Pnaz-SPh2Cl-OH)

[0921]

[0922] Under a nitrogen atmosphere, at room temperature, DMSO (15 mL) and triethylamine (0.95 g, 9.42 mmol) were added to a mixture of O-(2-chlorophenyl)-L-serine (compound aa63) (1.25 g, 5.80 mmol) synthesized by the method described in patent document (WO2018225864) and (4-nitrophenyl)-4-(2-(4-fluorophenyl)acetylamino)benzyl carbonate (compound ts11) (2 g, 4.71 mmol) synthesized by the method described in patent document (WO2018143145A1). The reaction mixture was stirred at room temperature for 16 hours and then purified by reverse phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid-acetonitrile solution) to give O-(2-chlorophenyl)-N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-L-serine (compound SS19, F-Pnaz-SPh2Cl-OH) (1.8 g, 73%).

[0923] LCMS (ESI) m / z = 523 (M + Na) +

[0924] Retention time: 1.26 minutes (Analysis conditions SMD method 1)

[0925] Cyanomethyl O-(2-chlorophenyl)-N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)- L-serine ester (compound SS20, F-Pnaz-SPh2Cl-OCH 2 Synthesis of CN)

[0926]

[0927] Under nitrogen atmosphere, O-(2-chlorophenyl)-N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-L-serine (compound SS19, F-Pnaz-SPh2Cl-OH) (800 mg, 1.60 mmol) and N-ethyl-isopropylpropan-2-amine (DIPEA) (0.412 g, 3.19 mmol) were dissolved in DCM (15 mL), 2-bromoacetonitrile (760 mg, 6.34 mmol) was added at room temperature, and the mixture was stirred at room temperature for 16 hours. The reaction solution was concentrated and purified by reverse phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid-acetonitrile solution) to obtain cyanomethyl O-(2-chlorophenyl)-N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-L-serine ester (compound SS20, F-Pnaz-SPh2Cl-OCH 2 CN) (((((220 mg, 26%). The obtained product was dissolved in acetonitrile (5 mL) and used in the next step.

[0928] LCMS (ESI) m / z = 562 (M + Na) +

[0929] Retention time: 1.15 minutes (Analysis conditions SMD method 2)

[0930] (2R,3S,4R,5R)-2-((((((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy 2-(((phosphonooxy)methyl)tetrahydrofuran-3-yl)oxy)(hydroxy)phosphoryl)oxy)methyl)-5-(6-amino- 9H-purin-9-yl)-4-hydroxytetrahydrofuran-3-ylO-(2-chlorophenyl)-N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl 1-(4 ... pCpA)

[0931]

[0932] ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-((((((2R,3S,4R,5R)-5-(6)-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)-4-((tetrahydrofuran-2-yl)oxy)tetrahydrofuran-2-yl)methyl dihydrogen phosphate (Compound PC01) (400 mg, 0.55 mmol) was dissolved in buffer A (100 mL), and cyanomethyl O-(2-chlorophenyl)-N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-L-serine ester (Compound SS20, F-Pnaz-SPh2Cl-OCH 2 CN) (220 mg, 0.41 mmol) in acetonitrile (5 mL) and stirred at room temperature for 5 minutes. Then, trifluoroacetic acid (2.3 mL) was added to the reaction solution. The reaction solution was freeze-dried and purified by reverse phase silica gel column chromatography (0.05% trifluoroacetic acid aqueous solution / 0.05% trifluoroacetic acid-acetonitrile) to obtain the title compound (Compound SS15, F-Pnaz-SPh2Cl-pCpA) (20.7 mg, 2%).

[0933] LCMS (ESI) m / z = 1133.4 (MH) -

[0934] Retention time: 0.55 minutes (analysis conditions SQDFA05_01)

[0935] Synthesis of ((S)-2-(methylamino)-4-phenylbutyric acid (Compound SS21, MeHph-OH)

[0936]

[0937] At room temperature, DCM (903 μL), water (903 μL) and piperidine (178 μL, 1.805 mmol) were added to (S)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-4-phenylbutyric acid (compound aa11) (150 mg, 0.361 mmol) synthesized by the method described in patent document (WO2018225864). The reaction mixture was stirred at room temperature for 30 minutes and then purified by reverse phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid-acetonitrile solution) to give ((S)-2-(methylamino)-4-phenylbutyric acid (compound SS21, MeHph-OH) (55 mg, 79%).

[0938] LCMS (ESI) m / z = 192 (MH) -

[0939] Retention time: 0.15 minutes (Analysis conditions SQDFA05_02)

[0940] (S)-2-((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)(methyl)amino)-4-phenyl Synthesis of butyric acid (compound SS22, F-Pnaz-MeHph-OH)

[0941]

[0942] Under nitrogen atmosphere, at room temperature, DMSO (727 μL) was added to a mixture of ((S)-2-(methylamino)-4-phenylbutyric acid (compound SS21, MeHph-OH) (35.1 mg, 0.182 mmol) and (4-nitrophenyl)-4-(2-(4-fluorophenyl)acetylamino)benzyl carbonate (compound ts11) (85 mg, 0.20 mmol) synthesized by the method described in patent document (WO2018143145A1) Triethylamine (76 μL, 0.545 mmol) was added at 50° C. The reaction mixture was stirred at 40° C. for 16 hours and then purified by reverse phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid-acetonitrile solution) to give (S)-2-((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)(methyl)amino)-4-phenylbutanoic acid (Compound SS22, F-Pnaz-MeHph-OH) (80 mg, 92%).

[0943] LCMS (ESI) m / z = 477 (MH) -

[0944] Retention time: 0.85 minutes (Analysis conditions SQDFA05_02)

[0945] Cyanomethyl (S)-2-(((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)(methyl)amino4-phenylbutyrate (compound SS23, F-Pnaz-MeHph-OCH 2 Synthesis of CN)

[0946]

[0947] Under nitrogen atmosphere, acetonitrile (533 μL) was added to a mixture of (S)-2-((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)(methyl)amino)-4-phenylbutyric acid (compound SS22, F-Pnaz-MeHph-OH) (77 mg, 0.16 mmol) and N-ethyl-isopropylpropan-2-amine (DIPEA) (31 μL, 0.176 mmol) at room temperature. Then, 2-bromoacetonitrile (86 μL, 1.280 mmol) was added at room temperature, and the reaction mixture was stirred at 40° C. for 1 hour. The reaction solution was concentrated to give a crude product of cyanomethyl (S)-2-(((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)(methyl)amino)-4-phenylbutyrate (compound SS23, F-Pnaz-MeHph-OCH 2 CN). The obtained crude product was dissolved in acetonitrile (5.00 mL) and used directly in the next step.

[0948] LCMS (ESI) m / z = 516 (MH) -

[0949] Retention time: 0.92 minutes (analysis conditions SQDFA05_02)

[0950] (2R,3S,4R,5R)-2-((((((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy 2-((phosphonooxy)methyl)tetrahydrofuran-3-yl)oxy)(hydroxy)phosphoryl)oxy)methyl)-5-(6-amino-9H- Purin-9-yl)-4-hydroxytetrahydrofuran-3-yl (2S)-2-((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl Synthesis of (4-(2-(methyl)amino)-4-phenylbutyrate (Compound SS16, F-Pnaz-MeHph-pCpA)

[0951]

[0952] ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-((((((2R,3S,4R,5R)-5-(6)-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)hydroxy)phosphoryl)oxy)-4-(((tetrahydrofuran-2-yl)oxy)tetrahydrofuran-2-yl)methyl dihydrogen phosphate (Compound PC01) (127m g, 0.176 mmol) was dissolved in buffer A (100 mL), a solution of cyanomethyl (S)-2-((((4-(2-(4-fluorophenyl)acetylamino)benzyl)-oxy)carbonyl)(methyl)amino)-4-phenylbutyrate (compound SS23, F-Pnaz-MeHph-OCH2CN) (83 mg, 0.16 mmol) in acetonitrile (5.00 mL) was added, and the mixture was stirred at room temperature for one hour. The reaction solution was cooled to 0°C, and trifluoroacetic acid (5.00 mL) was then added. The reaction solution was stirred at 0°C for one hour, purified by reverse phase silica gel column chromatography (0.05% trifluoroacetic acid aqueous solution / 0.05% trifluoroacetic acid-acetonitrile), and further purified by reverse phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid acetonitrile solution) to give the title compound (compound SS16, F-Pnaz-MeHph-pCpA) (26 mg, 14.6%).

[0953] LCMS (ESI) m / z = 1111.5 (MH) -

[0954] Retention time: 0.64 minutes (Analysis conditions SQDFA05_02)

[0955] (S)-3-(3-chlorophenyl)-2-(((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)amino) Synthesis of Propionic Acid (Compound SS41, F-Pnaz-F3Cl-OH)

[0956]

[0957] Under a nitrogen atmosphere, at room temperature, DMSO (15 mL) and triethylamine (1.43 g, 14.13 mmol) were added to a mixture of (S)-2-amino-3-(3-chlorophenyl)propanoic acid (H-Phe(3-Cl)-OH) (2.17 g, 10.87 mmol) synthesized by the method described in patent document (WO2018225864) and (4-nitrophenyl)-4-(2-(4-fluorophenyl)acetylamino)benzyl carbonate (compound ts11) (3.0 g, 7.07 mmol) synthesized by the method described in patent document (WO2018143145A1). The reaction mixture was stirred at room temperature for 16 hours and then purified by reverse phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid-acetonitrile solution) to give (S)-3-(3-chlorophenyl)-2-(((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)amino)propanoic acid (Compound SS41, F-Pnaz-F3Cl-OH) (0.7 g, 20%).

[0958] LCMS (ESI) m / z = 507 (M + Na) +

[0959] Retention time: 1.06 minutes (Analysis conditions SMD method 3)

[0960] Cyanomethyl (S)-3-(3-chlorophenyl)-2-(((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl 1-(4-amino)propionic acid ester (compound SS42, F-Pnaz-F3Cl-OCH 2 Synthesis of CN)

[0961]

[0962] Under nitrogen atmosphere, (S)-3-(3-chlorophenyl)-2-(((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)amino)propanoic acid (compound SS41, F-Pnaz-F3Cl-OH) (650 mg, 1.34 mmol) and N-ethyl-isopropylpropan-2-amine (DIPEA) (0.346 g, 2.68 mmol) were dissolved in DCM (28 mL), 2-bromoacetonitrile (640 mg, 5.34 mmol) was added at room temperature, and the mixture was stirred at room temperature for 48 hours. The reaction solution was concentrated and purified by normal phase silica gel column chromatography (ethyl acetate / petroleum ether) to give cyanomethyl (S)-3-(3-chlorophenyl)-2-((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)amino)propanoate (compound SS42, F-Pnaz-F3Cl-OCH 2 CN) (330 mg, 47%).

[0963] LCMS (ESI) m / z = 546 (M + Na) +

[0964] Retention time: 1.13 minutes (Analysis conditions SMD method 3)

[0965] (2R,3S,4R,5R)-2-((((((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy 2-(((phosphonooxy)methyl)tetrahydrofuran-3-yl)oxy)(hydroxy)phosphoryl)oxy)methyl)-5-(6-amino- 9H-purin-9-yl)-4-hydroxytetrahydrofuran-3-yl (2S)-(3-chlorophenyl)-N-(((4-(2-(4-fluorophenyl)acetamido Benzyl)oxy)carbonyl)-amino)propanoate (mixture SS39, F-Pnaz-F3Cl- Synthesis of pCpA

[0966]

[0967] ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-((((((2R,3S,4R,5R)-5-(6)-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)hydroxy)phosphoryl)oxy)-4-(((tetrahydrofuran- 2-((((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)amino)propanoate (compound SS42, F-Pnaz-F3Cl-OCH4) was added dropwise using a syringe pump over 15 minutes or more. 2 CN) (200 mg, 0.38 mmol) in acetonitrile (5 mL), and stirred at room temperature for 30 minutes. Trifluoroacetic acid (2.3 mL) was added to the reaction solution. The reaction solution was freeze-dried and purified by reverse phase silica gel column chromatography (0.05% trifluoroacetic acid aqueous solution / 0.05% trifluoroacetic acid-acetonitrile) to give the title compound (Compound 39, F-Pnaz-F3Cl-pCpA) (25.3 mg, 1%).

[0968] LCMS (ESI) m / z = 1117.4 (MH) -

[0969] Retention time: 0.55 minutes (analysis conditions SQDFA05_01)

[0970] N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-O-isopentyl-L-serine Synthesis of (Compound SS43, F-Pnaz-SiPen-OH)

[0971]

[0972] Under a nitrogen atmosphere, at room temperature, DMSO (15 mL) and triethylamine (1.3 mL, 9.42 mmol) were added to a mixture of O-isopentyl-L-serine (H-Ser(iPen)-OH) (1 g, 5.71 mmol) described in patent document (WO2018225864) and (4-nitrophenyl)-4-(2-(4-fluorophenyl)acetylamino)benzyl carbonate (compound ts11) (2 g, 4.71 mmol) synthesized by the method described in patent document (WO2018143145A1). The reaction mixture was stirred at room temperature for 16 hours and then purified by reverse phase silica gel column chromatography (0.1% formic acid aqueous solution / 0.1% formic acid-acetonitrile solution) to give N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-O-isopentyl-L-serine (compound SS43, F-Pnaz-SiPen-OH) (1.8 g, 83%).

[0973] LCMS (ESI) m / z = 483 (M + Na) +

[0974] Retention time: 1.04 minutes (Analysis conditions SMD method 3)

[0975] Cyanomethyl N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-O-isopentyl-L- Serine ester (compound SS44, F-Pnaz-SiPen-OCH 2 Synthesis of CN)

[0976]

[0977] Under nitrogen atmosphere, N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-O-isopentyl-L-serine (compound SS43, F-Pnaz-SiPen-OH) (1.8 g 3.91 mmol) and N-ethyl-isopropylpropan-2-amine (DIPEA) (1 g, 7.74 mmol) were dissolved in DCM (40 mL), 2-bromoacetonitrile (1.9 g, 15.84 mmol) was added at room temperature, and the mixture was stirred at room temperature for 48 hours. The reaction solution was concentrated and purified by normal phase silica gel column chromatography (ethyl acetate / petroleum ether) to obtain cyanomethyl N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-O-isopentyl-L-serine ester (compound SS44, F-Pnaz-SiPen-OCH 2 CN) (1.6 g, 82%).

[0978] LCMS (ESI) m / z = 522 (M + Na) +

[0979] Retention time: 1.35 minutes (Analysis conditions SMD method 4)

[0980] (2R,3S,4R,5R)-2-((((((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy 2-(((phosphonooxy)methyl)tetrahydrofuran-3-yl)oxy)(hydroxy)phosphoryl)oxy)methyl)-5-(6-amino- 9H-purin-9-yl)-4-hydroxytetrahydrofuran-3-yl N-(((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl Synthesis of 1-(4-(4-Pnaz-SiPen-pCpA)-O-isopentyl-L-serine ester (compound SS40, F-Pnaz-SiPen-pCpA)

[0981]

[0982] ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-((((((2R,3S,4R,5R)-5-(6)-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)-4-((tetrahydrofuran-2-yl)-1-((2R,3S,4R,5R)-5-(6)-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)phosphoryl)oxy)-4-((tetrahydrofuran-2-yl) 1-(4-((4-(2-(4-fluorophenyl)acetylamino)benzyl)oxy)carbonyl)-O-isopentyl-L-serine ester (compound SS44, F-Pnaz-SiPen-OCH 2 CN) (139 mg, 0.28 mmol) in acetonitrile (5 mL) and stirred at room temperature for 3 hours. Trifluoroacetic acid (2.3 mL) was added to the reaction solution. The reaction solution was freeze-dried and purified by reverse phase silica gel column chromatography (0.05% trifluoroacetic acid aqueous solution / 0.05% trifluoroacetic acid-acetonitrile) to obtain the title compound (Compound SS40, F-Pnaz-SiPen-pCpA) (39.5 mg, 3%).

[0983] LCMS (ESI) m / z = 1093.5 (MH) -

[0984] Retention time: 0.55 minutes (analysis conditions SQDFA05_01)

[0985] Example 6 Synthesis of BdpFL-Phe-pCpA (MT01)

[0986] (3-(5,5-difluoro-7,9-dimethyl-5H-4λ 4 ,5λ 4 -Dipyrrolo[1,2-c:2',1'-f][1,3,2]diazo Synthesis of (3-( ...

[0987]

[0988] Under nitrogen atmosphere, DIC (0.128 mL, 0.822 mmol) was added to 3-(2-carboxyethyl)-5,5-difluoro-7,9-dimethyl-5H-5λ at room temperature. 4-Bipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinane-4-ium (200 mg, 0.685 mmol) and 1-hydroxypyrrolidine-2,5-dione (87 mg, 0.753 mmol) in NMP (4.5 mL) solution, and then the mixture was stirred at 40 ° C overnight. After returning to room temperature, L-phenylalanine (113 mg, 0.685 mmol) and TEA (0.191 mL, 1.369 mmol) were added to the reaction solution and stirred at 40 ° C overnight. The reaction solution was purified by reverse phase column chromatography (0.1% FA-MeCN / H2O) to obtain (3-(5,5-difluoro-7,9-dimethyl-5H-4λ 4 ,5λ 4 -dipyrrolo[1,2-c:2',1'-f][1, 3,2]diazaborin-3-yl)propionyl)-L-phenylalanine (compound MT02, BdpFL-Phe-OH) (102 mg, 34% yield).

[0989] LCMS (ESI) m / z = 438.3 (MH) -

[0990] Retention time: 0.78 minutes (Analysis conditions SQDFA05_02)

[0991] (3-(5,5-difluoro-7,9-dimethyl-5H-4λ 4 ,5λ 4 -Dipyrrolo[1,2-c:2',1'-f][1,3,2]diazo Heteroborin-3-yl)propionyl)-L-phenylalanine cyanomethyl ester (compound MT03, BdpFL- Phe-OCH 2 Synthesis of CN)

[0992]

[0993] Under nitrogen atmosphere, (3-(5,5-difluoro-7,9-dimethyl-5H-4λ 4 ,5λ 4 -Dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborin Cyclohexene -3-yl)propanoyl)-L-phenylalanine (50 mg, 0.114 mmol) and N-ethyl-isopropylpropan-2-amine (DIPEA) (31.0 μL, 0.177 mmol) were dissolved in acetonitrile (500 μL), 2-bromoacetonitrile (12 μL, 0.177 mmol) was added at 0°C, and the mixture was stirred at 40°C for 3 hours. The reaction solution was concentrated to give (3-(5,5-difluoro-7,9-dimethyl-5H-4λ 4 ,5λ 4 -Dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborin Cyclohexene -3-yl)propionyl)-L-phenylalanine cyanomethyl ester (compound MT02, BdpFL-Phe-OCH 2 CN) as a crude product. The obtained crude product was used directly in the next step.

[0994] LCMS (ESI) m / z = 477.3 (MH) -

[0995] Retention time: 0.86 minutes (Analysis conditions SQDFA05_01)

[0996] 3-(3-(((2S)-1-(((2R,3S,4R,5R)-2-(((((2R,3S,4R,5R)-5-(4-amino)-2-oxopyrimidine pyridin-1(2H)-yl)-4-hydroxy-2-((phosphonooxy)methyl)tetrahydrofuran-3-yl)oxy)(hydroxy)phosphoryl)oxy)methyl yl)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-3-yl)oxy)-1-oxo-3-phenylpropionyl-2-yl) Amino)-3-oxypropyl)-5,5-difluoro-7,9-dimethyl-5H-5λ 4 -Dipyrrolo[1,2-c:2',1'-f][1,3,2]diazo Boron miscellaneous Cyclohexen-4-ium (Compound MT01, BdpFL-Phe-pCpA)

[0997]

[0998] ((2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-((((((2R,3S,4R,5R)-5-(6)-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)-4-((tetrahydrofuran-2-yl)oxy)tetrahydrofuran-2-yl)methyl dihydrogen phosphate (Compound pc01) (33.2 mg, 0.046 mmol) was dissolved in buffer A (11.3 mL), and (3-(5,5-difluoro-7,9-dimethyl-5H-4λ) was added. 4 ,5λ 4 -dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborin-3-yl)propanoyl)-L-phenylalanine cyanomethyl ester (compound MT03, BdpFL-Phe-OCH 2 CN) (11 mg, 0.023 mmol) in acetonitrile (0.13 mL), and the mixture was stirred at room temperature for 45 minutes. TFA (0.56 mL) was added to the reaction solution at 0°C and stirred for 5 minutes, and then stirred at room temperature for 10 minutes. The residue was purified by reverse phase silica gel column chromatography (0.05% TFA-MeCN / H 2 O) The reaction solution was purified to obtain the title compound (Compound MT01, BdpFL-Phe-pCpA) (2.1 mg, 8.5% yield).

[0999] LCMS (ESI) m / z = 1072.5 (MH) -

[1000] Retention time: 0.56 minutes (Analysis conditions SQDFA05_02)

[1001] Example 7 (2S, 3R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tetrahydro-2H-pyran-2-yl) Synthesis of Fmoc-Thr(THP)-OH for peptide synthesis of LCT-12

[1002]

[1003] Toluene (50 mL) was added to (2S,3R)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-hydroxybutanoic acid monohydrate (monohydrate of Fmoc-Thr-OH, purchased from Tokyo Chemical Industry, 5.0g, 13.9mmol) and pyridinium p-toluenesulfonate (PPTS, 0.175g, 0.70mmol), toluene was removed by reduced pressure distillation, and the contained water was removed azeotropically. Super dehydrated tetrahydrofuran (THF, 28mL) and 3,4-dihydro-2H-pyran (8.8mL, 97mmol) were added to the resulting residue, and it was stirred at 50 ° C for 4 hours under a nitrogen atmosphere. After confirming the disappearance of the raw material by LCMS (SQDFA05), the mixture was cooled to 25 ° C and ethyl acetate (30mL) was added. Then, a saturated sodium chloride aqueous solution (30mL) was added to wash the organic layer, and the aqueous layer was extracted with ethyl acetate (30mL). All the obtained organic layers were combined and further washed twice with a saturated sodium chloride aqueous solution (30mL). The organic layer was dried over sodium sulfate, and the solvent was removed by reduced pressure distillation to obtain a crude product (9.3g).

[1004] 4.65 g of the obtained crude product was dissolved in tetrahydrofuran (THF, 30 mL), and then 1.0 M phosphate buffer (30 mL) was added to adjust to pH 8.0. The mixture was stirred at 50 ° C for four hours. After cooling to 25 ° C, ethyl acetate (30 mL) was added to separate the organic layer and the aqueous layer. Ethyl acetate (30 mL) was added to the aqueous layer for extraction, and all the obtained organic layers were combined and washed twice with saturated sodium chloride aqueous solution (30 mL). The organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure, and further dried under reduced pressure with a pump at 25 ° C for 30 minutes.

[1005] The obtained residue was dissolved in ether (50 mL), and then heptane (50 mL) was added. Under controlled reduced pressure (about 100 hPa), only ether was distilled out, and the obtained mixture was filtered to obtain a solid. The washing operation was repeated twice with heptane. The obtained solid was dried under reduced pressure at 25 ° C with a pump for 2 hours to obtain the sodium salt of Fmoc-Thr (THP) -OH (2.80 g, 6.26 mmol).

[1006] Ethyl acetate (50 mL) at pH 2.1 and 0.05 M phosphoric acid aqueous solution (140 mL) were added to the total amount of sodium salt of Fmoc-Thr(THP)-OH obtained, and the mixture was stirred at 25°C for 5 minutes, and then the organic layer and the aqueous layer were separated. Ethyl acetate (50 mL) was added to the aqueous layer for extraction, and all the obtained organic layers were mixed, and then washed twice with saturated sodium chloride aqueous solution (50 mL). The organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. After the residue was dried under reduced pressure at 25°C with a pump for 2 hours, the obtained solid was dissolved in tert-butyl methyl ether (TBME, 50 mL), and the solvent was removed by distillation under reduced pressure. Furthermore, (2S,3R)-2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((tetrahydro-2H-pyran-2-yl)oxy)butanoic acid (Fmoc-Thr(THP)-OH, 2.70 g, 30 mol% of tert-butyl methyl ether (TBME) remaining) was obtained as a mixture of diastereomers derived from the asymmetric carbon on the THP protecting group by drying under reduced pressure using a pump at 25°C for 1 hour. The obtained Fmoc-Thr(THP)-OH was stored in a refrigerator at -25°C.

[1007] LCMS (ESI) m / z = 424.2 (MH) -

[1008] Retention time: 0.84 minutes, 0.85 minutes (Analysis conditions SQDFA05_01)

[1009] Example 8 Synthesis of a peptide (LCT-12) with BdpFL at the N-terminus for use as a standard for LC / MS

[1010]

[1011] Peptide extension was performed on a peptide synthesizer using 2-chlorotrityl resin with Fmoc-Ala-OH (100 mg), and Fmoc-Gly-OH, Fmoc-Thr(THP)-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, and Fmoc-Pro OH as Fmoc amino acids (the abbreviations of amino acids are described separately in this specification). Peptide extension was performed according to the peptide synthesis method using the Fmoc method (WO2013100132B2). After peptide extension, the N-terminal Fmoc group was removed on a peptide synthesizer, and the resin was then washed with DCM.

[1012] TFE / DCM (1:1, v / v, 2mL) was added to the resin and shaken for 1 hour, and then the peptide was cut from the resin. After the reaction was completed, the solution in the tube was filtered through a synthetic column to remove the resin, and the resin was washed twice with TFE / DCM (1:1, v / v, 1mL). All extracts were mixed, DMF (2mL) was added, and the mixture was concentrated under reduced pressure. The resulting residue was dissolved in NMP (0.5mL), and a quarter of it (125μL) was used for the next reaction. BdpFL succinimide ester (140μL) adjusted to 76.5mM was added to the peptide solution in NMP at room temperature, stirred overnight at 40°C, and then concentrated under reduced pressure. The resulting residue was dissolved in a 0.05M tetramethylammonium hydrogen sulfate solution in HFIP (1.2mL, 0.060mmol) and stirred at room temperature for 2 hours. The reaction solution was purified by reverse phase silica gel column chromatography (0.1% FA MeCN / H 2 The title compound (LCT-12) (0.3 mg) was obtained by purification. The amino acid sequence of LCT-12 is shown in SEQ ID NO: 53.

[1013] LCMS (ESI) m / z = 1972.9 (MH) -

[1014] Retention time: 0.74 minutes (Analysis conditions SQDFA05_01)

[1015] Example 9 Production of tRNA-CA by ligation reaction

[1016] Through the following steps, tRNA5' fragment, pNp (pUp, pLp or p(Agm)p) and tRNA3' fragment were connected using a ligation reaction to produce various tRNA-CA. tRNA5' fragment and tRNA3' fragment used chemical synthesis products (Gene Design Co., Ltd.). Each tRNA fragment and its full-length sequence, as well as the sample combination for connection (Table 4) are shown below.

[1017] SEQ ID NO:54 (FR-1)

[1018] tRNA(Glu)5'RNA sequence

[1019] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU

[1020] SEQ ID NO:55 (FR-2)

[1021] tRNA(Glu)3'ga RNA sequence

[1022] GAACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC

[1023] SEQ ID NO:56(UR-1)

[1024] lig-tRNA(Glu)uga-CARNA sequence

[1025] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU UGA ACGGCGGU

[1026] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1027] SEQ ID NO:57(LR-1)

[1028] tRNA(Glu)Lga-CARNA sequence

[1029] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU LGA ACGGCGGU

[1030] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1031] SEQ ID NO:58(FR-3)

[1032] tRNA(Glu)3’ag RNA sequence

[1033] AG ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC

[1034] SEQ ID NO:59(LR-2)

[1035] tRNA(Glu)Lag-CA RNA sequence

[1036] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU LAG ACGGCGGU

[1037] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1038] SEQ ID NO:60(FR-4)

[1039] tRNA(Glu)3’ac RNA sequence

[1040] AC ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC

[1041] SEQ ID NO:61 (LR-3)

[1042] tRNA(Glu)Lac-CA RNA sequence

[1043] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU LAC ACGGCGGU

[1044] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1045] SEQ ID NO:62 (FR-5)

[1046] tRNA(Glu)3’cc RNA sequence

[1047] CC ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC

[1048] SEQ ID NO:63 (LR-4)

[1049] tRNA(Glu)Lcc-CA RNA sequence

[1050] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU LCC ACGGCGGU

[1051] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1052] SEQ ID NO:132 (FR-6)

[1053] tRNA(Asp)5’RNA sequence

[1054] GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUU

[1055] SEQ ID NO:133 (FR-7)

[1056] tRNA(Asp)3’ag RNA sequence

[1057] AG GUGCAGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC

[1058] SEQ ID NO:134 (LR-5)

[1059] tRNA(Asp)Lag-CA RNA sequence

[1060] GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUU LAG GUGCAGG

[1061] GGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC

[1062] SEQ ID NO:135 (FR-8)

[1063] tRNA(AsnE2) 5’ RNA sequence

[1064] GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUU

[1065] SEQ ID NO:136 (FR-9)

[1066] tRNA(AsnE2) 3’ ag RNA sequence

[1067] AG GUUCCGUAUGUCACUGGUUCGAGUCCAGUCAGAGCCGC

[1068] SEQ ID NO:137 (LR-6)

[1069] tRNA(AsnE2)Lag-CA RNA sequence

[1070] GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUU LAG GUUCCGUA

[1071] UGUCACUGGUUCGAGUCCAGUCAGAGCCGC

[1072] SEQ ID NO:139 (FR-10)

[1073] tRNA(Glu) 3’ cg RNA sequence

[1074] CG ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC

[1075] SEQ ID NO:140 (LR-7)

[1076] tRNA(Glu)Lcg-CA RNA sequence

[1077] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU LCG ACGGCGGU

[1078] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1079] SEQ ID NO:141(FR-11)

[1080] tRNA(Glu)3’au RNA sequence

[1081] AU ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC

[1082] SEQ ID NO:142(LR-8)

[1083] tRNA(Glu)Lau-CA RNA sequence

[1084] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU LAU ACGGCGGU

[1085] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1086] SEQ ID NO:138(AR-1)

[1087] tRNA(Glu)(Agm)ag-CA RNA sequence

[1088] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU (Agm)AG ACGGCGGUAACAGGGGUUCGAAUCCCCUAGGGGACGC

[1089] Table 4

[1090]

[1091] Consisting of 50 mM HEPES-KOH (pH 7.5), 20 mM MgCl 2A reaction solution consisting of 1 mM ATP, 0.125-0.25 mM pNp (pUp, pLp or p(Agm)p), 25 μM tRNA5' fragment, 0.6 U / L T4 RNA ligase (New England Biolabs) and 10% DMSO was allowed to stand overnight at 15° C. to perform a ligation reaction between the tRNA 5' fragment and pNp (pUp, pLp or p(Agm)p). The ligation product was extracted with phenol-chloroform and recovered by ethanol precipitation.

[1092] To prevent unreacted tRNA 5' fragment from being carried over to the next ligation reaction, sodium periodate (NaIO 4 ) cleaves the ribose at the 3' end of the 5' fragment of tRNA. Specifically, 10 μM of the ligated product was placed on ice in the dark for 30 minutes in the presence of 10 mM sodium periodate for cleavage. After the reaction, one-tenth volume of 100 mM glucose was added and placed on ice in the dark for 30 minutes to decompose the excess sodium periodate. The reaction product was collected by ethanol precipitation.

[1093] After periodate treatment, T4 polynucleotide kinase (T4 PNK) treatment was performed to phosphorylate the 5' end of the ligation product and dephosphorylate the 3' end of the ligation product. The ligation product treated with 10 μM periodate, 50 mM Tris-HCl (pH 8.0), 10 mM MgCl 2 A reaction solution consisting of 5 mM DTT, 300 μM ATP and 0.5 U / μL T4 PNK (TaKaRa) was reacted by standing at 37° C. for 30 to 60 minutes. The reaction product was extracted with phenol-chloroform and collected by ethanol precipitation.

[1094] The ligation reaction was performed between the reaction product treated with PNK and the tRNA 3' fragment. First, the reaction product treated with 10 μM PNK, 10 μM tRNA 3' fragment, 50 mM HEPES-KOH (pH 7.5) and 15 mM MgCl 2The composed solution was heated at 65°C for 7 minutes and then allowed to stand at room temperature for 30 minutes to 1 hour to anneal the reaction product of the PNK treatment and the tRNA 3' fragment. Next, T4 PNK treatment was performed to phosphorylate the 5' end of the tRNA 3' fragment. T4 PNK treatment was performed by adding DTT (final concentration 3.5mM), ATP (final concentration 300μM) and T4PNK (final concentration 0.5U / μL) to the annealing solution and standing at 37°C for 30 minutes. Next, T4 RNA ligase (New England Biolabs) was added to the solution at a final concentration of 0.9U / μL, and the mixture was placed at 37°C for 30 to 40 minutes for the ligation reaction. The ligation product was extracted with phenol-chloroform and collected by ethanol precipitation.

[1095] The tRNA-CA produced by the ligation method was preparatively purified by high performance reverse phase chromatography (HPLC) (15 mM TEA and 400 mM HFIP in water / 15 mM TEA and 400 mM HFIP in methanol) and then subjected to denaturing urea-10% polyacrylamide electrophoresis to confirm whether they had the desired length.

[1096] Example 10 Analysis of RNase T 1 Cleaved tRNA fragments

[1097] Each tRNA-CA prepared using the ligation reaction was fragmented by RNase and analyzed to confirm whether each of U, L and (Agm) introduced by pUp, pLp or p(Agm)p had been introduced into the desired site.

[1098] The following Table 5 shows the combination of the SEQ ID NO of each tRNA-CA and the sequence of the RNA fragment containing U, L or (Agm) introduced by pUp, pLp or p(Agm)p.

[1099] [Table 5]

[1100]

[1101] The mixture contained 10 μM tRNA-CA, 5 U / μL RNaseT 1 (Epicentre or ThermoFisher Scientific) and 10 mM ammonium acetate (pH 5.3) were allowed to stand at 37°C for 1 hour to specifically cleave RNA at the 3' side of the G base, and RNA fragments containing U, L, or (Agm) introduced by pUp, pLp, or p(Agm)p were analyzed.

[1102] CCCU U Gp

[1103] LCMS (ESI) m / z = 944 ((M-2H) / 2) -

[1104] Retention time: 4.22 minutes (analysis conditions LTQTEA / HFIP05_03)

[1105] Comparison with the mass spectrum of the expected fragment (CCCUGp) when pUp is not ligated confirmed that most pUp ligation occurs ( Figure 1 ).

[1106] CCCU L Gp

[1107] LCMS(ESI)m / z=1008((M-2H) / 2)-

[1108] Retention time: 2.34 minutes (analysis conditions LTQTEA / HFIP05_03)

[1109] Comparison with the mass spectra of the expected fragments when pUp is not attached (CCCUGp) and when uridine is present instead of lysine (CCCUUGp) confirms that most pLp attachment occurs ( Figure 2 ).

[1110] CCCU L G

[1111] LCMS(ESI)m / z=1172((M-2H) / 2)-

[1112] Retention time: 3.81 minutes (analysis conditions LTQTEA / HFIP05_03)

[1113] The fragments expected when pLp is not attached (CCCUAGp) and when uridine is present instead of lysine (CCCU U AGp) mass spectra, confirming that most pLp ligation occurs ( Figure 3 ).

[1114] CCCU L ACACGp (SEQ ID NO: 197)

[1115] LCMS(ESI)m / z=1642((M-2H) / 2)-

[1116] Retention time: 5.78 minutes (analysis conditions LTQTEA / HFIP05_03)

[1117] The fragments are similar to those expected when pLp is not attached (CCCUACACGp) and when uridine is present instead of lysine (CCCU UACACGp / SEQ ID NO:198) mass spectrum was compared to confirm that most pLp ligation occurred ( Figure 4 ).

[1118] CCCU L CCACGp (SEQ ID NO: 199)

[1119] LCMS(ESI)m / z=1630((M-2H) / 2)-

[1120] Retention time: 5.64 minutes (analysis conditions LTQTEA / HFIP05_03)

[1121] The fragments expected when pLp is not attached (CCCUCCACGp) and when uridine is present instead of lysine (CCCU U CCACGp / SEQ ID NO: 200), confirming that most pLp ligation occurs ( Figure 5 ).

[1122] CUU L G

[1123] LCMS(ESI)m / z=1020((M-2H) / 2)-

[1124] Retention time: 3.84 minutes (analysis conditions LTQTEA / HFIP05_03)

[1125] Since the expected fragment without pLp ligation (CUUAGp) and the fragment originating from another part of the RNA (UUCAGp) have the same molecular weight, the unfragmented RNA was also analyzed.

[1126] pGGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUU L AGGUGC AGGGGGUCGCGGGUUCGAGUCCCGUCCGUUCCGC (SEQ ID NO:134)

[1127] LCMS(ESI)m / z=1109((M-22H) / 22)-

[1128] Retention time: 3.92 minutes (analysis conditions LTQTEA / HFIP05_01)

[1129] Comparison with the mass spectra of RNA expected in the absence of pLp ligation and in the presence of uridine rather than lysine confirmed that most pLp ligation occurred ( Figure 6 ).

[1130] AUUL G

[1131] LCMS(ESI)m / z=1032((M-2H) / 2)-

[1132] Retention time: 4.16 minutes (analysis conditions LTQTEA / HFIP05_03)

[1133] Comparison with the mass spectra of the expected fragments when pLp is not attached (AUUAGp) and when uridine is present instead of lysine (AUUUAGp) confirms that most pLp attachment occurs ( Figure 7 ).

[1134] CCCU L CGP

[1135] LCMS(ESI)m / z=1160((M-2H) / 2)-

[1136] Retention time: 4.21 minutes (analysis conditions LTQTEA / HFIP05_03)

[1137] Comparison with the mass spectra of the expected fragments when pLp is not attached (CCCUCGp) and when uridine is present instead of lysine (CCCUUCGp) confirms that most pLp attachment occurs ( Figure 8 ).

[1138] CCCU L AUACGp (SEQ ID NO: 202)

[1139] LCMS(ESI)m / z=1642((M-2H) / 2)-

[1140] Retention time: 5.95 minutes (analysis conditions LTQTEA / HFIP05_03)

[1141] Comparison with the mass spectra of the expected fragment when pLp is not attached (CCCUAUACGp) and the expected fragment when uridine is present instead of lysine (CCCUUAUACGp / SEQ ID NO:203) confirmed that most pLp attachment occurs ( Fig. 9 ).

[1142] CCCU (Agm) G

[1143] LCMS(ESI)m / z=1164((M-2H) / 2)-

[1144] Retention time: 4.02 minutes (analysis conditions LTQTEA / HFIP05_03)

[1145] Comparison with the mass spectra of the expected fragments when p(Agm)p is not attached (CCCUAGp) and when uridine is present instead of agmatine (CCCUUAGp) confirms that most p(Agm)p attachment occurs ( Fig.10 ).

[1146] Example 11 Synthesis of aminoacyl-tRNA

[1147] tRNA (SEQ ID NO: 77 (TR-1) to SEQ ID NO: 89 (TR-13), SEQ ID NO: 153 (TR-14) to SEQ ID NO: 162 (TR-23)) was synthesized from template DNA (SEQ ID NO: 64 (D-1) to SEQ ID NO: 76 (D-13), SEQ ID NO: 143 (D-26) to SEQ ID NO: 152 (D-35)) by in vitro transcription reaction using T7 RNA polymerase and purified using RNeasy kit (Qiagen).

[1148] Template DNA SEQ ID NO:64(D-1)

[1149] DNA sequence:

[1150] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1151] ACCGCCCT AGA ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1152] GC

[1153] Template DNA SEQ ID NO:65(D-2)

[1154] DNA sequence:

[1155] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1156] ACCGCCCT TGA ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1157] GC

[1158] Template DNA SEQ ID NO:66(D-3)

[1159] DNA sequence:

[1160] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1161] ACCGCCCT CGA ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1162] GC

[1163] Template DNA SEQ ID NO:67 (D-4)

[1164] DNA sequence:

[1165] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1166] ACCGCCCT AAG ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1167] GC

[1168] Template DNA SEQ ID NO:68 (D-5)

[1169] DNA sequence:

[1170] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1171] ACCGCCCT TAG ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1172] GC

[1173] Template DNA SEQ ID NO:69 (D-6)

[1174] DNA sequence:

[1175] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1176] ACCGCCCT CAG ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1177] GC

[1178] Template DNA SEQ ID NO:70 (D-7)

[1179] DNA sequence:

[1180] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1181] ACCGCCCT AAC ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1182] GC

[1183] Template DNA SEQ ID NO:71 (D-8)

[1184] DNA sequence:

[1185] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1186] ACCGCCCT TAC ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1187] GC

[1188] Template DNA SEQ ID NO:72 (D-9)

[1189] DNA sequence:

[1190] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1191] ACCGCCCT CAC ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1192] GC

[1193] Template DNA SEQ ID NO:73 (D-10)

[1194] DNA sequence:

[1195] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1196] ACCGCCCT GCCACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1197] GC

[1198] Template DNA SEQ ID NO:74 (D-11)

[1199] DNA sequence:

[1200] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1201] ACCGCCCT TCC ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1202] GC

[1203] Template DNA SEQ ID NO:75 (D-12)

[1204] DNA sequence:

[1205] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1206] ACCGCCCT CCC ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGAC

[1207] GC

[1208] Template DNA SEQ ID NO:76 (D-13)

[1209] DNA sequence:

[1210] GGCGTAATACGACTCACTATAGGCGGGGTGGAGCAGCCTGGTAGCTC

[1211] GTCGGGCT CAT AACCCGAAGATCGTCGGTTCAAATCCGGCCCCCGCA

[1212] AC

[1213] Template DNA SEQ ID NO:143 (D-26)

[1214] DNA sequence:

[1215] GGCGTAATACGACTCACTATAGGAGCGGTAGTTCAGTCGGTTAGAAT

[1216] ACCTGCTT aag GTGCAGGGGGTCGCGGGTTCGAGTCCCGTCCGTTCCG

[1217] C

[1218] Template DNA SEQ ID NO:144 (D-27)

[1219] DNA sequence:

[1220] GGCGTAATACGACTCACTATAGGAGCGGTAGTTCAGTCGGTTAGAAT

[1221] ACCTGCTT Tags GTGCAGGGGGTCGCGGGTTCGAGTCCCGTCCGTTCC

[1222] GC

[1223] Template DNA SEQ ID NO:145 (D-28)

[1224] DNA sequence:

[1225] GGCGTAATACGACTCACTATAGGAGCGGTAGTTCAGTCGGTTAGAAT

[1226] ACCTGCTT cag GTGCAGGGGGTCGCGGGTTCGAGTCCCGTCCGTTCCG

[1227] C

[1228] Template DNA SEQ ID NO:146 (D-29)

[1229] DNA sequence:

[1230] GGCGTAATACGACTCACTATAGGCTCTGTAGTTCAGTCGGTAGAACG

[1231] GCGGATT aag GTTCCGTATGTCACTGGTTCGAGTCCAGTCAGAGCCGC

[1232] Template DNA SEQ ID NO:147 (D-30)

[1233] DNA sequence:

[1234] GGCGTAATACGACTCACTATAGGCTCTGTAGTTCAGTCGGTAGAACG

[1235] GCGGATT tag GTTCCGTATGTCACTGGTTCGAGTCCAGTCAGAGCCGC

[1236] Template DNA SEQ ID NO:148 (D-31)

[1237] DNA sequence:

[1238] GGCGTAATACGACTCACTATAGGCTCTGTAGTTCAGTCGGTAGAACG

[1239] GCGGATT cag GTTCCGTATGTCACTGGTTCGAGTCCAGTCAGAGCCGC

[1240] Template DNA SEQ ID NO:149 (D-32)

[1241] DNA sequence:

[1242] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1243] ACCGCCCT gcg ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACG

[1244] C

[1245] Template DNA SEQ ID NO:150 (D-33)

[1246] DNA sequence:

[1247] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1248] ACCGCCCT ccg ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACG

[1249] C

[1250] Template DNA SEQ ID NO:151 (D-34)

[1251] DNA sequence:

[1252] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1253] ACCGCCCT aau ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACG

[1254] C

[1255] Template DNA SEQ ID NO:152 (D - 35)

[1256] DNA sequence:

[1257] GGCGTAATACGACTCACTATAGTCCCCTTCGTCTAGAGGCCCAGGAC

[1258] ACCGCCCT cau ACGGCGGTAACAGGGGTTCGAATCCCCTAGGGGACG

[1259] C

[1260] tRNA SEQ ID NO:77 (TR - 1)

[1261] tRNA(Glu)aga - CA RNA sequence:

[1262] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU AGA ACGGCGGU

[1263] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1264] tRNA SEQ ID NO:78 (TR - 2)

[1265] tRNA(Glu)uga - CA RNA sequence:

[1266] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU UGA ACGGCGGU

[1267] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1268] tRNA SEQ ID NO:79 (TR - 3)

[1269] tRNA(Glu)cga-CA RNA sequence:

[1270] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU CGA ACGGCGGU

[1271] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1272] tRNA SEQ ID NO:80(TR-4)

[1273] tRNA(Glu)aag-CA RNA sequence:

[1274] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU AAG ACGGCGGU

[1275] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1276] tRNA SEQ ID NO:81(TR-5)

[1277] tRNA(Glu)uag-CA RNA sequence:

[1278] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU UAG ACGGCGGU

[1279] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1280] tRNA SEQ ID NO:82(TR-6)

[1281] tRNA(Glu)cag-CA RNA sequence:

[1282] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU CAG ACGGCGGU

[1283] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1284] tRNA SEQ ID NO:83(TR-7)

[1285] tRNA(Glu)aac-CA RNA sequence:

[1286] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU AAC ACGGCGGU

[1287] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1288] tRNA SEQ ID NO:84(TR-8)

[1289] tRNA(Glu)uac-CA RNA:

[1290] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU UAC ACGGCGGU

[1291] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1292] tRNA SEQ ID NO:85(TR-9)

[1293] tRNA(Glu)cac-CA RNA:

[1294] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU CAC ACGGCGGU

[1295] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1296] tRNA SEQ ID NO:86(TR-10)

[1297] tRNA(Glu)gcc-CA RNA:

[1298] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU GCC ACGGCGGU

[1299] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1300] tRNA SEQ ID NO:87(TR-11)

[1301] tRNA(Glu)ucc-CA RNA:

[1302] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU UCC ACGGCGGU

[1303] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1304] tRNA SEQ ID NO:88(TR-12)

[1305] tRNA(Glu)ccc-CA RNA:

[1306] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU CCC ACGGCGGU

[1307] AACAGGGGUUCGAAUCCCCUAGGGGACGC

[1308] tRNA SEQ ID NO:89(TR-13)

[1309] tRNA(fMet)cau-CA RNA:

[1310] GGCGGGGUGGAGCAGCCCUGGUAGCUCCGUCGGGCU CAU AACCCGAA

[1311] GAUCGUCGGUUCAAAUCCGGCCCCCGCAA

[1312] tRNA SEQ ID NO:153(TR-14)

[1313] tRNA(Asp)aag-CA RNA:

[1314] GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUU aag GUGCAGGG

[1315] GGUCGCGGGUUCGAGUCCCCGUCCGUUCCGC

[1316] tRNA SEQ ID NO:154(TR-15)

[1317] tRNA(Asp)uag-CARNA:

[1318] GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUU UAG GUGCAGGG

[1319] GGUCGCGGGUUCGAGUCCCCGUCCGUUCCGC

[1320] tRNA SEQ ID NO:155 (TR-16)

[1321] tRNA(Asp)cag-CARNA sequence:

[1322] GGAGCGGUAGUUCAGUCGGUUAGAAUACCUGCUU cag GUGCAGGG

[1323] GGUCGCGGGUUCGAGUCCCGUCCGUUCCGC

[1324] tRNA SEQ ID NO:156 (TR-17)

[1325] tRNA(AsnE2)aag-CA RNA sequence:

[1326] GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUU aag GUUCCGUAU

[1327] GUCACUGGUUCGAGUCCAGUCAGAGCCGC

[1328] tRNA SEQ ID NO:157 (TR-18)

[1329] tRNA(AsnE2)uag-CA RNA sequence:

[1330] GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUU UAG GUUCCGUAU

[1331] GUCACUGGUUCGAGUCCAGUCAGAGCCGC

[1332] tRNA SEQ ID NO:158 (TR-19)

[1333] tRNA(AsnE2)cag-CA RNA sequence:

[1334] GGCUCUGUAGUUCAGUCGGUAGAACGGCGGAUU cag GUUCCGUAU

[1335] GUCACUGGUUCGAGUCCAGUCAGAGCCGC

[1336] tRNA SEQ ID NO:159 (TR-20)

[1337] tRNA(Glu)gcg-CA RNA sequence:

[1338] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU gcg ACGGCGGUA

[1339] ACAGGGGUUCGAAUCCCCUAGGGGACGC

[1340] tRNA SEQ ID NO:160(TR-21)

[1341] tRNA(Glu)ccg-CA RNA sequence:

[1342] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU ccg ACGGCGGUA

[1343] ACAGGGGUUCGAAUCCCCUAGGGGACGC

[1344] tRNA SEQ ID NO:161(TR-22)

[1345] tRNA(Glu)aau-CA RNA sequence:

[1346] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU aau ACGGCGGUA

[1347] ACAGGGGUUCGAAUCCCCUAGGGGACGC

[1348] tRNA SEQ ID NO:162(TR-23)

[1349] tRNA(Glu)cau-CA RNA sequence:

[1350] GUCCCCUUCGUCUAGAGGCCCAGGACACCGCCCU cau ACGGCGGUA

[1351] ACAGGGGUUCGAAUCCCCUAGGGGACGC

[1352] Preparation of mixed aminoacyl-tRNA solution using aminoacyl pCpA

[1353] The solution was adjusted to 25 μM transcribed tRNA(Glu)aga-CA (SEQ ID NO: 77 (TR-1)) by adding nuclease-free water, 50 mM HEPES-KOH pH 7.5, 20 mM MgCl 2 , 1mM ATP, 0.6 units / μL T4 RNA ligase (NewEngland Biolabs) and 0.25mM aminoacyl pCpA (DMSO solution of compound TS24 synthesized by the method described in patent document (WO2018143145A1)), and the ligation reaction was carried out at 15°C for 45 minutes. It should be noted that before adding T4 RNA ligase and aminoacyl pCpA, the reaction solution was heated to 95°C for 2 minutes and then allowed to stand at room temperature for 5 minutes to pre-fold tRNA.

[1354] Sodium acetate was added to the ligation reaction solution to a concentration of 0.3 M, and phenol-chloroform extraction was performed to prepare compound AAtR-1.

[1355] Similarly, the transcribed tRNA(Glu)uga-CA (SEQ ID NO: 78 (TR-2)) was linked to aminoacyl pCpA (SS15) by the above method. Sodium acetate was added to 0.3 M in the ligation reaction solution, and phenol-chloroform extraction was performed to prepare compound AAtR-2.

[1356] Similarly, lig-tRNA(Glu)uga-CA (SEQ ID NO: 56(UR-1)) was linked to aminoacyl pCpA(SS15) by the above method. Sodium acetate was added to the ligation reaction solution to 0.3 M, and phenol-chloroform extraction was performed to prepare compound AAtR-3.

[1357] Similarly, tRNA(Glu)Lga-CA (SEQ ID NO: 57 (LR-1)) was linked to aminoacyl pCpA (SS15) by the above method. Sodium acetate was added to 0.3 M in the ligation reaction solution, and phenol-chloroform extraction was performed to prepare compound AAtR-4.

[1358] Similarly, the transcribed tRNA (Glu) uga-CA (SEQ ID NO: 79 (TR-3)) was linked to aminoacyl pCpA (ts14; synthesized by the method described in patent document (WO2018143145A1)) by the above method. Sodium acetate was added to 0.3 M in the ligation reaction solution, and phenol-chloroform extraction was performed to prepare compound AAtR-5.

[1359] Phenol-chloroform extracts of three compounds: compound AAtR-1, compound AAtR-2 and compound AAtR-5 were mixed in equal amounts, and the mixed aminoacyl-tRNA solution (mixed solution of compound AAtR-1, compound AAtR-2 and compound AAtR-5) was subjected to ethanol precipitation to recover the compounds.

[1360] Phenol-chloroform extracts of three compounds: compound AAtR-1, compound AAtR-3 and compound AAtR-5 were mixed in equal amounts, and the mixed aminoacyl-tRNA solution (mixed solution of compound AAtR-1, compound AAtR-3 and compound AAtR-5) was subjected to ethanol precipitation to recover the compounds.

[1361] Phenol-chloroform extracts of three compounds: compound AAtR-1, compound AAtR-4 and compound AAtR-5 were mixed in equal amounts, and the mixed aminoacyl-tRNA solution (mixed solution of compound AAtR-1, compound AAtR-4 and compound AAtR-5) was subjected to ethanol precipitation to recover the compounds.

[1362] The reaction solution was adjusted to 25 μM transcribed tRNA(Glu)aag-CA (SEQ ID NO: 80 (TR-4)) by adding nuclease-free water, 50 mM HEPES-KOH pH 7.5, 20 mM MgCl 2 , 1 mM ATP, 0.6 units / μL T4 RNA ligase (New England Biolabs) and 0.25 mM aminoacylated pCpA (DMSO solution of ts14) were used to prepare the reaction solution, and the ligation reaction was carried out at 15°C for 45 minutes. It should be noted that before adding T4 RNA ligase and aminoacylated pCpA, the reaction solution was heated to 95°C for 2 minutes and then allowed to stand at room temperature for 5 minutes to pre-fold tRNA.

[1363] Sodium acetate was added to the ligation reaction solution to make the concentration 0.3 M, and phenol-chloroform extraction was performed to prepare compound AAtR-6.

[1364] Similarly, the transcribed tRNA(Glu)uag-CA (SEQ ID NO: 81 (TR-5)) was ligated to aminoacylated pCpA (SS14) by the above method. Sodium acetate was added to 0.3 M in the ligation reaction solution, and phenol-chloroform extraction was performed to prepare compound AAtR-7.

[1365] Similarly, tRNA(Glu)Lag-CA (SEQ ID NO: 59(LR-2)) was linked to aminoacylated pCpA(SS14) by the above method. Sodium acetate was added to the ligation reaction solution to 0.3 M, and phenol-chloroform extraction was performed to prepare compound AAtR-8.

[1366] Similarly, tRNA(Glu)cag-CA (SEQ ID NO: 82 (TR-6)) was ligated to aminoacylated pCpA (TS124) by the above method. Sodium acetate was added to the ligation reaction solution to 0.3 M, and phenol-chloroform extraction was performed to prepare compound AAtR-9.

[1367] Phenol-chloroform extracts of three compounds: compound AAtR-6, compound AAtR-7 and compound AAtR-9 were mixed in equal amounts, and the mixed aminoacylated tRNA solution (mixed solution of compound AAtR-6, compound AAtR-7 and compound AAtR-9) was subjected to ethanol precipitation to recover the compounds.

[1368] Phenol-chloroform extracts of three compounds: compound AAtR-6, compound AAtR-8 and compound AAtR-9 were mixed in equal amounts, and the mixed aminoacylated tRNA solution (mixed solution of compound AAtR-6, compound AAtR-8 and compound AAtR-9) was subjected to ethanol precipitation to recover the compounds.

[1369] The solution was adjusted to 25 μM transcribed tRNA(Glu)aac-CA (SEQ ID NO: 83 (TR-7)) by adding nuclease-free water, 50 mM HEPES-KOH pH 7.5, 20 mM MgCl 2 , 1 mM ATP, 0.6 units / μL T4 RNA ligase (NewEngland Biolabs) and 0.25 mM aminoacylated pCpA (DMSO solution of ts14) were used to prepare the reaction solution, and the ligation reaction was carried out at 15°C for 45 minutes. It should be noted that before adding T4 RNA ligase and aminoacylated pCpA, the reaction solution was heated to 95°C for 2 minutes and then allowed to stand at room temperature for 5 minutes to pre-fold tRNA.

[1370] Sodium acetate was added to the ligation reaction solution to make the concentration 0.3 M, and phenol-chloroform extraction was performed to prepare compound AAtR-10.

[1371] Similarly, the transcribed tRNA(Glu)uac-CA (SEQ ID NO: 84 (TR-8)) was ligated to aminoacylated pCpA (SS14) by the above method. Sodium acetate was added to 0.3 M in the ligation reaction solution, and phenol-chloroform extraction was performed to prepare compound AAtR-11.

[1372] Similarly, tRNA(Glu)Lac-CA (SEQ ID NO: 61(LR-3)) was linked to aminoacylated pCpA(SS14) by the above method. Sodium acetate was added to 0.3 M in the ligation reaction solution, and phenol-chloroform extraction was performed to prepare compound AAtR-12.

[1373] Similarly, tRNA(Glu)cac-CA (SEQ ID NO: 85 (TR-9)) was linked to aminoacylated pCpA (TS24) by the above method. Sodium acetate was added to 0.3 M in the ligation reaction solution, and phenol-chloroform extraction was performed to prepare compound AAtR-13.

[1374] Phenol-chloroform extracts of three compounds: compound AAtR-10, compound AAtR-11 and compound AAtR-13 were mixed in equal amounts, and the mixed aminoacylated tRNA solution (mixed solution of compound AAtR-10, compound AAtR-11 and compound AAtR-13) was subjected to ethanol precipitation to recover the compounds.

[1375] Phenol-chloroform extracts of three compounds: compound AAtR-10, compound AAtR-12 and compound AAtR-13 were mixed in equal amounts, and the mixed aminoacyl-tRNA solution (mixed solution of compound AAtR-10, compound AAtR-12 and compound AAtR-13) was subjected to ethanol precipitation to recover the compounds.

[1376] The solution was adjusted to 25 μM transcribed tRNA(Glu)gcc-CA (SEQ ID NO: 86 (TR-10)) by adding nuclease-free water, 50 mM HEPES-KOH pH 7.5, 20 mM MgCl 2 , 1 mM ATP, 0.6 units / μL T4 RNA ligase (New England Biolabs) and 0.25 mM aminoacylated pCpA (DMSO solution of TS24) were used to prepare the reaction solution, and the ligation reaction was carried out at 15°C for 45 minutes. It should be noted that before adding T4 RNA ligase and aminoacylated pCpA, the reaction solution was heated to 95°C for 2 minutes and then allowed to stand at room temperature for 5 minutes to pre-fold tRNA.

[1377] Sodium acetate was added to the ligation reaction solution to make the concentration 0.3 M, and phenol-chloroform extraction was performed to prepare compound AAtR-14.

[1378] Similarly, the transcribed tRNA(Glu)ucc-CA (SEQ ID NO: 87 (TR-11)) was ligated to aminoacylated pCpA (SS14) by the above method. Sodium acetate was added to 0.3 M in the ligation reaction solution, and phenol-chloroform extraction was performed to prepare compound AAtR-15.

[1379] Similarly, tRNA(Glu)Lcc-CA (SEQ ID NO: 63(LR-4)) was linked to aminoacylated pCpA(SS14) by the above method. Sodium acetate was ad...

Claims

1. The compound or its salt as shown below:

2. A method for producing a mutant tRNA having lysine at position 34 according to the tRNA numbering rule, comprising linking the compound according to claim 1 and a nucleic acid fragment constituting tRNA by an enzymatic reaction.

3. A method for producing a mutant tRNA having lysine at position 34 according to the tRNA numbering rule and having an amino acid or an amino acid analogue linked to the 3' terminus, comprising linking the compound according to claim 1, one or more nucleic acid fragments constituting tRNA, and an amino acid or an amino acid analogue by an enzymatic reaction.

4. The compound or its salt as shown below:

5. A method for producing a mutant tRNA having agmatine at position 34 according to the tRNA numbering rule, comprising linking the compound according to claim 4 and a nucleic acid fragment constituting tRNA by an enzymatic reaction.

6. A method for producing a mutant tRNA having agmatine at position 34 according to the tRNA numbering convention and having an amino acid or an amino acid analogue linked to the 3' terminus, comprising linking the compound according to claim 4, one or more nucleic acid fragments constituting tRNA, and an amino acid or an amino acid analogue by an enzymatic reaction.

7. The method according to claim 3 or 6, wherein the amino acid is an amino acid other than methionine (Met) and isoleucine (Ile).

8. A mutant tRNA produced by the method according to claim 2 or 5.

9. A mutant tRNA having an amino acid or an amino acid analog linked to the 3' terminus, produced by the method according to claim 3, 6 or 7.

10. A translation system comprising the mutant tRNA according to claim 8 or 9.

11. A method for producing a peptide, comprising translating a nucleic acid using the translation system according to claim 10.

12. A method for producing lysine diphosphate or a derivative thereof, or agmatine diphosphate or a derivative thereof represented by the following formula A, ( in: R 1 and R 2 Each independently is H or C 1 -C 3 alkyl, L is C 2 -C 6 Straight chain alkylene or C 2 -C 6 Straight chain alkenylene, optionally substituted by one or more selected from hydroxyl and C 1 -C 3 The alkyl group is substituted with a substituent, wherein C 2 -C 6 The carbon atoms of the straight chain alkylene group are optionally substituted by an oxygen atom or a sulfur atom, M is a single bond Wherein the wavy line indicates the point of connection to the carbon atom, the * indicates the point of connection to the hydrogen atom, and the ** indicates the point of connection to the nitrogen atom, provided that when M is a single bond, the H connected to M does not exist). The method comprises the following steps: The intramolecular cyclization is a compound represented by the following formula B1: (PG 11 is a protecting group for an amino group) To obtain a compound represented by the following formula C1: (PG 11 Same as above); An amine represented by the following formula D1 is introduced: (Among them, R 1 , R 2 , L, M as above) Or a salt of a compound represented by formula C1 to obtain a compound represented by the following formula E1: (Among them, R 1 , R 2 , L, M, PG 11 Same as above); PG 12 and / or PG 13 The compound represented by formula E1 is introduced to obtain a compound represented by the following formula F1A or F1B: (in: R 2 It is C 1 -C 3 alkyl, PG 12 is a protecting group for amino groups, PG 13 is a protecting group for a carboxyl group or an imino group, and R 1 , L, M and PG 11 Same as above. The premise is that when M is a single bond, there is no PG 13 hour); The acetone compound in the compound represented by formula F1A or F1B is removed and PG is introduced 14 and PG 15 , to obtain a compound represented by the following formula G1A or G1B: (in: R 2 It is C 1 -C 3 alkyl, PG 14 is a protecting group for the hydroxyl group, PG 15 is a protecting group for the hydroxyl group, and R 1 、L, M, PG 11 、PG 12 、PG 13 The same as above); PG 16 Introduced into the compound represented by formula G1A or G1B to obtain the compound represented by the following formula H1A or H1B: (in: R 2 It is C 1 -C 3 alkyl, PG 16 is a protecting group for a hydroxyl group and / or an amino group, and R 1 , L, M, PG 11 , PG 12 , PG 13 , PG 14 , PG 15 Same as above); Removal of PG from a compound represented by formula H1A or H1B 14 and PG 15 , to obtain a compound represented by formula I1A or I1B: (in: R 2 It is C 1 -C 3 Alkyl, and R 1 、L, M, PG 11 、PG 12 、PG 13 、PG 16 Same as above); The compound represented by formula I1A or I1B is phosphitated and then oxidized to obtain a compound represented by the following formula J1A or J1B: (in: R 2 It is C 1 -C 3 alkyl, PG 17 is a protecting group for the hydroxyl group, and R 1 、L, M, PG 11 、PG 12 、PG 13 和PG 16 Same as above); Removal of PG from the compound represented by Formula J1A 11 PG 12 PG 13 and PG 17 , or removing PG from the compound represented by formula J1B 11 PG 13 and PG 17 , to obtain a compound represented by the following formula K1: (in: R 2 Is H or C 1 -C 3 Alkyl, and R 1 , R 2 , L, M and PG 16 Ibid.); and Removal of PG from the compound represented by formula K1 16 , to obtain the compound represented by formula A.

13. The method according to claim 12, wherein the compound represented by formula A is cytosine diphosphate: , or agmatine diphosphate:

14. The method according to claim 12, wherein PG 11 is p-bromobenzoyl, optionally substituted benzoyl, pyridinecarbonyl or acetyl.

15. The method according to claim 12, wherein PG 12 It is Fmoc.

16. The method according to claim 12, wherein when M is PG 13 is methyl, ethyl or optionally substituted benzyl, and when M is PG 13 is optionally substituted benzyl, Cbz or optionally substituted benzyloxycarbonyl.

17. The method according to claim 12, wherein PG 14 and PG 15 Together they form a di-tert-butylsilyl group.

18. The method according to claim 12, wherein PG 16 It's TOM.

19. The method according to claim 12, wherein PG 17 It is cyanoethyl.

20. The method according to claim 12, wherein the intramolecular cyclization is carried out in the presence of diisopropyl azodicarboxylate and triphenylphosphine.

21. The method according to claim 12, wherein the introduction of the amine represented by formula D1 or a salt thereof is carried out in the presence of lithium chloride and DBU.

22. The method according to claim 12, wherein PG 12 Fmoc, used to introduce PG 12 The reagents are (2,5-dioxopyrrolidin-1-yl)(9H-fluoren-9-yl)methyl carbonate and sodium carbonate.

23. The method according to claim 12, wherein PG 13 It is a methyl group, used to introduce PG 13 The reagents are N,N'-diisopropylcarbodiimide, methanol and N,N-dimethyl-4-aminopyridine.

24. The method of claim 12, wherein the reagent used to remove acetonide is TFA.

25. The method of claim 12, wherein PG 14 and PG 15 The di-tert-butylsilyl group is formed together, and the reagent used to introduce the di-tert-butylsilyl group is di-tert-butylsilyl bis(trifluoromethanesulfonate).

26. The method of claim 12, wherein PG 16 TOM, used to introduce PG 16 The reagents are DIPEA and (triisopropylsilyloxy)methyl chloride.

27. The method according to claim 12, wherein the 14 and PG 15 The reagent is hydrogen fluoride pyridine complex.

28. The method according to claim 12, wherein the reagent for phosphitylation is bis(2-cyanoethyl)-N,N-diisopropylaminophosphoramidite.

29. The method of claim 12, wherein the reagent used for oxidation is tert-butyl hydroperoxide.

30. The method according to claim 12, wherein the 11 PG 12 PG 13 and PG 17 The reagents are bis-(trimethylsilyl)acetamide and DBU.

31. The method according to claim 12, wherein the 16 The reagent is ammonium fluoride.

32. The method of claim 12, wherein R 1 It's H.

33. The method according to claim 12, wherein R 2 It's H.

34. The method according to claim 12, wherein C 2 -C 6 Straight chain alkylene or C 2 -C 6 Straight chain alkenylene is C 4 -C 5 Straight chain alkylene or C 4 -C 5 Straight chain alkenylene.

35. The method of claim 12, wherein L is -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 、-(CH 2 ) 2 -O-CH 2 -、-(CH 2 ) 2 -S-CH 2 -、-CH 2 CH(OH)(CH 2 ) 2 -or-CH 2 CH=CH- (cis or trans).

36. A method for producing lysine diphosphate or a derivative thereof, or agmatine diphosphate or a derivative thereof represented by the following formula A, ( in: R 1 and R 2 Each independently is H or C 1 -C 3 alkyl, L is C 2 -C 6 A straight chain alkylene group or optionally one or more selected from hydroxyl and C 1 -C 3 The substituents of the group consisting of alkyl groups are substituted with C 2 -C 6 Straight chain alkenylene, where C 2 -C 6 A carbon atom of a straight-chain alkylene group is replaced by an oxygen atom or a sulfur atom. M is a single bond, Wherein the wavy line indicates the point of connection to the carbon atom, the * indicates the point of connection to the hydrogen atom, and the ** indicates the point of connection to the nitrogen atom, provided that when M is a single bond, the H connected to M does not exist). The method comprises the following steps: The intramolecular cyclization is a compound represented by the following formula B2: (PG 21 is a protecting group for an amino group) To obtain a compound represented by the following formula C2: (PG 21 Same as above); An amine represented by the following formula D2A or D2B is introduced: (in: R 2 It is C 1 -C 3 alkyl, PG 22 is a protecting group for amino groups, PG 23 is a protecting group for a carboxyl group or an imino group, and R 1 , L and M are the same as above, The premise is that when M is a single bond, there is no PG 13 hour); Or a salt of a compound represented by formula C2 to obtain a compound represented by the following formula E2A or E2B: (in: R 2 It is C 1 -C 3 Alkyl, and R 1 、L, M, PG 21 、PG 22 和PG 23 Same as above); Remove the acetone compound from the compound represented by formula E2A or E2B and introduce PG 24 and PG 25 , to obtain a compound represented by the following formula F2A or F2B: (in: R 2 It is C 1 -C 3 alkyl, PG 24 is a protecting group for the hydroxyl group, PG 25 is a protecting group for the hydroxyl group, and R 1 、R 2 、L, M, PG 21 、PG 22 and PG 23 Ibid.); PG 26 Introduced into the compound represented by formula F2A or F2B to obtain the compound represented by the following formula G2A or G2B: (in: R 2 It is C 1 -C 3 alkyl, PG 26 is a protecting group for the hydroxyl group, and R 1 、R 2 、L, M, PG 21 、PG 22 、PG 23 、PG 24 and PG 25 Same as above); Removal of PG from a compound represented by formula G2A or G2B 24 and PG 25 , to obtain a compound represented by formula H2A or H2B: (in: R 2 It is C 1 -C 3 Alkyl, and R 1 、L, M, PG 21 、PG 22 、PG 23 和PG 26 Same as above); The compound represented by formula H2A or H2B is phosphitated and then oxidized to obtain the compound represented by the following formula I2A or I2B: (in: R 2 It is C 1 -C 3 alkyl, PG 27 is a protecting group for the hydroxyl group, and R 1 、L, M, PG 21 、PG 22 、PG 23 和PG 26 Same as above); Removal of PG from the compound represented by formula I2A 21 PG 22 PG 23 and PG 27 , or removing PG from the compound represented by formula I2B 21 PG 23 and PG 27 , to obtain a compound represented by the following formula J2: (in: R 2 Is H or C 1 -C 3 Alkyl, and R 1 , L, M and PG 26 Ibid.); and Removal of PG from the compound represented by Formula J2 26 , to obtain the compound represented by formula A.

37. The method according to claim 36, wherein the compound represented by formula A is cytosine diphosphate: or agmatine diphosphate:

38. The method of claim 36, wherein PG 21 is Cbz, optionally substituted benzyloxycarbonyl or optionally substituted benzyl.

39. The method of claim 36, wherein PG 22 is Cbz, optionally substituted benzyloxycarbonyl or optionally substituted benzyl.

40. The method of claim 36, wherein when M is When M is PG 23 is an optionally substituted benzyl group, and when M is PG 23 is optionally substituted benzyl, Cbz or optionally substituted benzyloxycarbonyl.

41. The method of claim 36, wherein PG 24 and PG 25 Together they form a di-tert-butylsilyl group.

42. The method of claim 36, wherein PG 26 It is tetrahydropyranyl, tetrahydrofuranyl or methoxymethyl.

43. The method of claim 36, wherein PG 27 It's benzyl.

44. The method of claim 36, wherein the intramolecular cyclization is carried out in the presence of diisopropyl azodicarboxylate and triphenylphosphine.

45. The method according to claim 36, wherein the introduction of the amine represented by formula D2 or a salt thereof is carried out in the presence of lithium chloride and DBU.

46. ​​The method of claim 36, wherein the reagent used to remove acetonide is TFA.

47. The method of claim 36, wherein PG 24 and PG 25 The di-tert-butylsilyl group is formed together, and the reagent used to introduce the di-tert-butylsilyl group is di-tert-butylsilyl bis(trifluoromethanesulfonate).

48. The method of claim 36, wherein PG 26 Is a tetrahydropyranyl group, used to introduce PG 26 The reagents are TFA and 3,4-dihydro-2H-pyran.

49. The method according to claim 36, wherein the 24 and PG 25 The reagent is tetrabutylammonium fluoride.

50. The method of claim 36, wherein the reagent used for phosphitylation is dibenzyl N,N-diisopropylphosphoramidite.

51. The method of claim 36, wherein the reagent used for oxidation is Dess-Martin periodinane.

52. The process of claim 36, wherein PG is removed by catalytic hydrogenation 21 PG 22 PG 23 and PG 27 .

53. The method according to claim 36, wherein the 26 The reagent is hydrochloric acid.

54. The method of claim 36, wherein R 1 It's H.

55. The method of claim 36, wherein R 2 It's H.

56. The method of claim 36, wherein C 2 -C 6 Straight chain alkylene or C 2 -C 6 Straight chain alkenylene is C 4 -C 5 Straight chain alkylene or C 4 -C 5 Straight chain alkenylene.

57. The method of claim 36, wherein L is -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 、-(CH 2 ) 2 -O-CH 2 -、-(CH 2 ) 2 -S-CH 2 -、-CH 2 CH(OH)(CH 2 ) 2 -or-CH 2 CH=CH- (cis or trans).